Test evaluation in a resource-limited country context from a health economics perspective by Frempong, Samuel Nkansah
	
Test evaluation in a resource-limited country 




Samuel Nkansah Frempong 
 
 
A thesis submitted to 
The University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
      Health Economics Unit 
      Institute of Applied Health Research 
      College of Medical and Dental Sciences 
      The University of Birmingham 
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 






In Ghana, there are issues with the diagnosis of typhoid fever such as delays in diagnosis, 
concerns about the accuracy of current tests, and lack of availability. All of which highlight the 
need for the development of a rapid, accurate and easily accessible diagnostic test. Whilst 
several studies have indicated the importance of an iterative use of economic evaluations 
during the early phases of development of medical devices, there is little specific guidance on 
their implementation. The aim of this research was to examine the potential cost-effectiveness 
of a hypothetical rapid test for typhoid fever diagnosis in Ghana.  
 
Two systematic reviews, a qualitative survey and an early cost-effectiveness analysis were 
conducted to achieve the research aim.  
 
The results here show that there is a general lack of clarity on the methods used in the early 
economic evaluation of medical tests, and the techniques available to modellers that can 
demonstrate the value of conducting further research and product development (i.e., value of 
information (VOI) analysis, headroom analysis) should be better utilized. For a hypothetical 
test to perform better than the current available tests in terms of QALYs gained and cost-
effectiveness, it is necessary that it has a high specificity (at least 70%) and should not be priced 
more than $10.   
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Over the past few decades, the introduction of medical tests has accelerated substantially 
(Redekop, 2006; Koffijberg et al., 2013). Despite this increase, there exist challenges for the 
economic evaluation of tests which represent on-going research priorities (such as linking 
information from different studies that may not be comparable in the absence of test-treat 
randomised controlled trials) even in countries where research is relatively well developed 
(Merlin et al., 2013; Merlin, 2014). Resource-limited countries have additional challenges such 
as there being no proper systems in place to ensure the adequate evaluation of tests, and health 
informatics not being comprehensive or clearly linked to priority (Odame, 2013; Schroeder et 
al., 2015). Consequently, testing in some disease areas that pose serious public health threats 
and the resulting increased cost to health care systems are being neglected; one such disease is 
typhoid fever (Wain et al., 2015).  
 
In Ghana (a resource-limited country), previously reported annual incidence of typhoid fever 
in 2017 was 60,892 cases (Kim et al., 2017) and this ranks among the leading 20 causes of 
outpatient illness in the country, accounting for 0.92% of all hospital admissions (Marks et al, 
2010). The two tests for typhoid fever diagnosis in Ghana are the Widal test (a serological test) 
and blood culture (GNDP, 2014). Compared to blood culture, the Widal test is easier and 
requires fewer resources to perform, however, the Widal test is an inaccurate indicator of 
typhoid fever, resulting in inappropriate treatment frequently being administered in Ghana 
(GNDP, 2014). This has led to the development of resistance of Salmonella typhi and paratyphi 
(the causative organisms of typhoid fever) to previously effective cheap treatments such as 
chloramphenicol, and this has resulted in the current use of the more expensive ciprofloxacin 
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in Ghana (GNDP, 2014). Blood culture lacks sensitivity (the proportion of people with disease 
who will have a positive test result) (Wain et al., 2015), meaning that the disease will be missed 
in many patients (i.e., a high false negative rate) resulting in lost opportunities for treatment, 
which might lead to increased morbidity and mortality. Furthermore, culture requires 
equipment, supplies, trained laboratory personnel and electricity which may hardly be available 
in primary health care facilities in Ghana, and when performed, can take 2-3 days before test 
results are obtained. Thus, diagnosis may be delayed or overlooked because patients may not 
return for their lab results. Patients may end up with complications such as intestinal 
perforation resulting in death if treatment is postponed or patients are lost to follow up (Huang 
et al., 2013). Furthermore, those without typhoid fever may receive unnecessary and 
inappropriate antimicrobial treatment if treated presumptively (Keddy et al., 2011).	Another 
issue is that typhoid fever clinically resembles other febrile conditions such as malaria and is 
easily misdiagnosed without laboratory confirmation which could lead to an overprescribing 
of antimalarial therapies associated with a huge economic impact on the Ghanaian economy. 
For example, Nonvignon at al. (2016) showed that businesses in Ghana lost about US$6.58 
million to malaria in 2014, 90% of which was direct cost. Therefore, the development of a test 
for typhoid fever in the Ghanaian setting which is accurate, simple and affordable with a quick 
turnaround time to enable prompt implementation of an appropriate effective treatment for 
typhoid fever has an obvious attraction. 
 
To comprehensively evaluate the potential value of a new test (which is the focus of this thesis) 
there is the need for an in-depth understanding of the principles underpinning test evaluation 
and the implementation of economic evaluations of medical tests (and for the purpose of this 
thesis, economic evaluations conducted at the early phases of test development). Economic 
evaluation is defined as “the comparative analysis of alternative courses of action in terms of 
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their cost and consequences” (Drummond et al., 2005, p.9). Central to economic evaluation is 
the fact that, an imbalance between available resources and the potential use for these resources 
will always exist (Morris et al., 2012). Therefore, choosing to deploy resource to one use means 
that the opportunity to use that resource in their next best alternative is foregone (i.e., there is 
an opportunity cost associated with every decision made) (Drummond et al., 2005). The 
purpose of economic evaluation is to ensure that there is good value for money spent. Economic 
evaluation is a tool that can help users make the most of resources, decide between promising 
interventions, and demonstrate the benefits of an intervention. Economic evaluations are either 
conducted alongside randomised controlled trials (RCTs) or using decision analytic modelling. 
In the case of medical tests, decision analytic modelling has been advocated as the most 
systematic and transparent method for assessing cost-effectiveness in the absence of test-treat 
RCTs (Trikalinos et al., 2009). Decision analytic modelling involves combining evidence from 
a number of sources to provide evidence on clinical and cost-effectiveness. There are are two 
main types of decision analytic models namely: static and dynamic models (Drummond et al., 
2005). The evaluation of medical tests differs in some important ways from the evaluation of 
treatments (Kip et al., 2018). Medical testing affects the quality of life of a patient primarily in 
two ways. These are the direct effects associated with the test or the testing process (which 
could either be positive or negative), and the downstream benefits arising from clinical 
decisions made based on the test results (AHRQ, 2012). It is only by capturing these effects 
(which is dependent on an in-depth understanding of the care pathway) that the true value of a 
medical test can be established (Van den Bruel et al., 2007; Whiting et al., 2015). Knowledge 
of the care pathway is essential when evaluating the impact of testing on patient outcomes and 
should involve all stakeholders (those for whom the use of a test will have an impact personally 
or from an organisation perspective or from a population perspective). Economic evaluations 
are usually conducted at the late stage of product development (including medical tests) 
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(Pietzsch and Paté-Cornell, 2008), the rationale being that at this point there will be enough 
device-specific data for their proper evaluation (Redekop and Mikudina, 2013). However, 
economic evaluations conducted at the early phases of product development are conducted at 
a time when there is a lack of data (for example, lack of data describing the effectiveness of an 
intervention) and are more iterative in nature. The lack of data implies that economic 
evaluations conducted at the early phases of product development are associated with increased 
uncertainty (Buisman et al., 2016), and is likely to be more pertinent for tests. This is further 
compounded by the fact that, due to the indirect nature of tests in terms of their impact on 
patient relevant outcomes, data on test accuracy and downstream consequences may only be 
acquired by mapping clinical pathways (which is difficult when the role of a new test is not 
clear) leading to potentially more uncertain data. Furthermore, early economic evaluations are 
used to inform investment decisions, whilst late economic evaluations are used to inform 
adoption decisions.   
 
Clearly, there exist some differences in the evaluation of medical tests compared to treatments, 
as well as in the implementation of economic evaluations at an early stage of technology 
development compared to the late stage. These differences highlight the need for a better 
understanding of the key principles of test evaluation needed to ensure the effective evaluation 
of the true value of a new test. Furthermore, these differences suggest that the methodologies 
used in the analysis of late economic evaluation need modification for use in early economic 
evaluation. An understanding of these principles is key to this study because the intervention 
being evaluated is a medical test which is at the early development phase, and there is little 
specific guidance on the implementation of economic evaluations at the early stages of 
technology development (Buisman et al., 2016). 
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1.2 Study aim and objectives 
	
The aim of this research was to examine the potential cost-effectiveness of a hypothetical test 
(hereafter referred to as the HT-test) for typhoid fever diagnosis in Ghana. Specifically: 
1. To examine the methodologies and tools that have been employed in the early economic 
evaluation of medical tests. 
2. To explore the variations in existing test-treat strategies for typhoid fever in Ghana to 
delineate the care pathway for typhoid fever. 
3. To explore the types of models that have been adopted for test-treat evaluations of typhoid 
fever and to capture data on model inputs that may be useful for a de novo model.  
4. To design an economic model to estimate the maximum price and the minimum test 
performance required for the HT-test to be cost-effective in the Ghanaian setting. 
 
1.3 Study design and relevance of study 
	
This research was conducted over four distinct but interrelated stages (two systematic reviews, 
a qualitative survey, and early cost-effectiveness analysis). Each of these stages addressed one 
of the objectives outlined. The first systematic review addressed objective 1, the qualitative 
survey addressed objective 2, the second systematic review addressed objective 3 and the early 
cost-effectiveness analysis addressed objective 4. These are presented in Chapters 3, 4, 5 and 
6 respectively. 
 
The findings of this thesis provide valuable information to test developers about the market 
potential of developing a new test for typhoid fever that can be applied in the Ghanaian setting.    
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The findings also provide valuable information for decision makers to support their decision 
making on the further development of a rapid test for typhoid diagnosis in Ghana. This could 
help allocate limited budgets more efficiently and greatly improve the delivery of care for 
typhoid fever patients in Ghana. The findings also have wider implications for the early 
economic evaluation of tests by contributing to a limited evidence base and identifying areas 
requiring further research.  
 
Decision maker in the context of adoption of health technologies in Ghana refers to the 
Government of Ghana through the management of the National Health Insurance Authority 
(NHIA). The NHIA are responsible for entering into purchasing agreements with providers 
and reimbursing those providers (Soddzi-Tettey et al., 2012). The decision criteria previously 
adopted by the NHIA in choosing which health interventions to fund and which not to fund 
were based on the World Health Organization’s (WHO) suggested cost-effectiveness threshold 
based on multiples of a country’s gross domestic product (GDP). That is, an intervention that 
per disability-adjusted life-year (DALY) avoided, costs less than three times the national 
annual GDP per capita is considered cost-effective, those that exceed this level are considered 
not cost–effective, whereas one that costs less than once the national annual GDP per capita is 
considered highly cost-effective. However, due to the recognition of major shortcomings 
associated with the use of this threshold, the WHO has recently withdrawn this threshold 
(Bertram et al., 2016) which has lead to the adoption of the new estimated country-specific 
threshold of less than $104-$951/QALY by the NHIA. This threshold has been calculated from 
estimates of opportunity cost, estimates of the relationship between the Ghanaian GDP per 
capita and the value of statistical life, and a series of explicit assumptions (Woods et al., 2016). 
This threshold is expressed as a range rather than a single estimate to reflect the uncertainty in 
the data used. Thus, to examine the potential cost-effectiveness of the HT-test in this study, the 
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threshold value of less than $104-$951/QALY was adopted, consistent with what decision 
makers currently use in Ghana.  
 
1.4 Structure of the thesis 
	
Following this introductory chapter, this thesis consists of six further chapters. Chapter 2 sets 
the context for this thesis by exploring and summarising the relevant literature related to the 
topic area. It presents the literature on test evaluation by highlighting the main types and 
applications of medical tests, test performance characteristics, the current focus of test 
evaluation and the paradigm shift from focussing on diagnostic accuracy to evidence on clinical 
effectiveness and cost-effectiveness. It further presents the literature on the methods, examples 
and challenges of economic evaluations with specific focus on the reasons for undertaking 
economic evaluations at the early phases of medical test development. Then the literature on 
testing in resource-limited settings is presented with specific focus on typhoid testing in Ghana 
and related issues.  
 
Chapter 3 presents a systematic review focussed on examining the methodologies and tools 
that have been employed in early economic evaluation studies of medical tests. Specifically, it 
summarises how the problem of insufficient data for model parameterization in early modelling 
studies of medical tests has been managed, whether and how testing pathways have been 
modelled, and whether and how the uncertainty that accompanies early modelling studies has 
been acknowledged in sensitivity analysis. 
 
Chapter 4 presents the collection of primary data. It shows how the qualitative methodology 
(framework analysis) was used to explore and delineate existing test-treat pathways for typhoid 
fever in Ghana. Specifically, it summarises the typhoid test-treat pathways in Ghana, existing 
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variations in care pathways and the reasons for the existing variations. It further presents the 
views of a range of health care professionals working in Ghana on the role of a hypothetical 
rapid diagnostic test for typhoid fever in the care pathway they work in. 
  
Chapter 5 presents a systematic review focussed on exploring the literature on typhoid 
economic evaluations, the types of models that have been previously adopted for modelling 
typhoid interventions and capturing of data on model inputs that may be useful for a de novo 
model. Specifically, it summarises how interventions for typhoid fever have been evaluated.  
 
Chapter 6 presents the methodology and results of an early cost-effectiveness study which 
examines the potential cost-effectiveness of the HT-test, with specific focus on the estimation 
of the maximum cost and the minimum test performance required for the test to be cost-
effective. It explores the value of methodologies such as headroom analysis, the cost-
effectiveness acceptability curve (CEAC) and value of information (VOI) analysis. 
 
Chapter 7 brings together the findings of the thesis and discusses its relevance as a valuable 
source of information to technology developers on the market potential of developing the HT-
test. It further discusses its relevance as a valuable source of information to policy makers to 
support their decision-making on the further development of a rapid test for typhoid diagnosis 
in Ghana, which could help allocate limited budgets more efficiently. It also discusses the 
findings of the study and its implications for policy changes that will greatly improve the 
delivery of care for typhoid fever patients in Ghana. Finally, it discusses the implications of 
the findings for the early economic modelling of tests.  
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Chapter 2: Literature review 
 
This chapter sets the context for this thesis by exploring and summarising the relevant literature 
on test evaluation and economic evaluation of medical tests. First, medical tests are defined 
and their role in the health care setting is highlighted. Then, the literature on test evaluation is 
presented by highlighting the main types and applications of medical tests, test performance 
characteristics, the current focus of test evaluation, the paradigm shift from diagnostic accuracy 
to evidence on clinical effectiveness and cost-effectiveness. Furthermore, the literature on the 
methods, examples and challenges of economic evaluations at the early and late phases of 
product development are presented, with specific focus on the reasons for undertaking 
economic evaluations at the early phases of medical test development. Lastly, the literature on 
testing in resource-limited settings is presented with specific focus on typhoid testing in Ghana 
and related issues of test accuracy, cost, slow turnaround time and the lack of availability of 
current testing strategies. 
 
2.1 Medical tests: purpose in the health care setting  
 
A medical test is defined as “a characteristic, measurement, observation, or medical procedure 
made on a person that provides information that relates to some aspect of their health state’’ 
(Deeks et al., 2014, p.5). As a concept, the application of tests can be seen primarily as an 
information gathering process in health care (Lee et al., 2010). The information gathered can 
be useful in a variety of ways including modifying the probability of the presence or absence 
of disease, assessing stages of disease progression, risk stratification, monitoring of chronic 
disease progression, monitoring a patient’s condition following treatment and predicting future 
events (Knottnerus et al., 2002; MSAC, 2005). Tests are sometimes an integral part of 
treatment. For example, endoscopy is used not only to detect lesions but also to remove the 
detected lesions. As a result of the valuable role they continue to play in health care delivery 
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(Redekop, 2006), the number of tests has been increasing rapidly over the past decade and is 
likely to increase further (Koffijberg et al., 2013). 
 
2.2 Main types of tests 
 
The following describes the main types of tests or measures employed in health care settings 
to evaluate a patient’s condition: medical history taking, physical examination, laboratory tests 
and pathology, physiological measurements and imaging tests. 
 
Medical history taking involves a structured assessment carried out to elicit information that 
can provide a comprehensive evaluation of a patient’s health status. It involves an assessment 
of the patient’s current and previous health problems and medical treatment, factors which 
might affect the patient’s health and their family’s history. Taken together, the medical history, 
information from physical examination and the results of other tests are often used to produce 
a list of plausible diagnoses. The medical history of a patient is captured using questionnaires 
which may differ between settings.  
 
Physical examination involves an examination of the body of a patient for signs that are 
diagnostic of a particular disease or complications of a particular disease. There are different 
tests that can be performed during a physical examination that depend on their rationale. For 
example, there is physical examination for abdominal tenderness and severe abdominal pain in 
typhoid fever as an indication for intestinal perforation. 
 
Laboratory tests and pathology normally involve taking samples of blood, urine, stool or tissue 
and subjecting them to either chemical or mechanical analysis or by observation to look for 
abnormalities within the samples. In most cases, the side effects attributable to these tests are 
 11	
those resulting from obtaining the samples (Stockham and Scott, 2013). Examples include 
urine or blood culture test, pap smear, blood glucose test and full blood count test. 
 
Physiological measurements are made to assess how well the body functions. These may range 
from simple measurements of body temperature, blood pressure, weight and height to more 
complicated measures such as measuring heart functioning by taking an ECG (Webster, 2014).   
 
Imaging tests are tests that produce images of parts of the body. The type of test requested will 
depend on the symptoms of the patient and the part of the body being examined. They include 
X-rays, Computed Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, 
Ultrasound, positron emission tomography (PET) and endoscopic investigations.  
 
2.3 Applications of tests 
 
Tests can be categorised into their use for the purposes of screening, assessing predisposition, 
diagnosis, staging, prognosis, surveillance, clinical monitoring, assessing response and for 
stratification (Deeks et al., 2014). An appreciation of the various ways in which tests can be 
used is very important because, tests used in different ways may require different evaluative 
approaches. The applications of a test where management decisions are based on a test result 
at one point in time (i.e., the test is done and a management decision is made) fits the diagnostic 
evaluation paradigm. Whereas questions of longitudinal nature (i.e. tests that seek to predict a 
future event or management decisions are based on repeated test results or a change) do not fit 
the diagnostic evaluation paradigm. The test applications which fit the diagnostic evaluation 





Diagnosis is the process of establishing the presence or absence of a particular disease, 
condition or syndrome in a patient at the time of testing through the evaluation of the patient’s 
history, review of laboratory data and examination of the individual (WHO, 2005). Tests are 
performed in patients who exhibit signs and symptoms indicative of the presence of a particular 
disease. The role of tests in diagnosis includes increasing or decreasing the probability of a 
particular condition being present, for staging or measurement of disease severity and for 
general examination for clues to the cause of symptoms (MSAC, 2005). An example of a 
diagnostic test is the Widal test used for the diagnosis of typhoid fever. To evaluate the potential 
value of a diagnostic test involves an assessment of its accuracy, how it influences diagnoses 
and therefore patient management, and ultimately how it improves outcomes relevant to the 
patient (see Fig 2-2). Summary statistics such as sensitivity, specificity, predictive values and 
likelihood ratios are all measures of test accuracy (Deeks et al., 2014). All of these terms are 




Screening involves testing asymptomatic patients to identify those people for whom further 
tests or treatments may be beneficial (Wilson and Jungner, 1968). Screening requires the use 
of accurate tests for early detection of conditions to allow for timely treatment and also the 
provision of information on risk to allow for efforts to modify the risk (Wilson and Jungner, 




2.3.3 Staging  
 
Tests performed for staging purposes are implemented with the objective of establishing how 
advanced or severe a disease is. Such tests are performed in persons already known to have the 
disease leading to the identification of the optimal intervention for them. Staging tests further 
classify diagnosed patients into sub-diagnoses groups (Deeks et al., 2014). Staging answers the 
question, ‘what stage of disease does the patient have’. An example of a staging test is the 
Oncotype DX test for breast cancer.  
 
2.3.4 Surveillance  
 
Tests performed for the purposes of surveillance are conducted to identify whether patients 
with established disease have progressed or regressed or had a recurrence. Detection of 
progression or recurrence may prompt changes in patient management. For example, patients 
who have received treatment for prostate cancer will have their prostate specific antigen (PSA) 
test measured to detect recurrence, and those with severe liver disease will have tests 
undertaken to assess progression of fibrosis.   
 
2.4 Test evaluation: what is the current focus? 
 
As previously described, the number of tests has been increasing rapidly over the past decade 
and is likely to increase further (Koffijberg et al., 2013), which is as a result of the valuable 
role they continue to play in health care delivery (Redekop, 2006). However, in an era of 
constrained government budgets and rising costs, this situation highlights the need for the 
proper evaluation of tests before their introduction into clinical practice. This will promote the 
adoption of innovative clinically and cost-effective tests. 
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Consequently, before a medical test is introduced in practice, payers, clinicians, policy makers 
and patients need information on the evaluative dimensions of the test. These evaluative 
dimensions include test performance (safety, analytical validity and reliability of the test), test 
accuracy (clinical validity; performance in ‘suspected disease’), clinical effectiveness, cost, 
and cost-effectiveness. Although it is expected that all these evaluative dimensions are 
completely assessed before the introduction of a test into clinical practice, in reality, this is not 
so with the evaluation of test accuracy (not test effectiveness) predominating in test evaluation. 
The evaluation of tests typically stops after quantifying the accuracy of the test compared to 
the prevailing reference standard (Koffijberg et al., 2013).  
 
2.4.1 What is test accuracy and how is it assessed? 
 
Test accuracy is defined as the proportion of subjects that the test correctly identifies as being 
positive or negative for the presence of disease (Van den Bruel et al., 2007). The two most 
commonly reported measures of test accuracy are sensitivity and specificity (Gazelle et al., 
2005). Summary performance characteristic measures include the diagnostic odds ratio and 
area under the receiver operator characteristic (ROC) curve (AUC) (Davenport et al., 2014). 
Other measures include positive and negative predictive values. In test accuracy studies, the 
results of the test under evaluation (index test), are compared with those of the reference 
standard (the most accurate currently available test) (see Fig 2-1 and Table 2-1) (Leeflang et 
al., 2008). Test accuracy is not fixed and may vary between patient subgroups and their 
spectrum of disease, the clinical setting, test interpreters and the result of prior testing (Leeflang 
et al., 2008). It is important to state that test accuracy is an explicit recognition that most tests 
































The information obtained using the above study design is then used to estimate the metrics for 
expressing test accuracy using the 2x2 table.  
 
The population and the 
problem 
A representative sample is 
required 
Study sample 
The intervention (s) 
The (index) test(s) Index test 
Index Test positive Index Test negative 
Reference standard Reference standard 
The outcomes 
The index test result 
verified by a suitable 
reference standard 



























A measure that allows us 
to determine the accuracy 
of the test 
Estimation of test accuracy 
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2.4.2 Metrics for expressing test accuracy 
 
Metrics for expressing test accuracy which as described in the previous section include, 
sensitivity, specificity and likelihood ratio, the diagnostic odds ratio, receiver operator 
characteristic (ROC) curve, positive and negative predictive values (Davenport et al., 2014). 
The information from a 2x2 table (Table 2-1) is used for calculating the measures of test 
accuracy. 
 









The sensitivity of a test is defined as the proportion of patients that have the target disease who 
test positive (Akobeng, A.K, 2006). It is calculated mathematically from the 2x2 table using 
the formula a/(a+c). If the estimated sensitivity is sufficiently high, the presence of disease is 
ruled out by a negative test result. A high sensitivity is particularly important if the consequence 
 Patients with target disease Patients without target disease 












TOTAL a+c b+d 
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of missing a disease has serious implications in terms of health outcomes for the patient and 




The specificity of a test is defined as the proportion of patients without the target disease who 
will test negative (Parikh et al., 2007). This can be calculated from the 2x2 table as d/(b+d). If 
the estimated specificity is sufficiently high, a positive result rules in disease. A high specificity 
is particularly important if a false positive result can harm the patient (i.e., harms due to 
treatment and associated costs). 
 
Advantage of sensitivity and specificity as an accuracy measure  
It allows for the full implications of test accuracy to be examined in model-based economic 
evaluation studies. That is, it allows for each of the different possible test results to be modelled 
explicitly (i.e., TP, FP, FN, TN). Sensitivity and specificity are not directly affected by 
prevalence of the target condition and thus the results from one study may be applicable to 
different populations (although they may vary by disease severity which may in turn vary with 
disease prevalence).  
 
2.4.2.3 Likelihood ratio (Positive Likelihood ratio (LR+) and Negative 
likelihood ratio (LR-)) 
 
A likelihood ratio estimates the probability of a test result (positive or negative) in patients 
with the target disease compared to those without the target disease (Thornbury et al., 1975). 
The positive likelihood ratio is defined mathematically as the probability of a “diseased” person 
testing positive divided by the probability of a “non-diseased” person testing positive. This is 
calculated as sensitivity/(1-specificity). The negative likelihood ratio is defined mathematically 
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as the probability of a “diseased” person testing negative divided by the probability of a “non-
diseased” person testing negative. This is calculated as (1-sensitivity)/specificity. 
 
A likelihood ratio greater than 1 increases the probability that the target condition is present 
whereas a likelihood ratio less than 1 decreases the probability that the target condition is 
present. A likelihood ratio of 1 indicates no change in the likelihood of disease and the test 
does not provide any useful diagnostic information.  
 
2.4.2.4 Diagnostic odds ratio (DOR) 
 
This is defined as “a measure of the odds of a positive test in those with the disease compared 
to those without the disease to show the association between a dichotomous test result and the 
diagnosis of the target disorder” (MSAC, 2005, p.49). The diagnostic odds ratio is calculated 
using the formula  
(sensitivity/(1-specificity))/((1-specificity)/specificity) or (LR+/ LR-).  
Estimates of diagnostic odds ratio ranges from 0 to infinity, with higher values indicative of 
better discriminatory test performance. A diagnostic odds ratio value of 1 indicates that the test 
does not discriminate between patients with or without the target condition.   
 
2.4.2.5 Receiver-operator characteristic (ROC) curve 
 
The ROC curve is a plot of test sensitivity (on the vertical axis) versus its false positive rate (1-
specificity on the horizontal axis) at different thresholds (MSAC, 2005). The ROC curve 
demonstrates the trade-offs between the sensitivity and specificity of the test. The area under 
the ROC curve is a useful measure of the overall accuracy of the test. Values for the area under 
the curve (AUC) range from 0 to 1. An AUC value of 1 indicates that the test is perfect and the 
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sensitivity and specificity of the test is 100% at each cut-off point. An AUC value of 0.5 
indicates that the test does not discriminate between the presence and absence of disease. 
  
2.4.2.6 Positive Predictive Value (PPV) and Negative Predictive Value 
(NPV) 
 
Positive predictive value represents the proportion of positively tested individuals who are 
diseased whereas negative predictive value represents the proportion of individuals with a 
negative test who do not have the disease. Although these are the most clinically informative 
measure of the accuracy of diagnostics, they are affected by prevalence of the target condition 
and thus cannot be readily transferred to different populations or pooled to produce a summary 
estimate (MSAC, 2005). PPV can be calculated from the 2x2 table using the formula a/ (a+b) 
and NPV is calculated using the formula d/(c+d). 
 
2.4.3 Measures of analytical validity 
 
The following describes the measures of analytical validity of a medical test: reproducibility, 
repeatability, precision and bias. 
 
2.4.3.1 Reproducibility and repeatability 
Reproducibility refers to the variation in measurements made on a subject under changing 
conditions (Bartlett and Frost, 2008). A valid statement of reproducibility requires specification 
of the conditions changed. The changing conditions may be due to different measurement 
methods or instruments being used, measurements being made by different observers, or 
measurements being made over a period of time (Bartlett and Frost, 2008). 
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Repeatability refers to the variation in repeat measurements made on the same subject under 
identical conditions (Bartlett and Frost, 2008). Thus, measurements are made by the same 
instrument or method, the same observer, and that the measurements are made over a short 
period of time over which the variable being measured can be considered to be constant. 
Variability in measurements made on the same subject in a repeatability study can then be 
ascribed only to errors due to the measurement process itself (Bartlett and Frost, 2008). 
  
2.4.3.2 Precision and bias 
A test method is said to be precise when repeated determinations (analyses) on the same sample 
give similar results (Schmidt, 2013). When a test method is precise, the amount of random 
variation is small. Precision is a function of random error and ‘balances out’ upon repetition 
(Schmidt, 2013). 
 
Bias is defined as a systematic difference in an observed measurement from the true value 
(Schmidt, 2013). In the context of test accuracy study, bias occurs when there is a systematic 
deviation from the true estimate of accuracy. If bias exists, a study would consistently 
overestimate or underestimate the true accuracy parameters if the study were repeated. Thus, 
bias is error that does not ‘balance out’ upon repetition (Schmidt, 2013).   
  
2.5 Moving beyond Test accuracy: evaluating how tests 
impact on patient health on test-treatment pathways 
 
Increasingly, decision makers, physicians and other users of medical tests request more than 
simple measures of test accuracy. They also want to know how testing leads to improved 
decision making and patient relevant outcomes, as well as the cost-effectiveness of testing to 
determine whether the test is good enough to use and represents value for money (Van den 
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Bruel et al., 2007). Moving beyond test accuracy, evaluation of tests should always be linked 
to the context of use (care pathway). This assertion supports the notion that tests are not neutral 
reporters of reality independent of context, rather, they are used in and are highly dependent 
on context (Matchar, 2012). Therefore, in order to establish the impact of a new test on relevant 
patient outcomes, it must be examined as part of a broader care pathway where the test is 
administered, and the test results are considered alongside other evidence to decide subsequent 
management decisions. It is only by considering this entire care pathway that the true value of 
a test can be determined, because changes to any stage of this pathway after the introduction 
of the test can impact on the outcomes experienced by patients (di Ruffano et al., 2012). The 
care pathway includes all the tests, decision making, and treatments associated with the use of 
the test both beneficial and harmful and their costs (NICE, 2011).  
 














Medical Test Medical Test 








An in-depth understanding of the care pathway is also relevant for the following reasons. The 
introduction of a new test into clinical practice could serve as either a replacement test, a triage 
test or an add-on test (Bossuyt et al., 2006). Identification of its role in an existing care pathway 
is crucial in test evaluation, as it will determine which characteristics the new test should have. 
This is very important, as depending on the role of a test and its place in a pathway, maximising 
either sensitivity or specificity might be more important. Furthermore, the application of tests 
is associated with a series of outcomes (Lee et al., 2010); categorised into those resulting 
directly from the test, the testing process or both (AHRQ, 2012). Therefore, an in-depth 
understanding of the care pathway is key to the identification and selection of the relevant 
outcomes necessary for the evaluation of the test (especially in modelling). An a priori 
statement specifying the proposed care pathway between test results, treatment decisions, and 
patient outcomes is useful in the identification of the intended test population and comparator 
test strategy (distinct from reference standard) in the test evaluation process. Delineating the 
care pathway also helps clinicians, the majority of whom have difficulties in understanding test 
accuracy metrics (Whiting et al., 2015) to make a link between test accuracy and patient 
relevant outcomes. An understanding of the care pathway is very important in test evaluation 
and therefore, should be a rigorous undertaking involving all the necessary stakeholders such 
as clinicians, experts, and patients. Existing and emerging clinical guidelines may also provide 
a good source of information for this purpose. 
 
2.5.1 Understanding the role of a test on the test-treat pathway 
 
As previously described, a new test introduced into clinical practice can serve as either a 
replacement test, a triage test, or an add-on test (Bossuyt et al., 2006). Its role in the care 
pathway should be clearly defined and stated in order to enable the assessment of the test in 
terms of its use in the specific context. 
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2.5.1.1 Replacement test 
 
A test intended to be a replacement test is expected to be at least one of: more accurate, less 
invasive, easier to interpret, quicker to yield results results compared to an existing test. For 
example, a replacement test could be of comparable accuracy, but its lower cost will make it a 
more cost-effective option.  
 
Study design 
To establish whether an index test can replace an existing test, it is important to compare the 
diagnostic accuracy of both tests. For a replacement test, a head-to-head comparison of the new 
and existing test is preferable, using a fully paired design (performing the new and existing test 
in each patient and comparing both to the reference standard) (Bossuyt et al., 2006). Indirect 
comparisons can also be conducted by randomly performing the new or existing test. Though 
indirect comparisons may be seen as a substitute to paired studies, they should be considered 
with great caution as the patient population, and reference standard should be the same in the 
studies that are being compared. Paired studies have the advantage of evaluating the two tests 
in the same patient group and it is also possible to use fewer patients (Bossuyt et al., 2006). In 
practice, head-to-head comparisons and RCTs are less common. Head-to-head comparisons 
may not be possible because of the burden to the patient of having to undergo more than one 
test. An example of where head-to-head comparisons are feasible would be comparison of 2 
blood tests. 
   
2.5.1.2 Triage test 
 
In triage, the index test is used prior to the existing test or testing pathway, and only patients 
with a particular result on the triage test continue the testing pathway (Bossuyt et al., 2006). 
Triage tests are used to reduce the number of people who undergo the existing test, for example 
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because the existing test is invasive, expensive, difficult to access. In terms of accuracy, a 
sensitive triage test would be used to rule out the target condition prior to testing with the 
existing test (triage test negatives likely to be TN and do not receive further testing; triage test 
positives receive the existing test). Conversely, a specific triage test would be used to rule in 
the target condition and only negative triage test results would receive the existing test.  
 
Study design 
A test used for the purposes of triage does not aim to improve the accuracy of the current testing 
pathway. Rather it reduces the use of existing tests that are more invasive, cumbersome or 
expensive. Several designs can be used to compare the accuracy of the triage strategy. In a fully 
paired study design, all patients undergo the triage test, the existing test and the reference 
standard. As the primary concern is to find out whether disease will be missed and how efficient 
the triage test is, one option is to use a paired design and verify the results only of patients who 
tested negative on the triage test but positive on the existing test. This will identify patients in 
whom disease would be missed if the triage test is used as well as patients in whom the existing 
test can be avoided. 
 
2.5.1.3 Add-on test 
 
A test may be used as an add-on test as part of a clinical pathway if combination of 2 tests is 
more accurate than the accuracy of one test alone. For example, one test might have sensitivity 
greater than specificity and the add on test specificity greater than sensitivity for the target 
condition. Any increase in accuracy of add-on must be balanced against increased burden of 
testing for patient. Consequently, its application is reserved for specific patient subgroups in 
which the test is deemed a final resort. When a test is to be used as an add-on test, its necessary 
test characteristics depends on its goal. If the goal is to increase the number of patients to 
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receive treatment, then a high sensitivity is needed whereas if the goal is to increase the number 
of patients in which treatment is to be withheld, then a high specificity is required. 
 
Study designs 
More efficient methods with complete verification can be used to evaluate the effect of the add-
on test diagnostic accuracy. For example, evaluating the accuracy of the existing test plus add-
on test versus existing test alone. The difference in accuracy between the existing test testing 
strategy and the add-on test will depend exclusively on the patients who are positive on the 
add-on test. A study could therefore be limited to patients who were negative after the existing 
test but positive with the add-on test with verification by the reference standard. This design 
allows for the calculation of the extra true positives and false positives from using the add-on 
test.  
  
2.6 The concept of economic evaluation 
 
Economic evaluation is defined as “the comparative analysis of alternative courses of action in 
terms of their cost and consequences” (Drummond et al., 2005, p.9). Economic evaluations 
primarily seek to identify, measure, value and compare competing alternatives. Central to 
economic evaluation is the concept of opportunity cost (Morris et al., 2012). That is, by 
choosing to deploy resources to one use, the benefits of using those resources in their next best 
alternative are forgone. Therefore, it is important that health care resource allocation decisions 
are made such that there is value for money (WHO, 2000). Increasingly, economic evaluations 
are being used as a valuable tool in health care resource allocation both more explicitly and 
scientifically based, worldwide. 
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2.6.1 Types of economic evaluation 
 
There are five types of economic evaluation (Morris et al., 2012). These are: cost-benefit 
analysis (CBA), cost-effectiveness analysis (CEA), cost-utility analysis (CUA), cost-
consequence analysis (CCA) and cost-minimization analysis (CMA). These can be further 
categorized into partial economic evaluation methods (CCA and CMA) and full economic 
evaluation methods (CBA, CEA and CUA). In full economic evaluations, both cost and 
benefits are compared between two or more interventions. Partial economic evaluations 
consider costs and/or benefits, but either do not involve a comparison between competing 
interventions or do not relate costs to benefits. It is important to state that unlike full economic 
evaluations, partial economic evaluations do not provide information on efficiency (Morris et 
al., 2012). The main difference between the three types of full economic evaluation methods 
stems from the way benefits are measured and valued. In all three methods, cost is measured 
and valued in monetary terms. CEA measures benefits in terms of natural health outcomes 
(Jackson, 2012). For example, in terms of lives saved, complications avoided, symptom free 
days and ulcers avoided. CEAs are used to compare programmes with similar outcomes and 
the results are presented in cost per unit effect. For example, cost per successful typhoid 
treatment. Like any method, CEA has its own limitations. The use of a uni-dimensional 
outcome measure can be problematic because the total effects of a treatment may not be 
reflected in any one outcome measure and results cannot be compared when outcome measures 
are different. This may lead to inaccurate conclusions on the relative worth of the competing 
alternatives under investigation (WHO, 2000). 
 
In CUA, benefits are measured in terms of quality-adjusted-life years (QALYs) gained or 
disability-adjusted life years (DALYs) averted (Kind et al., 2009; Murray et al., 2012). CUAs 
are used when health-related quality of life is the main outcome, interventions affect both 
 27	
mortality and morbidity and the interventions affect a wide range of outcomes, but a single unit 
of comparison is required (Drummond et al., 2005). CUAs are presented in cost/QALY gained 
or cost/DALY averted. The limitation of this method of analysis as argued by some health 
economists is the implicit assumption that a “QALY is a QALY” regardless of who accrues it. 
However, as shown by Tsuchiya and Dolan (2009), society places different weights on QALYs 
gained across different population groups and thus “a QALY is not a QALY” regardless of 
who accrues it. 
 
CBA attempts to measure benefits in monetary terms, thus, it is possible to determine whether 
the benefits of an intervention justify the cost. CBA is broader in scope than CEA and CUA. 
CBAs are presented in terms of net benefit (i.e., benefits minus cost). Its appeal over the other 
forms of analyses is that it provides a stronger basis for implementing an intervention or not 
because it can be seen whether the monetary value of benefits outweighs the cost (WHO, 2000). 
However, the limitation of CBA is that measuring and valuing benefits in monetary terms can 
be problematic. 
 
It is worth stating that the three forms of full economic evaluation discussed above lend 
themselves to different decision rules. The choice to use a particular method of analysis should 
be made such that it is appropriate to the question(s)/objective(s) being addressed in the study. 
CEA and CUA seek to address technical efficiency questions. That is, seeking the best 
alternative that achieves a desired outcome at a minimised cost. Drummond et al (2005) puts 
it this way, “both CEA and CUA are techniques that relate to constrained maximisation; that 
is where a decision-maker is considering how best to allocate an existing budget” (Drummond 
et al., 2005, p.15). Whereas, CBA recommends choosing the alternative with the greatest net 
benefit. 
 28	
2.6.2 Conducting economic evaluations 
 
Economic evaluations are conducted in two main ways. They are either conducted alongside 
randomised controlled trials or they are conducted using decision analytic modelling. In trial 
based economic evaluation, cost and effectiveness data are collected simultaneously as the trial 
is being undertaken (Petrou and Gray, 2011). The advantages of doing this are that, it provides 
the opportunity for the researcher to collect data on resource use and cost pertaining to each 
patient in a study which may not be available at any other time and also, the cost of collecting 
economic data may be modest because it will be collected at the same time the trial is being 
conducted (Johnston et al., 1999).  Despite these advantages, economic evaluations conducted 
alongside RCTs have limitations such as atypical patients/setting, truncated time horizons and 
limited comparators (Drummond et al., 2005). Decision analytic modelling is defined as “an 
analytic methodology that accounts for events over time and across populations, that is based 
on data drawn from primary and/or secondary sources, and whose purpose is to estimate the 
effects of an intervention on valued health consequences and costs” (Weinstein et al., 2003, pp. 
10). Decision models can be used to structure the economic question and compare all relevant 
alternatives, extrapolate beyond observed data, link intermediate and final endpoints, 
generalize results to other settings and synthesise evidence and facilitate head-to-head 
comparisons where RCTs are not feasible (Drummond et al., 2005). The are two main types of 
models used in model-based economic evaluations namely: static and dynamic models. Static 
models used in health economics implicitly assume that the probability of disease exposure is 
constant over time and unaffected by interventions. For transmissible infectious diseases, this 
is not realistic and requires the use of dynamic models which allows for the explicit inclusion 
of transmission in the analysis (Lugner et al., 2010). There are two main types of static models 
namely: decision tree and Markov model. Decision trees are used for ‘one-off’ decisions and 
are particularly suited to acute care problems, once-only diseases and short term diagnostic or 
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screening decisions. Markov models represent disease processes which evolve over time, are 
suited to modelling the progression of chronic disease, can handle recurrence and can estimate 
long term costs and life years gained.     
The concept of the economic evaluation is widely known for its application in the evaluation 
of pharmacological interventions and usually at the late phase of product development (Morris 
et al, 2012). Its application to medical tests is relatively new (including its application to tests 
at the early phases of development). Despite the increasing advocacy by many agencies that 
economic evaluations are best conducted alongside randomised controlled trials, this is not 
entirely the case in the cost-effectiveness analyses of medical tests. The reason is that test-treat 
randomised controlled trials capturing the downstream health outcomes arising from decisions 
made based on the test results are not feasible and are rare (Lord et al., 2009). Hence, decision 
analytic models are advocated as the most systematic and transparent method for the economic 
evaluation of medical tests to provide evidence on clinical and cost-effectiveness in the absence 
of test-treat RCTs (Trikalinos et al., 2009). 
 
2.6.3 Decision analytic modelling of test-treat strategies: uses and 
issues 
 
The following sections describe the uses and the issues associated with decision analytic 
modelling.  
 
2.6.3.1 Uses of modelling in test-treat pathways 
 
Evidence of test performance, treatment effectiveness and the prevalence of disease are 
reported in different studies across different populations and settings. Modelling provides a 
means of integrating this evidence from all these studies in a given setting to demonstrate 
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clinical effectiveness of a test. Furthermore, modelling allows for assumptions and 
uncertainties in key input parameters to be dealt with in sensitivity analyses to test the 
robustness of results when evaluating the clinical and cost-effectiveness of tests (Pauker and 
Kassirer, 1987). The application of all tests is associated with benefits, harms and cost and 
decision analytic modelling allows for such trade-offs to be assessed to aid in decision-making. 
Furthermore, modelling provides a framework for comparing multiple test-and-treat strategies 
and it also allow for exploring hypothetical conditions for diseases with no effective treatment 
by estimating under what conditions it would be worthwhile to employ such a test (Trikalinos 
et al., 2009). Decision models also provide the appropriate framework to extrapolate beyond 
trial evidence to a longer, more appropriate time horizon. 
 
2.6.3.2 Modelling challenges faced in the evaluation of tests 
 
Despite the advantages of using modelling in test-treatment pathways, it also has some 
challenges. There are challenges with insufficient/unreliable data, transferability of test 
performance across studies, choice of outcomes to model, and the parameterization of a model. 
 
Issues with insufficient data 
Excluding cost from this consideration, there are generally three main groups of important 
input parameters modelled in test-treat strategies (Trichinosis et al., 2009). These are 
prevalence of the disease in the setting of interest, test performance and the benefits and harms 
associated with the test-treat pathway. Problems arise when there is insufficient or unreliable 
data pertaining to any of these important input parameters as this can lead to an under or 
overestimation of incremental cost-effectiveness ratio resulting in the misallocation of scarce 
health care resources. Obtaining valid prevalence data especially for a particular setting or 
subpopulation is challenging but very important because prevalence significantly impacts on 
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the positive and negative predictive values of testing. Using unreliable or insufficient data on 
test performance can greatly affect estimates of sensitivity and specificity employed in 
modelling, which can consequently result in wrong estimates leading to a misallocation of 
scarce resources. Insufficient or unreliable data on treatment effectiveness would obviously 
also limit the validity of modelling results obtained on the clinical effectiveness of a test.  
 
Issues with non-transferability of test performance data across studies 
 
Estimates of sensitivity and specificity used in making calculations possible in models are often 
borrowed across studies. However, studies of test performance are not always performed in the 
setting of interest (Irwig et al., 2002), do not always evaluate the comparative accuracy of the 
test in its anticipated role (Bossuyt et al., 2006), and can evaluate the accuracy of different 
versions of the same test (Trikalinos et al., 2009). Hence transferring performance estimates 
across studies is problematic if no judgement calls are made on the appropriateness of these 
estimates before using them. Thus, because sensitivity and specificity are often considered not 
to be directly affected by prevalence of the target condition, these are frequently applied across 
settings with different prevalence estimates (Trikalinos et al., 2009). The challenge here is that 
differences in the inclusion criteria of different studies can result in spectrum effects 
(differences in the sensitivity or specificity of a diagnostic test according to the patient 
characteristics or disease features) hence highlighting the need for careful consideration when 
transferring test performance estimates across studies. Depending on the intended role of a 
medical test on the care pathway, the accuracy of the test is determined in that specific context. 
Therefore, one has to be careful when transferring performance estimates across studies that 
evaluate the test in different roles because performance estimates may differ depending on the 
intended role of the test. Ignoring this and generalizing estimates of test performance will lead 
to estimates that are not a true representation of the real value of the test under evaluation. 
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Furthermore, test performance can differ for different versions of the same test, thus when 
transferring test performance modellers should consider whether it is for the same version of a 
test or not, as using different estimates can provide misleading conclusions and have negative 
consequences on policy decisions.     
 
Issues with the choice of relevant outcomes to be modelled  
 
A key issue for trials and decision models is the selection of outcomes that need to be measured 
or modelled to evaluate how tests are affecting patients (di Ruffano et al., 2012). Key outcome 
categories include clinical management outcomes, direct health effects, emotional, social, 
cognitive and behavioural responses to testing (Bossuyt and McCaffery, 2009) and 
intermediate outcomes (diagnostic test accuracy statistics). In order to comprehensively 
evaluate the value of diagnostics, the full range of outcomes associated with their use should 
be examined and selected based on their effect on the care pathway. If the full range of 
outcomes is not explored from the outset, the likelihood of excluding important outcomes is 
high. Consequently, recommendations made about tests may not be appropriate in those 
circumstances. Some useful suggestions have been made for choosing relevant outcomes and 
a two-stage approach has been proposed (AHRQ, 2012). The first stage is to list outcomes 
methodically and the second stage is to solicit input from stakeholders. At the first stage, 
outcomes can be separated into those attributable to the testing process and those attributable 
to knowledge of the test results. Outcomes attributable to the testing process are the direct 
effects of testing whereas outcomes attributable to the test results are numerous and include the 
patient’s response to the test results and how patients and clinicians act upon the results. The 
relative importance of these outcomes varies depending on the intended purpose of the test 
(screening, diagnosis or prognosis) and researchers should be aware of this in order to aid in 
their selection of outcomes. For example, the adverse emotional effects of testing will be more 
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significant for screening tests than for diagnostic tests due to the high proportion of false 
positive test results associated with many screening tests. 
 
Issues with incorporating the value of testing unrelated to treatment effects 
 
An important yet most overlooked subject in the assessment of the value of diagnostics is the 
value of testing unrelated to treatment effects. Many studies evaluating the value of diagnostics 
using the conventional cost-effectiveness analysis framework have typically valued diagnostics 
at the extent to which they improve medical decision making and outcomes directly related to 
treatment effects (Lin et al., 2013). This is worrisome because patients’ perceptions of testing, 
their experience of the testing process, and their understanding of test results can all affect 
downstream health. Asch et al. (1990) observed that clinical impact alone is an insufficient 
measure of value for diagnostics because diagnostics also have the potential to affect patients’ 
psychological wellbeing whether or not they affect treatment. For example, a test for dementia 
may have relatively little impact on treatment or outcomes but may have substantial effects on 
a patient’s psychological wellbeing (Lee et al., 2010). Furthermore, a genetic test that can 
determine with certainty whether one would eventually contact Huntington’s disease may be 
considered to have little value from the medical perspective because it does not affect 
treatment. However, it could be highly valued by a patient concerned with childbearing if she 
is at high risk for the disease based on family history. Patients may value or have preference 
for test information unrelated to treatment effects even in the absence of immediate treatment 
(Neumann et al., 2010). A study by Schwartz et al. (2004) in the USA found that 87% of adults 
favoured cancer screening. Neumann et al (2010) also found that most respondents were 
willing to take tests predictive of future cancer, Alzheimer’s disease, and arthritis. In both 
instances, tests were favoured even though the respondents were made aware from the outset 
that there were no immediate treatments available after testing. Their preference stems from 
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several reasons. Test information may reduce uncertainty and provide reassurance, assist in 
life-planning decisions and enable them to live differently (Lin et al., 2013). Clearly, patients 
may value test information even when it does not lead to changes in treatment. 
 
Incorporating the value of testing unrelated to treatment effects into economic evaluations 
could significantly impact on estimated benefits and their allocation. These effects of testing 
could accumulate to outweigh any clinical benefits of testing or may bring additional benefits 
adding to the clinical effects of testing (Bossuyt and McCaffery, 2009). Despite the potential 
impact of the value of testing unrelated to treatment effects, it has typically not been included 
in previous economic evaluations. This may be because collecting such information is seen as 
an expensive and time-consuming endeavour, its value may be considered too small to have a 
meaningful impact on the assessment, researchers are simply unaware of these effects, and 
there are methodological complexities associated with their measurements (Lee et al., 2010). 
Failure to recognise the importance of “patient preference” for test information unrelated to 
treatment effects runs a risk of under or overestimating the true value of tests, leading to a 
misallocation of scarce health resources. As the number of new diagnostics proliferates, this 
issue will only become widespread.  
 
Issues with model parameterization 
 
Although models are considered a simplified representation of what occurs in the real world 
(Trikalinos et al., 2009), they should be comprehensive enough to capture all the necessary 
components of the simulated situation. Parameterization of a model should always be done 
based on an in-depth understanding of the real-world situation (care pathway). The challenge 
here is that, modellers might not be intimately familiar with the intricacies of the topic area and 
getting clinicians (or experts) in the field to verbalise the diagnostic decision-making process 
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and the wider care pathway more generally can be difficult. The result is that modellers might 
miss important information that should be included in the model structure and parameterization 
and hence generate results that are not very representative of what happens in real life. Such 
situations can lead to a misallocation of scarce health care resources highlighting the need for 
further work to be conducted in this area.  
 
2.7 Economic evaluation of medical tests at the early phases 
of development 
 
Figure 2-3 shows the various phases on the medical technology innovation pathway and the 
stages at which economic analyses are conducted (i.e., early and late phases). The early phase 
of development is categorized into two stages: the concept stage and, the early development 
stage. The concept stage is primarily the discovery and ideation phase. At this stage, the product 
is still hypothetical and in the case of medical tests, there is no available data on test parameters 
(e.g. accuracy, cost, etc.). The early development phase occurs between the equivalent of phase 
I clinical trials of drugs and the end of the concept stage. During this stage, certain test 
properties are assessed, and some form of experimental data may be available. 
 
Typically, economic evaluations are conducted at the late stage of product development 
(Pietzsch and Paté-Cornell, 2008). For example, they may be done after Phase III of drug trials 
(Figure 2-3). The rationale is that this is the point at which there would be enough data on the 
product for its proper evaluation (Drummond et al., 2005). In the case of medical tests, it is 
expected that at this point test performance, test accuracy and clinical effectiveness would have 
been assessed. Test performance can be assessed at the preclinical stages, test accuracy in 
phases I and II, and clinical effectiveness in phases III and IV (Figure 2-3). Coverage and 
reimbursement decisions are therefore typically made on medical tests at the late phase of 
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development when a substantial amount of resource has already been committed to their 
research and development. This implies that any negative coverage and reimbursement 
decisions made on a test at this point would lead to no returns on investment and a loss being 
incurred (loss to manufacturers; opportunity cost for research; and inefficient use of resources 
allocated to Health Technology Assessment). Typically, advances in medical testing 
technology occur more frequently than for drugs (NICE, 2011). Therefore, leaving an 
economic evaluation to late stages of development may make any new findings redundant. 
Thus, there is now a growing interest in the economic analyses of medical tests at their early 
phases of development by investors, innovators, and policy makers, to identify their potential 
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2.7.1 Early economic evaluation: definition and characteristics 
 
The early economic evaluation of a medical technology is defined as an iterative economic 
evaluation process to assess its economic value and likely impact (Buisman et al., 2016) at a 
time where it can still be considered experimental or emerging (Hartz and John, 2009). In the 
case of medical tests, this is usually from the concept stage up to stage I clinical trials 
(Markiewicz et al., 2014). Early economic evaluation provides useful information that can 
inform investment and design decisions under conditions of high uncertainties before the 
clinical performance of the test is actually established (Pietzsch and Paté-Cornell, 2008).  
 
A key characteristic of early economic evaluation is the use of limited data, which is associated 
with increased uncertainty (Tappenden et al., 2004; Tuffaha et al., 2014). Value of information 
(VOI) analysis is recommended when there is considerable amount of uncertainty associated 
with data (as will be the case for early economic evaluations) (Briggs et al., 2006). VOI analysis 
is recommended because it is an important tool that decision makers can use to decide whether 
the available evidence used in an analysis is sufficient or not to fund the further development 
of a test. It can also be used to identify specific areas where further information is needed to 
decide on further development decisions (Chen and Willan, 2014). This will ensure the 
efficient use of limited resources and potentially assist to avert investing in a test that is not 
economically viable. Evaluating the potential value of any new technology at its early stage of 
development would require the use of models because of the lack of data describing its 
effectiveness during its early stages of development. Models are associated with the ubiquitous 
existence of uncertainty in their structure and model parameter estimates. This situation 
highlights the need to include sensitivity analysis in early economic evaluation to test the 
robustness of parameter estimates, determine the range of parameters which have the greatest 
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impact on cost-effectiveness, and determine how sensitive the results are to changes in model 
structure (Morris et al., 2012). 
 
Another key issue in early economic evaluation is the “maximum cost” at which the new testing 
strategy is still cost-effective at a given willingness-to-pay (WTP) threshold. This “maximum 
cost” is known as the headroom (McAteer et al., 2007). In the headroom paradigm, the price 
at which the net monetary benefit of using the new technology equals the net monetary benefit 
of using the comparator technology is the headroom price. The estimated headroom provides 
valuable information that would guide decision making on the feasibility of further product 
development (in this case further test development). Thus, its consideration at the early stages 
of development especially the concept stage will promote the efficient use of limited resources. 
The decision rule in the headroom paradigm is that, if the estimated headroom is too low and 
realistically it is not possible to develop the new technology below this price, resources should 
not be committed to its further development. The WTP threshold at which the headroom of the 
new technology is determined is informed by the country within which the product will be 
adopted for use. For example, a new technology intended for use in the UK will be assessed at 
the WTP threshold of £20-30,000 (McCabe et al., 2008). 
.  
2.7.2 Early economic evaluation of medical tests: importance to 
decision makers and innovators 
 
Economic evaluations conducted at the early phases of medical test development have 
potentially profound advantages for both decision makers and innovators. For decision makers, 
results of an early economic analysis could help allocate limited budgets more efficiently by 
identifying which tests to fund for further development, and which tests to reimburse on 
condition of further data collection (known as “coverage with Evidence Development” as 
 40	
practiced in the USA and UK) (Hartz and John, 2009). Furthermore, early economic analyses 
studies speed up decision making regarding test adoption in the late phase of development, and 
support the management of test diffusion through “horizon scanning”: the early identification 
of new economically viable medical devices (Hartz and John, 2009). For innovators, early 
economic evaluation helps to estimate the maximum cost of a new test and the minimum test 
performance required for the test to be cost-effective at a given willingness-to-pay threshold. 
In addition, it provides valuable information for making decisions on further test development 
(Grabowski, 1997), designing and managing reimbursement strategies, setting realistic 
performance-price goals and guiding decisions on resource investment in the test development 
process (Hartz and John, 2008). Clearly, early economic evaluation of medical tests has 
profound advantages for both decision makers and innovators and has become increasingly 
important as there is the demand to demonstrate value for money (Buisman et al., 2016).   
 
2.7.3 The similarities and differences between early and late health 
technology assessment (HTA) 
 
The similarities and differences between economic evaluations conducted at the early and late 
phases of a medical test development are summarised in Table 2-2 below. It provides 
information on the aims, the level of evidence used and how early and late HTA assessments 







Table 2-2 Similarities and differences between early and late HTA   
 
 
 Traditional HTA Early HTA 
Aim To evaluate the safety, effectiveness and cost-
effectiveness of a new medical technology 
To evaluate the potential safety, 
effectiveness and cost-effectiveness of a 
new medical technology 
Decision 
support 
To support payers, regulators and patients on payment, 
clearance and test usage decisions respectively 
To support innovators and investors on 
decisions of further development, 




Clinical studies of new technology Earlier version of the medical technology, 




Normally does not influence the clinical performance 
of the technology although it can occasionally have 
limited influence   
It can potentially influence greatly the 










2.8 Medical testing in resource-limited countries  
 
Despite the potentially valued role medical tests continue to play in health care delivery 
worldwide, many of these tests are centralised, need highly trained staff and specialised 
facilities, are generally expensive and require skilled technicians for their regular maintenance 
(Drain et al., 2013). This has resulted in standard laboratory tests being cost prohibitive and 
inaccessible in resource-limited countries leading to avoidable morbidity and mortality from 
ailments that would have otherwise be easily treated (Peeling et al., 2010). In recognition of 
this disparity, the World Health Organisation (WHO) and other agencies have called for new 
diagnostic methods that can function in resource-limited settings (Urdea et al., 2006). This is 
because it has been estimated that more than 1.2 million deaths each year could be prevented 
in resource-limited countries through the deployment of rapid diagnostic laboratory 
independent tests for only four infections; syphilis, tuberculosis, bacterial pneumonia and 
malaria (RAND Corporation, 2007). For these tests to be useful in these settings, they have 
been accurate and available with a quick turnaround time that has enabled prompt 
implementation of appropriate effective therapy. There are studies that have demonstrated 
“value for money” of rapid diagnostic testing in resource-limited settings (Ansah et al., 2013; 
Hansen et al., 2015; Mallma et al., 2016). It is therefore not surprising that there has been an 
increase in the popularity and potential application of rapid diagnostic laboratory independent 
testing in resource-limited countries (Schito et al., 2012). Despite this increase, priority setting 
regarding test evaluation and development is not effective and does not reflect priorities in 
individual countries (Odame, 2013; Schroeder et al., 2015). Consequently, some disease areas 
that pose serious public health threats and increasing cost to health care systems are neglected. 
One such neglected disease is typhoid fever (which is the case in the resource-limited country 
Ghana) (Wain et al., 2015).  
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2.8.1 Typhoid testing in Ghana and related issues 
 
Typhoid fever is an acute infection caused by the bacteria Salmonella typhi and paratyphi 
(incubation period 3-60 days) (WHO, 2003). Humans serve as the only natural host and 
reservoir for the causative organisms. Transmission is via the consumption of food or water 
contaminated with the pathogens and not direct person-to-person (Akullian et al., 2015). 
Typhoid fever remains an important cause of disease worldwide, but particularly in resource-
limited countries (Keddy et al., 2011), because of inadequate diagnostic laboratory capacity to 
differentiate typhoid fever from other febrile conditions (Wain et al., 2015), and poor hygiene 
practices (Tilahun et al, 2017). In Ghana, of a population of about 29 million, the population 
with adequate sanitation facility access is, total: 14.96%, urban: 20.2%, rural: 8.6% and 
inadequate sanitation facility access is, total: 85.1%, urban: 79.8%, rural: 91.4% (CIA, 2015). 
Thus, the country is high risk for typhoid fever. Once ingested, Salmonella typhi multiplies and 
spread through the blood stream to all organs. Typhoid fever can be a serious illness with 
symptoms usually developing between 1-3 weeks after ingestion and may be mild or severe 
(WHO, 2003). The symptoms of typhoid fever include high fever, fatigue, weakness, stomach 
pains, constipation or diarrhoea and loss of appetite. In some cases, patients have rose-coloured 
spots on the chest, enlarged spleen and liver (GNDP, 2014). If left untreated, intestinal 
perforation with peritonitis may occur, resulting in a sudden drop in blood pressure leading to 
shock and death. Acute psychosis and severe intravascular haemolysis leading to acute renal 
failure may also occur. Typhoid fever is associated with an estimated case fatality rate of 
approximately 1% with prompt appropriate antimicrobial therapy but approaches 30-40% after 




2.8.2 What are the issues of concern with typhoid testing?    
 
In Ghana, there are issues of concern with the diagnosis of typhoid fever such as delays in 
diagnosis, concerns about the accuracy of current tests, and lack of availability (see Chapter 1, 
p.1-2). All of which highlight the need for the development of a rapid, accurate and easily 
accessible diagnostic test in Ghana. 
 
The availability of such a test will improve prompt diagnosis of typhoid fever, promote rational 
and judicious antibiotic prescribing practices by health professionals in Ghana (which is a 
major cause of drug resistance), and provide accurate surveillance data on disease burden that 
will aid in monitoring and preventing outbreaks. Furthermore, the availability of such a test 
can save the Ghanaian economy huge sums of money reimbursed for the unnecessary treatment 
of typhoid fever in patients without the disease, and treatment of patients with complications 
of typhoid fever because of delayed or overlooked diagnosis. Furthermore, monies that would 
be spent during outbreaks or on the research and development of effective treatments for 
resistant strains can also be saved and used in other disease areas to improve the health and 
well-being of Ghanaians. The added benefit of testing in this area cannot be relegated to the 
background because of the serious implications it has both on the health of Ghanaians and on 
the economy of Ghana. This has resulted in the urgent need to develop a cost-effective rapid 




Having discussed the relevant issues, concepts and principles that relate to the topic area, 
highlighting the need for the development of a rapid diagnostic test kit for typhoid fever in 
Ghana, the next chapter (Chapter 3) is focused on examining how early economic evaluations 
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of medical tests have been conducted to date. This helps to gain greater insight into the 
methodologies and tools that have been employed in early evaluations of medical tests and 
thereby ensure that the most robust methodologies are adopted in the evaluation of the 
hypothetical test described in Chapter 6.  
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Chapter 3: Economic evaluation of medical tests at 
the early phases of development: a systematic review 
of empirical studies 
 
This chapter focussed on examining the methodologies and tools that have been employed in 
early economic evaluation studies of medical tests to answer the question, how have economic 
evaluations conducted during the early phases of test development been done to date, and can 
any lessons be learnt from them? This chapter seeks to provide a greater understanding of the 
methodologies and tools that have been employed in early evaluations of medical tests and to 




There is an increasing demand to demonstrate value for money in health care systems 
worldwide and early economic evaluations are becoming increasingly important in this regard. 
As discussed in Chapter 2, early economic evaluations of medical tests have potentially 
profound advantages for both decision makers and innovators and their relevance in decision-
making cannot be ignored. As a result of their role in promoting efficiency, there is now 
increasing interest in the economic analysis of medical tests at the early phases of development. 
However, despite this increasing interest there is little specific guidance on its implementation 
(Buisman et al., 2016). Early economic evaluations are more iterative in nature, are conducted 
at a time when there is a lack of data, and thus, are associated with increased uncertainty 
compared to late economic evaluations. This is further compounded by the increased 
uncertainties associated with mapping clinical pathways in test evaluation (see Chapter 1, p.3). 
These differences suggest that the methods used in economic evaluations conducted at the late 
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phase of medical test development are not applicable and need modification for use at the early 
phases.  
 
3.2 Study aim and objectives  
 
The aim of this systematic review was to examine the methodologies and tools that have been 
used in previous early economic evaluation studies of medical tests. Specifically: 
1. To gain a greater understanding of how the problem of insufficient data for model 
parameterization has been managed. 
2. To understand whether and how testing pathways have been modelled. 
3. To explore whether sensitivity analysis has acknowledged the uncertainty that accompanies 




For this systematic review, the following databases were searched for studies published from 
inception to July 2016. No language restrictions were applied. 
1. Cochrane Library (CENTRAL) 
2. Medline 
3. EconLit 
4. Centre for Reviews and Dissemination [Database of Abstracts of Reviews of Effects 
(DARE), Heath Technology Assessment (HTA), and NHS Economic Evaluation 
Database (NHS EED)] 
5. Health Management Information Consortium (HMIC) 
6. Excerpta Medica dataBASE (EMBASE) 
Internet searches were also conducted (e.g., Google scholar and the websites of relevant 
organisations related to innovations in health care such as EuroScan). This was done to identify 
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any grey literature and references missed by the database search. The nature of early economic 
evaluations means that they are less likely to be published. Therefore, seven medical 
technology companies were contacted to identify evaluations that have not been published to 
complement the literature review. A reference search was undertaken by scanning the 
bibliographies of the relevant articles finally included in the review for additional relevant 
articles. The reference management software Endnote was used to manage the list of articles. 
 
3.3.1 Search terms 
	
The search strategy was customized for each database. A combination of MESH terms and 
index terms were used as shown in Table 3-1 below. To ensure that all relevant studies on the 
topic area were retrieved, the search strategy was piloted after it was developed in consultation 
with an information specialist. The complete search strategy including how all the different 













Table 3-1 Question elements and terms used for searching 
Question element   Terms used for searching 
Time (early) aspect of the search new or novel or emerging or innovati* or early 
earl* or mid* or develop* or formative* or determinative* or 
design* or concept* or investigation*) adj2 (phase* or stage* 
or process* or "life cycle" or lifecycle)  
nascent or original or "ground breaking" or groundbreaking or 
promising or "cutting edge" or "cutting-edge" or seminal or 
"recently introduced") 
 early adj3 (valuation* or evaluation* or assessment* or 
model*) 
(early-stage adj3 (valuation* or evaluation* or assessment* or 
model*)).  
early adj2 (economic or estimate*) 
Economic evaluation aspect of the search models, economic/ or models, econometric/ 
(headroom or "head room"). markov chain/, Decision Trees/, 
decision support techniques/, (discrete event* adj8 model*), 
(decision* adj5 model*), (model* adj5 markov*), (econom* 
or cost or costs) adj model*), decision making/, cost benefit 
analysis/, technology assessment, biomedical/  
Medical test aspect of the search test*, exp "diagnostic test"/, exp screening/, exp prognosis/, 








3.3.2 Inclusion criteria 
	
A primary study was deemed potentially relevant to be included in the review if:  
1. It was an economic evaluation (CEA, CUA, CBA, CCA or CMA) conducted at the early 
phases of development (early phase as defined in Chapter 2, p. 38); and 
2. The evaluated technology was a medical test or series of tests used together (at least one 
test needed to be present in at least one arm of the analysis); and 
3. A decision model was used in the analysis. 
 
3.3.3 Exclusion criteria 
	
Studies were excluded from the review if they were: 
1. Trial protocols or commentaries; or 
2. Letters or editorials.  
 
3.3.4 Selection of articles for the review 
	
After the removal of duplicates, a two-stage approach to article selection was used. The first 
stage involved screening of abstracts and titles to identify potentially relevant articles whilst 
the second stage involved screening of the full text articles. The screening process was 
undertaken by two reviewers (S.F and P.B) independently and any disagreements regarding 
eligibility were resolved using the opinion of a third reviewer (C.D) where necessary. The 
screening process during both stages was conducted against the inclusion and exclusion 





3.3.5 Data extraction 
	
A data extraction form was developed in Excel and piloted. Then data extraction was conducted 
for each study included in this review to answer the following questions: 
1. How was the problem of insufficient data for model parameterisation managed? 
– What sources (type) of data were used? 
– Was the source (type) of data used influenced by the stage of evaluation? 
2. Modelling of testing pathways 
– What was the type of model used in modelling disease progression and the testing 
pathways (e.g. decision tree, Markov)? 
– Were test accuracy and all possible test results considered (i.e. true positives (TP), true 
negatives (TN), false negatives (FN), and false positives (FP))? 
– Were all the issues on the test-treat pathway that may be important to patients included 
in the analysis (e.g., personal costs incurred when accessing testing, effect of testing 
pathway on quality of life, value of knowing)? 
– Did the analysis include headroom analysis, and at what stage of the analysis was it 
included? 
3. Uncertainty 
– Was the uncertainty that accompanies early modelling acknowledge in sensitivity 
analysis? 
– Was value of information (VOI) analysis conducted? 
 
3.3.6 Quality assessment 
	
The methodological quality of included studies was assessed using a 10-point checklist for 
economic evaluations (Drummond and Jefferson, 1996). Table 3-2 below shows the quality 
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assessment tool employed in the study. A score was assigned based on how well criteria were 
met; scores of 1, 0.5 and 0 were assigned to “yes”, “cannot tell” and “no” respectively. Thus, 
each study scored from worst (0) to best (10) (Gonzalez-Perez, 2002). However, because the 
focus of this systematic review was to explore the methodologies used and not to comment on 
the validity of results and conclusions drawn from these studies, none of the studies were 
rejected based on the quality assessment undertaken. It is worth stating that some level of 
caution is needed when scoring studies because items are not always equivalent and different 
methods are likely to produce different scores and in some instances, scoring may even bias 
quality assessment. However, in this methodological piece of work spanning a range of clinical 
areas where the purpose of quality assessment was concerned with the presence or absence of 
a methodological approach (i.e., descriptive rather than decisions about inclusion or exclusion 
or scoring), the potential limitations of quality scores were not considered applicable.  
 
Table 3-2 10-point checklist for assessing economic evaluations 
1. Was a well-defined question posed in answerable form? 
1.1.    Did the study examine both costs and effects of the service(s) or programme(s)? 
1.2.    Did the study involve a comparison of alternatives? 
1.3.    Was a viewpoint for the analysis stated and was the study placed in any decision-making context? 
2. Was a comprehensive description of competing alternatives given? 
2.1.    Were there any important alternatives omitted? 
2.2.    Was (should) a do-nothing alternative be considered? 
3. Was the effectiveness of the programmes or services established?  
3.1.    Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect 
what would happen in regular practice? 
3.2.    Was effectiveness established through an overview of clinical studies? 
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3.3.    Were observational data or assumptions used to establish effectiveness? If so, what are the potential 
biases in results? 
4. Were all the important and relevant costs and consequences for each alternative identified? 
4.1.    Was the range wide enough for the research question at hand? 
4.2.    Did it cover all relevant viewpoints? (Possible viewpoints include the community or social 
viewpoint, and those of patients and third-party payers. Other viewpoints may also be relevant depending 
upon the particular analysis.) 
4.3.    Were the capital costs, as well as operating costs, included? 
5. Were costs and consequences measured accurately in appropriate physical units? 
5.1.    Were any of the identified items omitted from measurement? If so, does this mean that they carried 
no weight in the subsequent analysis? 
5.2.    Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? 
Were these circumstances handled appropriately? 
6. Were costs and consequences valued credibly? 
6.1.    Were the sources of all values clearly identified? (Possible sources include market values, patient 
or client preferences and views, policy-makers’ views and health professionals’ judgements) 
6.2.    Were market values employed for changes involving resources gained or depleted? 
6.3.    Where market values were absent (e.g. volunteer labour), or market values did not reflect actual 
values (such as clinic space donated at a reduced rate), were adjustments made to approximate market 
values? 
6.4.    Was the valuation of consequences appropriate for the question posed (i.e. has the appropriate type 
or types of analysis – cost-effectiveness, cost-benefit, cost-utility – been selected)? 
7. Were costs and consequences adjusted for differential timing? 
7.1.    Were costs and consequences that occur in the future ‘discounted’ to their present values? 
7.2.    Was there any justification given for the discount rate used? 
8. Was an incremental analysis of costs and consequences of alternatives performed? 
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8.1.    Were the additional (incremental) costs generated by one alternative over another compared to the 
additional effects, benefits, or utilities generated? 
9. Was allowance made for uncertainty in the estimates of costs and consequences 
9.1. If data on costs and consequences were stochastic (randomly determined sequence of observations), 
were appropriate statistical analyses performed? 
9.2.    If a sensitivity analysis was employed, was justification provided for the range of values (or for key 
study parameters)? 
9.3.    Were the study results sensitive to changes in the values (within the assumed range for sensitivity 
analysis, or within the confidence interval around the ratio of costs to consequences)? 
10. Did the presentation and discussion of the study results include all issues of concern to users? 
10.1.    Were the conclusions of the analysis based on some overall index or ratio of costs to consequences 
(e.g. cost-effectiveness ratio)? If so, was the index interpreted intelligently or in a mechanistic fashion? 
10.2.    Were the results compared with those of others who have investigated the same question? If so, 
were allowances made for potential differences in study methodology? 
10.3.    Did the study discuss the generalisability of the results to other settings and patient/client groups? 
10.4.    Did the study allude to, or take account of, other important factors in the choice or decision under 
consideration (e.g. distribution of costs and consequences, or relevant ethical issues)? 
10.5.    Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ 
programme given existing financial or other constraints, and whether any freed resources could be 
redeployed to other worthwhile programmes? 







3.4 Results  
	
After the removal of duplicates, 4,494 unique articles were identified for the first stage of 
screening (title and abstract screening). Eighty-eight (88) titles and abstracts were identified as 
potentially eligible for inclusion. After the second screening stage (full text screening), and 
unsuccessful attempts to contact medical technology companies, manufacturers of the 
technologies identified from the EuroScan website and obtain full text conference abstracts, 
five studies were included for narrative synthesis. The PRISMA flow diagram (Fig 3-1) below 


















Fig 3-1 The PRISMA flow diagram summarising the search strategy and 
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searching (Cochrane, Medline, 
EMBASE, EconLit, CRD, HMIC) 


























Additional records identified through 
internet searching (n = 5) 
2 conference abstracts, 2 EuroScan 
promising technologies and 1 article  
Total records identified  
(n = 4,671) 
Records screened  
(n = 4,494) 
Records excluded at title 
and abstract stage  
(n = 4,406) 
Full-text articles 
assessed for eligibility  
(n = 88) 
Full-text articles excluded 
with reasons  
  
Conference abstracts- full 
text articles not available 
when authors were contacted 
(n = 2) 
 
Non-economic evaluation 
studies (n = 27) 
 
Conventional economic 
evaluation studies (n = 52)  
 
EuroScan - not able to 
contact manufacturers (n=2) 
 
Studies included in 
synthesis 
 (n = 5) 
Duplicates removed  
(n = 177) 
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Table 3-3 Characteristics of included studies 
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3.4.1 Study characteristics 
	
The included studies, which were published between 2005 and 2016, are summarised in Table 
3-3 above. Two studies were conducted in the Netherlands (Buisman et al., 2016; Vaidya et 
al., 2014) and three studies were conducted in the USA (Wu et al., 2015; Huang et al., 2013; 
Bosch et al., 2005). All studies stated the clinical condition explored, which spanned a range 
of disease areas, namely rheumatoid arthritis, persistent asthma, chlamydia trachomatis, 
peripheral artery disease, and coronary artery disease. All studies stated the intended 
application of the tests under evaluation. These were diagnosis, predicting a response to 
treatment, screening, and risk assessment. Four studies were conducted at the early 
development stage (Fig 2-3) (Buisman et al., 2016; Wu et al., 2015; Huang et al., 2013; Vaidya 
et al., 2014) and one study was conducted at the concept stage (Bosch et al., 2005). Model-
based approaches were used in cost-utility and cost-effectiveness analyses. Cost-utility 
analyses were conducted in four studies (Buisman et al., 2016; Wu et al., 2015; Vaidya et al., 
2015; Bosch et al., 2005), and a cost-effectiveness analysis was conducted in one study (Huang 
et al., 2013). The societal perspective was adopted in four studies (Buisman et al., 2016; Wu et 
al., 2015; Vaidya et al., 2014; Bosch et al., 2005) whereas the public healthcare perspective 
was adopted in one study (Huang et al., 2013). A time horizon of ≤ 10yrs was adopted in 3 
studies (Buisman et al., 2016; Wu et al., 2015; Huang et al., 2013), a lifetime time horizon was 
adopted in one study (Vaidya et al., 2014), and one study did not state the time horizon adopted 





3.4.2 Quality assessment of included studies 
	
Based on the results from the quality assessment checklist, two studies had a score of 8.5 
(Huang et al., 2013; Buisman et al., 2016), two studies had a score of 8 (Vaidya et al., 2014; 
Wu et al., 2015) and one study had a score of 7 (Bosch et al., 2005) (Table 3-4). All studies 
lost a point each because it was difficult to tell whether any important alternatives were omitted 
from the studies as insufficient information about clinical pathways were provided. Three 
studies lost a point each for not identifying and including all the important outcomes for each 
alternative (such as those from the patient’s perspective) (Vaidya et al., 2014; Wu et al., 2015; 
Bosch et al., 2005). One study lost a point because it was not clear whether cost and 
consequences were valued credibly or adjusted for differential timing as all the data used were 
based on assumptions, but no information based on the assumptions was provided (Bosch et 
al., 2005). It is worth stating that due to word count restrictions, not all clinical information 
may be incorporated in the description of an economic evaluation (especially those conducted 
alongside randomised controlled trials). Usually these would have to be read together with 
other publications (such as clinical publications) to get an impression of the total evidence on 
a research question for evaluation. In this study, this was done before and during quality 

















Table 3-4 Summary of checklist scores 
 
 Studies included in the review and score 
DRUMMOND 10-point checklist component Buisman 
et al 
(2016) 







Bosch et al 
(2005) 
Was a well-defined question posed in answerable form 1 1 1 1 1 
Was a comprehensive description of the competing alternatives given 0 0 0 0 0 
Was the effectiveness of the programme or services established? 1 1 1 1 1 
Were all the important and relevant costs and consequences for each alternative identified? 0.5 0 0.5 0 0 
Were costs and consequences measured accurately in appropriate physical units?  1 1 1 1 1 
Were the cost and consequences valued credibly? 1 1 1 1 0.5 
Were costs and consequences adjusted for differential timing? 1 1 1 1 0.5 
Was an incremental analysis of costs and consequences of alternatives performed? 1 1 1 1 1 
Was allowance made for uncertainty in the estimates of costs and consequences? 1 1 1 1 1 
Did the presentation and discussion of study results include all issues of concern to users? 1 1 1 1 1 






3.4.3 Data extraction 
	
Data was extracted for each study to answer the research questions and the results are presented 
in the ensuing sections. 
 
3.4.3.1 How was the problem of insufficient data for model parameterisation 
managed? 
 
To populate the index testing strategy arm of the models, several sources of data were utilized 
across the different studies from four main perspectives (test accuracy, costs, measures of 
effectiveness and transitional probabilities describing the disease states) and were found to be 
















Table 3-5 Sources of data utilized in each study 
Sources of data on index testing strategy 
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(2016) 
Netherlands 
Estimates based on 
expert opinion (test 
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data was also from 
a recent evaluation 
of IL-6 serum level 
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Estimate based on 
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assumptions (basis 
of assumptions not 
stated ) and,                           
Dutch Healthcare 
Authority 





and the                                                                     
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Wu et al (2015) 
USA 
Estimates based on 
assumptions (based 
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on the REACH 
registry data 
 











One study was conducted at the concept stage (Bosch et al., 2005) and all the parameters used 
(test accuracy, costs, measures of effectiveness and transitional probabilities describing the 
disease states) were based on assumptions. However, no information was provided based on 
these assumptions. Sources of data utilized varied across the studies conducted at the early 
development stage (Table 3-5). It was noted that, in all these studies, the plausibility of the 
estimates utilized, and the robustness of the results obtained by utilizing these estimates were 
examined in sensitivity analysis. 
 
3.4.3.2 What was the type of model used in modelling disease progression 
and the testing pathways (e.g. Decision tree, Markov)? 
 
A Markov state transition model was utilized in three studies (Wu et al., 2015, Vaidya et al., 
2014 and Bosch et al., 2005), a decision tree was utilized in one study (Huang et al., 2013) and 
both the decision tree and Markov model were utilized in one study (Buisman et al., 2016). In 
all cases, the Markov model described the disease and the decision tree described the testing 
pathways. Information was provided to justify the model structure in only three studies 
(Buisman et al., 2016; Wu et al., 2015; Vaidya et al., 2014).  
 
3.4.3.3 Was test accuracy and all possible test results considered (i.e. true 
positives (TP), true negatives (TN), false negatives (FN), and false positives 
(FP))? 
 
Each of the different possible test results were modelled explicitly in four studies (i.e., TP, TN, 
FP and FN) (Buisman et al., 2016, Wu et al., 2015, Huang et al., 2013 and Bosch et al., 2005). 
Vaidya et al (2014) assumed a perfect biomarker and therefore only considered TP and TN. 
Despite this assumption, no information was given on what the consequence of test error will 
be for this test. In one study, the first year of the 5-year time horizon was modelled as a decision 
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tree with chance nodes at 6 and 12 months as (repeated testing is part of the clinical pathway) 
to classify patients as TP, FP, TN and FN. Those classified as TP or FN at 12 months entered 
the patient level state transition model and followed for 4 years (Buisman et al., 2016). In 
another study, four subpopulations based on the test result of TP, FN, TN and FN were 
considered within the same model (Wu et al., 2015).  
 
3.4.3.4 Were all the issues on the test-treat pathway that may be important 
to patients included in the analysis? 
 
It is notable that, only one of the four studies that were conducted from the societal perspective 
acknowledged and included some issue on the test-treat pathway that may be relevant to the 
patient (Buisman et al., 2016). The issue of the patient’s perspective was ignored in the other 
studies (Wu et al., 2015; Vaidya et al., 2014; Bosch et al., 2005). In one study, follow-up visit 
costs and productivity costs (measured by the number of days that a patient with a paid job was 
absent from work) were included (Buisman et al., 2016). In another study, the effects of how 
long patients were willing to wait for their test results was considered (Huang et al., 2013). 
This seemed reasonable as the study was conducted from a public health care perspective and 
one of the key mechanisms by which the test in this study might impact on outcomes was being 
able to treat patients at the time they are tested to prevent onward transmission of infection. 
Indeed, it was demonstrated in one-way sensitivity analyses in this study that one of the key 
parameters driving the results of the cost-effectiveness analysis was how long patients were 
willing to wait to obtain their results.  The reason was that, a short processing time reduced the 
time between testing and treatment thereby increasing treatment rates and subsequent 
improvement in the quality of life of patients at the population level. 
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3.4.3.5 Did the analysis include headroom analysis, and at what stage of the 
analysis was it included? 
 
Headroom analysis was noted to be included in the two studies conducted in the Netherlands 
(Buisman et al., 2016; Vaidya et al., 2014). It was also noted that in both these studies, neither 
was conducted at the concept stage of development but at the early development stage when 
there was some data available to describe the test parameters. Hence, headroom analysis was 
included in the early development stage but not the concept stage. 
  
3.4.3.6 Was the uncertainty that accompanies early modelling acknowledged 
in sensitivity analysis? 
 
The issue of a lack of data and the simplification of models to represent reality were 
acknowledged as study limitations in all the studies. It was noted that to deal with these 
limitations in all the studies, extensive sensitivity analyses was undertaken on all important 
parameters (e.g., sensitivity analysis of test accuracy) to evaluate the influence of uncertainty 
on model predictions. Probabilistic and deterministic sensitivity analyses were conducted in 
four studies (Buisman et al., 2016; Wu et al., 2015; Huang et al., 2013; Vaidya et al., 2014) 
and deterministic sensitivity analysis was conducted in one study (Bosch et al., 2005).  
 
3.4.3.7 Was value of information (VOI) analysis conducted?  
 
It was noted that VOI analysis was not conducted in any of the studies. However, considering 
the importance and role of VOI analysis in supporting decision making under conditions of 
uncertainty (typically characteristic of early economic evaluation), one would have expected it 





Typically, economic evaluations are conducted as a one-off exercise at the late stage of 
development of medical technologies (Vallejo-Torres et al., 2008). However, several studies 
have noted the importance of early economic analysis at the early stages of development of 
medical technologies to identify their potential economic value and likely impact, and to 
support and guide decision-making under conditions of high uncertainties (Sculpher and 
Buxton, 1997; Fenwick et al., 2006). However, there is little specific guidance on the 
implementation of early economic analysis. This systematic review focussed on exploring the 
methods and approaches that have been used in the early economic analysis of medical tests. 
Five studies were identified, and data extracted from each study to gain a greater understanding 
of how the problem of insufficient data for model parameterization has been dealt with, 
whether and how testing pathways have been modelled, and whether sensitivity analysis 
acknowledged the uncertainty that accompanies early modelling and the stage at which it is 
conducted. 
 
The major issue associated with test evaluation is the rather difficult connection between 
testing and final health outcomes. However, in order to effectively evaluate the cost-
effectiveness of a test, there is the need for the final health outcomes based on the downstream 
consequences of testing to be included in the analysis. This usually involves extensive 
modelling of delineated test-treat pathways. This is difficult enough to do for an established 
test, but for a new test, it is even more complicated and difficult to do because test-treat 
pathways may not be defined. This may explain why there are so few early economic 
evaluations of medical tests, and hence, the small number of studies identified in this study. 
Furthermore, early economic evaluations may take place within industry as a commercial in 
confidence activity whereby if disclosed, may result in damage to an organisation’s 
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commercial interests, intellectual property or trade secrets, hence, the reason why such analysis 
may not be readily made available to the public.  
 
To deal with the issue of an early analysis not having sufficient data for model 
parameterization, different sources of data were relied on by studies in this review and the 
sources of data used were influenced by the stage of the analysis (concept stage or early 
development stage). One study was conducted at the concept stage and as expected, all the data 
used were based on assumptions. However, no information on the basis for these assumptions 
were provided making these estimates somewhat arbitrary and weakly informed, although they 
were extensively examined in sensitivity analyses. Four studies were conducted at the early 
development stage and within the confines of this stage, varying data sources were utilized 
across the different studies. This observation is explained by the fact that the tests were at 
different phases of development even within the early development stage; thus, different levels 
of data were available specific to the different tests. For example, primary data was available 
for most of the parameters used in the evaluation in one study as the test was at an experimental 
phase. In the other studies, primary data were not available for all the parameters, thus, other 
plausible data sources were utilized to supplement primary data (making investigation of 
uncertainty particularly important). The plausibility and robustness of these estimates were 
however examined extensively in sensitivity analyses and their effects on the conclusions 
drawn from the models examined. 
 
In all the studies, test accuracy was considered with four studies modelling explicitly each of 
the possible test results. This implied that, the full implications of test accuracy could be 
examined in the analysis. In the study that did not model each of the test results, this implied 
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that the consequences of test error were not examined. It was notable that even though a societal 
perspective was adopted in four studies, only one of these four considered and included in their 
analysis issues on the test-treat pathway that may be important to patients. Underpinning this 
statement is the fact that, the societal perspective is the broadest perspective to adopt in 
economic evaluations, and one would have expected that the issues on the testing pathway that 
are important to the patient would be more likely to be considered here compared to other 
perspectives (e.g., the hospital or healthcare system). This is important because including 
patient perspectives (issues that may be important to the patient on the test-treat pathway) could 
have a significant impact on the conclusions drawn from models. For example, in one study it 
was noted that how long patients were willing to wait for their test results was a key parameter 
driving the results of the cost-effectiveness analysis. Clearly, overlooking this important 
parameter in this particular analysis would have led to misleading conclusions. The most 
obvious and most studied way in which a test might produce benefits aside from improvements 
in test accuracy is probably the timing of test results (rapid tests). However, it is important to 
state that other aspects such as test acceptability to patients and professionals, procedural harms 
or benefits of the testing process are equally important and should also be considered (Ferrante 
Di Ruffano et al., 2012 and 2017). 
 
Headroom analysis was included in two studies, and it was noted that in both studies it was not 
conducted at the concept stage but at the early development stage. However, the headroom 
method of analysis can be utilized as early as the concept stage to make a preliminary 
assessment of whether a test warrants further development. Then later in the early development 
stage when more data becomes available, this can be updated in the face of new evidence. This 
reduces the risk of investing in a technology that may not be economically viable. Though it 
may be argued that if a project is terminated at the early development stage not many resources 
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would have been invested, it is equally true that, if the headroom had been established at the 
concept stage and the project terminated at that stage, the invested resources could be used 
efficiently in another project or elsewhere. Thus, headroom analysis has the potential to 
promote efficiency at the beginning of the test development process. 
 
Sensitivity analysis is an important undertaking in early economic analysis (which is 
characterized by a lack of data), as initial parameter estimates may have to be derived from 
data sources associated with high levels of uncertainty. All the studies included in this review 
acknowledged the uncertainty that is associated with the data used in their analysis and 
conducted extensive sensitivity analyses on important parameters to evaluate the influence of 
uncertainty on model predictions. It was also noted that VOI analysis was not conducted in any 
of the studies and this implies that no insights into the value of future research were obtained. 
Thus, there was the possibility of drawing wrong conclusions about whether to fund the further 
development of a new test or not based on the available evidence used. This observation could 
be explained by the fact that studies were conducted at a time when VOI analysis was not well 
established as a concept or it was deemed irrelevant.  
 
3.6 Strengths and limitations of the study 
 
To the best of our knowledge, this is the first study that has focussed on systematically 
exploring the tools and methodologies that have been employed in the implementation of early 
economic analysis of medical tests. It has contributed to gaining a greater understanding of 
what currently pertain in this field and has identified areas requiring further research in order 
to maximise the value of such analysis.  
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Like every study, this study has its own limitations. Few studies were found to be eligible to 
be included in the review. Having additional studies from the industry would have 
supplemented the review and given a broader and more holistic view of the current state of the 
implementation of early economic analysis of medical tests. Furthermore, it was not possible 
to compare results as studies were conducted to answer different research questions. 
   
3.7 Recommendations 
	
1. To fully capture the potential benefits of testing on patient relevant outcomes and thus the 
potential health economic impact of medical tests, the assessment of the outcomes of testing 
should transcend health and specific payer perspectives to include all the issues on the test-
treat pathway that may be important to the patient. This will mitigate against over- or 
underestimating the true value of tests in early economic analysis and thereby appropriately 
informing decision-making. 
2. The full implications of test accuracy should be considered in an analysis by including all 
the possible test results and their subsequent patient pathways in a model. 
3. The influence of uncertainty on model predictions should be evaluated through extensive 
sensitivity analyses of all the important parameters. 
4. The potential adoption of VOI analysis should be considered in early economic analysis 
studies. This can be beneficial in mitigation against drawing incorrect conclusions about 
whether to fund the further development of a test. 
5. Headroom analysis has the potential to provide information about the viability of 
developing a new test and should be considered at the early stages of development, 
particularly at the concept stage to promote efficiency at the start of the test development 
process.  
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3.8 Suggestions for future work 
	
The review has shown that some of the methods available (VOI and Headroom analysis) are 
not being utilized in the early economic evaluation of test. Is there a need to refine or develop 
these methods in this specific context? To answer this question, further research is needed in 




Having provided a greater understanding of how economic evaluations focussed on medical 
tests have been conducted at the early phases of development, the next chapter (Chapter 4), is 
focused on delineating the existing test-treat pathway(s) for typhoid fever in Ghana. This was 
undertaken to provide the necessary background information to undertake an early economic 









Chapter 4: Delineating the test-treat pathway(s) for 
typhoid fever in Ghana: a case study using the 
framework approach 
 
This chapter is focussed on exploring and delineating the existing test-treat pathway(s) for 
typhoid fever in Ghana. Using the framework approach, it highlights the potential role of the 
application of qualitative methodologies in enhancing the process of test-treat pathway 
delineation. This was necessary so that the models developed for the early economic analysis 





For an informative economic model to represent appropriately the disease, persons not having 
the disease, and misclassifications, and for the model to be fit for purpose for decision making, 
an in-depth understanding of the care pathway is required (Briggs et al., 2006). Therefore, 
delineating care pathways and any existing variations, is a key information requirement to 
effective medical test evaluation (see Chapter 2, p.18-20). 
 
Delineating the care pathway is a difficult undertaking, and qualitative methods can play a key 
role in enhancing this process (Chilcott et al., 2010; Kaltenhaler et al., 2012; Roberts et al., 
2012; Kaltenhaler et al., 2014; Husbands, 2016). For example, qualitative methods can serve 
as a medium through which the perspectives of all the different types of experts knowledgeable 
on a topic area can be captured (Kelley et al., 2003). These may include capturing variability 
in practice when defining care pathways to assist in model structure conceptualisation (Iglesias 
et al., 2016). Variability may arise in different ways in practice. For example, it may arise from 
clinicians and patients involved at different points in a care pathway and in different settings 
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or locations. Capturing variability can potentially assist in improving the validity as well as the 
generalizability and credibility of models. Different qualitative research methods and the 
studies in which they have been applied to the model process include the Delphi technique 
(Sullivan and Payne, 2011; Iglesias et al., 2016), focus groups (Roberts et al., 2012), and 
stakeholder workshops (Squires et al., 2016). Despite the potential usefulness of qualitative 
methods, there has been limited uptake of formal qualitative methods in model development 
by modellers and health economists (Husbands et al., 2017). Possible explanations for their 
limited uptake are the general assumption that qualitative methods are resource intensive, and 
the lack of familiarity of their potential to assist with model development. 
 
Information on the care pathways for typhoid fever in Ghana, their variations, diagnostic 
challenges (which are likely to arise from the different levels of care) and the potential 
placement and role (replacement, triage or add-on) of a new test on existing care pathways was 
lacking, and research was needed to be done to inform it.  
 
4.2 Study aims and objectives 
	
The primary aim of this chapter was to gain insight into the current practice (to delineate 
existing care pathways) of typhoid fever testing and treatment in Ghana with a view to using 
the information for later model structure conceptualisation. The secondary aim was to highlight 
how a qualitative approach can be applied in a real-world context to gain insights into current 
practice. Specifically, the work reported in this chapter sought to: 
1. Describe the existing care pathway for typhoid fever in Ghana and any variations. 
2. Explore the reasons for any variations in the existing care pathways for typhoid fever in 
Ghana. 
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3. Capture the views of a range of healthcare professionals working in Ghana on the potential 




The perspectives of a range of healthcare professionals working in different settings and across 
different practices in the Eastern region of Ghana were explored to answer a series of questions: 
What is the test-treat pathway for typhoid fever in Ghana? Are there variations in the existing 
test-treat pathway? Finally, what would be the potential role(s) of a new test on the existing 
pathway in Ghana? One region was chosen as a case study because the literature available on 
the structure of the health care delivery system in Ghana indicated that, variations in practice 
were likely to result from the different levels of care (which is the same across all regions) 
rather than resulting from the individual regions. The Eastern region was selected because the 
Principal Investigator (PI) was familiar with the region having previously lived and worked 
there. Thus, it was comparatively less resource-intensive for the PI to collect the necessary data 
from this location. A purposive, maximum variation sampling approach was adopted. This 
involved approaching all those who were knowledgeable on the topic of interest and could give 
potentially different perspectives on the topic (Kelley et al., 2003). The results of the study 
were compared between health care settings because this was the main factor likely to drive 




To be eligible for inclusion in the study, the participant had to meet the inclusion criteria of 
being a clinician or medical assistant who worked in a healthcare provision facility (Health 
Centre, Polyclinic, hospitals, etc.) in the Eastern region of Ghana. These experts were chosen 
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to participate in this study because they were considered knowledgeable in the topic of interest 
and thus were in a better position to provide valuable information to aid the study. To avoid 
sampling bias, participants of all ages and genders were included. 
 
4.3.2 Data collection (March-July 2017) 
	
Some level of pragmatism was required to choose the most appropriate approach to collect data 
in this study because, in-depth interviews were not possible due to participants’ time 
constraints. Consequently, a self-administered survey using open-ended questions was used 
(Jansen, 2010). Acknowledging the limitations of using a survey approach (i.e., responses were 
likely to lack depth, and a survey would not allow probing by the researcher or checking of the 
participants’ understanding of the questions), a well written questionnaire was required to elicit 
adequate valuable information. A questionnaire was piloted in the Greater Accra region and 
revised based on responses into the final version used in this study. After ethics approval from 
the University of Birmingham (ERN_16-0947) and from the Ghana Health Service Ethical 
Review Committee (GHS-ERC: 03/12/16), medical superintendents of various health facilities 
were contacted to arrange a meeting between the researcher and the clinicians and/or medical 
assistants working at their facilities. At these meetings, the aims and the expected outcomes of 
the study were explicitly explained to the experts and interested persons were recruited into the 
study after having gone through the informed consent process and signed the consent form. In 
each institution, groups of recruited participants were given the opportunity to go through the 
questionnaire. This was done to ensure that they understood the questions, and explanations 
were offered to clarify issues where necessary. To enable easy analysis of the data set, 
questionnaires were coded for easy identification of the facility and its location within the 
region. Participants were anonymized. A total of 70 self-administered questionnaires were 
distributed to the participants by the researcher in person.            
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The following themes were generated a priori and informed the content of the questionnaire: 
presumptive treatment views (treatment of clinically suspected cases without, or prior to, 
confirmatory laboratory test), diagnostic test(s) used, test negative management (i.e., care plan 
for those with a negative test result), test positive management (i.e., care plan for those with a 
positive test result), prescribed antimicrobial for test positives, dosage of antimicrobial, 
assessment of test-treat outcome and intended role of new test. All the themes except “intended 
role of a new test” were generated to gain insight into current practice. To do this, these themes 
had to be considered together. Thus, they are reported and discussed together under the section 
“delineating existing test-treat pathway and reasons for variations”. The theme “intended role 
of new test” was generated to capture the views of the participants on the potential role of a 
hypothetical new test, and where it should be placed on the testing pathway to improve current 
practice. To capture these views, participants were asked to choose a statement which best 
described the role of a hypothetical new rapid diagnostic test for typhoid to them: (a) to test 
patients first to decide on who should receive further testing with the test you use now (triage); 
(b) as the main investigative tool without further testing with the test you use now 
(replacement); or (c) to provide additional diagnostic information after testing with the test you 
use now (add-on). The questionnaire is shown in Appendix 2. 
 
4.3.3 Data analysis 
	
The analytical framework adopted for analysing the data collected in this study is framework 
analysis (Gale et al., 2013). Framework analysis belongs to a wider group of analysis methods 
(known as thematic analysis) that seeks to identify, analyse and report patterns within data 
(Braun and Clarke, 2006). The data collected using this method are based on pre-defined 
themes (deductive) rather than emerging from data (inductive). The matrix output is the 
distinctive attribute of this method of analysis (Pope and May, 2006). It provides a systematic 
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structure into which data is charted (inputted) to enable in-depth analysis. The matrix consists 
of rows, columns and cells of summarised data. In this case study, rows referred to participants, 
columns referred to the pre-defined themes, and cells of summarised data referred to 
participants’ responses. Framework analysis was chosen in this study particularly due to its 
deductive approach, which makes it especially suited to research that has specific data needs 
set in advance (Srivastava and Thompson, 2009). Adopting this method of analysis in this study 
allowed for pre-defined themes to be developed that shaped the nature of the data collection. 
Furthermore, framework analysis was chosen because it is intuitive and allows for easy 
recognition of patterns in the data set once a matrix has been developed (Gale et al., 2013). In 
addition, the systematic approach embedded in the framework method of analysis ensures that 
the rigour of the analytical process is maintained, thereby enhancing the credibility of the 
findings (Ritchie and Lewis, 2003). Figure 4-1 illustrates the procedure for analysis using the 
framework approach. 
Fig 4-1 Procedure for analysis using the framework approach 
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Written responses retrieved from participants were first converted into electronic form and read 
repeatedly to ensure familiarisation with the data. This provided a good opportunity to become 
immersed in the data set and have a better recollection of key information (Braun and Clarke, 
2006). To classify all the data set according to the pre-defined themes, the textual data was 
colour coded. There were no emerging new themes from the survey; thus, the pre-defined 
themes generated were then developed into a working analytic framework, a matrix consisting 
of rows and columns into which data was charted to enable in-depth analysis (Pope and Mays, 




The findings of the study are reported under the following sections: demographics of 
participants, delineating existing test-treat pathway(s) and reasons for variations, and the 
perceived role of a new test. 
 
4.4.1 Demographics of participants 
	
Fifty-one questionnaires were retrieved in total representing a 73% response rate. All non-
respondents were noted to be participants working in primary hospital facilities, and time 
constraint was the main reason given for non-response. Twenty responses were from 
participants recruited from secondary care settings and thirty-one were from participants 
recruited from primary care settings. To ensure participant anonymity, the names, gender and 
age of the participants were not captured. 
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4.4.2 Delineating existing test-treat pathway and reasons for 
variations 
	
Two main pathways were delineated from the analysis of the matrix: The Widal care pathway 
(suspected typhoid cases have Widal test) (Fig 4-2) and the culture pathway (suspected typhoid 
cases have culture, i.e., blood stool or urine) (Fig 4-3). Underpinning this variation was the 
type of health care facility from which the participants were recruited. It was noted from the 
analysis of the matrix that, the Widal care pathway was predominantly adopted in primary 
health care facilities (typically district level facilities that provide the most basic care). And the 
culture pathway was predominantly adopted in secondary hospital facilities (typically regional 
hospitals which are an upgrade of primary hospitals in terms of infrastructure and resources). 
There were two exceptions to these observations. Participant 50(P) stated blood or stool 
culture as the diagnostic tool used even though the participant was recruited from a primary 
hospital facility and Participant 31(S) stated that the Widal test was used even though the 
participant was recruited from a secondary hospital facility (letters P and S in parenthesis 
indicate whether a participant was recruited from primary care or secondary care respectively). 
Participant 31(S) stated, “it is the commonest and simple to do” as the reason for using the 
Widal test. This quote is suggestive of the fact that the Widal test could be available in 
secondary hospitals even though culture might be the preferred test in such settings. 
Participant 50(P) stated, “it is readily available in our lab” as the reason for employing 
culture.  
 
It was noted that, the management aspect of the two care pathways following testing with either 
the Widal test or culture was similar. Test negative patients were investigated further for other 
conditions especially malaria and treated according to the final diagnosis in both pathways. For 
example, Participant 16(P) stated, “when negative, we check for other conditions like malaria 
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and treat them”. Participant 19(P) stated, “I look out for other conditions presenting like 
typhoid fever in typhoid-negative clients and treat”. Participant 35(S) stated, “when negative 
I investigate the underlying cause of symptoms and treat appropriately”. And Participant 
38(S) stated, “when negative, I investigate further to get the specific condition”. From the 
analysis, it was noted that typhoid positive patients were treated with antibiotics, mainly oral 
ciprofloxacin at a dose of 500mg every 12h for a period of 7-14 days. After a course of 
treatment, they were reviewed, and in most cases re-tested to ascertain whether the test-treat 
process was successful in improving the patient’s health. For example, Participant 19(P) 
stated, “I treat typhoid positive patients with oral ciprofloxacin. Dosage: Tb Ciprofloxacin 500 
mg bd* 7-14 days”. Participant 25(P) stated, “positives: I treat with ciprofloxacin. Dosage: 
Tb Ciprofloxacin 500mg bd *14 days”. And Participant 32(S) stated, “I give oral antibiotics 
medication for positive patients. Dosage: Tb Ciprofloxacin 500 mg bd* 10 days”. It was noted 
that the choice of oral ciprofloxacin was mainly due to it being the first-line treatment of choice 
in typhoid fever management and also for other reasons such as its efficacy against the 
causative organism, availability and cost. For example, Participants 31(S) and 51(P) stated, 
“it is the first-line drug to manage typhoid”, and Participant 33(S) stated, “because of its 
efficacy and sensitivity against the causative organism Salmonella typhi”. In addition to this 
observation, some participants prescribed alternative antibiotics in addition to oral 
ciprofloxacin. For example, Participant 1(P) stated, “positive cases are put on treatment. 
Dosage: Tb Metronidazole 200-400mg tds* 7days”. Participant 4(P) stated, “treat positives 
with antimicrobials. Dosage: Tb Cefixime 200mg bd*7 days”. Participant 8(P) stated, “I give 
antibiotics for test positive cases. Dosage: Tb Azithromycin 1g daily* 7days”. And Participant 
30(S) stated, “positives: I give antibiotics. Dosage: Tb Cefixime 400mg bd*10-14 days”. 
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Of further interest in this study was to explore the views of participants on applying 
presumptive treatment for typhoid fever. It was noted that, the majority of participants were 
averse to presumptive treatment, because they expressed the opinion that this may lead to 
treatment failure and the development of antimicrobial resistance. For example, Participant 
18(P) stated, “it could lead to treatment failure and antimicrobial resistance”. Participant 
28(S) stated, “it can cause antibiotic resistance”. Participant 11(P) stated, “presumptive 
treatment may be prophylactic but can cause antimicrobial resistance”. And Participant 1(P) 
stated, “typhoid fever presents like malaria and presumptive treatment may lead to treatment 
failure”. However, it was also noted that few participants advocated for presumptive treatment, 
but only under certain circumstances. For example, Participant 50(P) stated, “since culture 
usually takes 72 h, presumptive treatment can be started”. Participant 30(S) stated, “this is a 
good intervention to prevent complications since the most precise blood/stool cultures are not 
available in most district and health centres”. And Participant 23(P) stated, “Widal test is not 
wholly reliable hence treatment can be made if test is not done but clinical features are 
present”. It is clear from these quotes that; presumptive treatment appears to be used because 
of delays in diagnosis or concerns about the accuracy of the Widal tests or lack of availability 
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4.4.3 Perceived role of new test 
	
Twenty-eight participants from across the different levels of care stated that they saw 
themselves using a new test, “to provide additional diagnostic information after testing with 
the test they were using currently (add-on)”. Sixteen participants from across the different 
levels of care stated that they saw themselves using a new test, “to test patients first to decide 
on who should receive further testing with the test you use now (triage)”. And six participants 
from across the different levels of care stated that they saw themselves using a new test, “as 
the main investigative tool without further testing with the test they were using currently 
(replacement)”. This observation was further explored according to health care setting, and a 
similar trend in the response was noted by health care setting. 
  
In addition to exploring the participants’ views on the role of a new test, their views on what 
test properties the new test should possess were also explored because, the chosen role of a test 
implies the necessary properties it should possess (see Chapter 2, p.20-22). It was noted that, 
most of the participants (32) wanted the new test to be more sensitive followed by those who 
wanted it to be more specific (15). Participants 8(P) and 30(S) stated that, they wanted the 
new test to be more sensitive and more specific compared to the test they were currently using. 
Participants 13 (P) and 24 (P) did not answer the question. The following are some other 
properties as stated by the participants: improved reliability, low cost, greater availability, 
better accuracy, the ability to use other fluids apart from blood, easy to use, fast results, and 
high predictive values.  For some participants, it was noted that their views on what test 
properties a new test should have did not correspond with their choice of what the role of the 
test should be. For example, Participant 37(S) stated “better accuracy, low cost, accessibility 
and ease to perform” as the properties of the new test but wanted the test to be used as an add-
on to culture. However, it is intuitive that from these stated properties, the test should ideally 
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be placed before culture in the care pathway to enable expedite clinical decision- making to 




An in-depth understanding of test-treat pathways is key to the effective economic evaluation 
of medical tests. Qualitative methods can play a potentially key role in enhancing this process 
despite their limited uptake in practice. This study focussed on gaining insight into current 
practice for typhoid fever testing and treatment in Ghana by utilizing the framework analysis 
method. Two main care pathways for typhoid fever in Ghana were identified (Widal and culture 
pathways), and the majority of the participants were averse to applying presumptive treatment 
to typhoid fever and saw themselves using a new rapid test if it was introduced into clinical 
practice as an add-on test.  
 
The two main pathways identified in this study were primarily due to variations in the 
laboratory diagnostic capacity of healthcare facilities from which the participants were 
recruited. The Widal test is a simpler technology to employ compared to culture and therefore 
was more likely to be employed in primary hospitals which lacked resources, whereas culture 
was more likely to be employed in secondary hospitals. It was noted that, although most 
participants were averse to applying presumptive treatment to typhoid fever, a few advocated 
for presumptive treatment. They did so for valid reasons such as delays in diagnosis or concerns 
about accuracy of test or lack of availability. These circumstances reflect the characteristics of 
current practice in Ghana and therefore a new test would need to be “better” in these respects 
for healthcare professionals in Ghana to use if current practice is to be improved. The following 
were stated by participants as the properties that a new test should have to improve current 
practice: improved reliability, low cost, greater availability, better accuracy, the ability to use 
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other fluids apart from blood, easy to use, fast results, and highly predictive. These findings 
provide key information that cannot be ignored in any effort to develop a new test to be used 
in the Ghanaian setting. The use of alternative antibiotics in addition to ciprofloxacin as noted 
from this study demonstrates the potential for waste in current practice, indicating the need for 
standardisation in, or adherence to, the treatment regimen for typhoid fever patients. 
 
It was noted that regardless of the setting, most participants saw themselves using a new rapid 
test if it was introduced into clinical practice as an add-on test. However, one would have 
expected responses to vary depending on the setting in which they worked. This viewpoint is 
espoused on the premise that, if the main limitation of the Widal test as acknowledged by the 
participants who follow the “Widal care pathway” is unreliability of the test, then it is intuitive 
that a majority of them should be more inclined towards using a new test which is intended to 
be more reliable as their main investigative tool rather than as an add-on to the test they use 
currently. The argument might be that the very limitation of the Widal test is the reason why 
the new test should be used as an add-on test to the Widal test (to provide additional diagnostic 
information). However, the counterargument is that if the new test is accurate enough to be 
used to confirm diagnosis after the Widal test, then it is intuitive that it will replace it to save 
money (although it is acknowledged that such a decision should be informed by a cost-
effectiveness analysis comparing the two tests). Also, it was expected that for those participants 
who follow the “culture pathway”, most of them would be more inclined towards using the 
new test to triage patients in their setting. Underpinning this argument is that, if culture takes 
2-3 days (causing potential treatment delays), a triage test may be used to rule out diagnosis, 
so triage test negatives are discharged, and triage test positives receive further testing to 
confirm the diagnosis. However, in this study it was not possible to explore the reasoning 
behind the participants’ choices (which could be due to a lack of understanding, perception of 
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the accuracy of the existing tests, scepticism about the reality of a new test, acceptability and 
accessibility of a new test).  
 
Furthermore, it was noted that there seemed to be a lack of understanding by health 
professionals (clinicians and medical assistants) in Ghana on test characteristics. The clinical 
implications are that, clinicians and medical assistants in Ghana are likely to order more 
laboratory tests than required, order inappropriate tests which will consequently result in 
inappropriate treatment being administered, all of which have obvious implications for the 
quality of patient care. Also, there are large socioeconomic implications as inappropriate or 
superfluous tests may significantly add up to healthcare expenditure. This highlights the need 
for further education for clinicians and medical assistants in Ghana on the diagnostic properties 
of available test to improve the quality of patient care whilst decreasing cost to the healthcare 
system. 
 
The findings from this survey informed the modelling process in Chapter 6 in a number of 
ways. First, the delineated test-treat pathways informed and assisted in defining the boundaries 
and structures of the models utilized. The findings also indicated that, the settings in Ghana are 
different depending on the level of care, and its implication was that any cost-effectiveness 
analysis should consider these alternative pathways separately (and this was duly followed). 
Furthermore, the findings of this research assisted in identifying the appropriate comparator 
testing strategies required for the cost-effectiveness analysis. Also, in order to have effectively 
and appropriately evaluated the true value of the new test, its intended role in the care pathway 
was to be clearly defined in the model to enable the assessment of the test in that role. Although, 
the study findings indicated that there was no consensus amongst participants on what this role 
should be, this finding highlighted the need to evaluate the new test in all the possible roles in 
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each of the delineated pathways.  
 
Adopting the framework method worked well in this study. The relatively well structured and 
deductive approach to questioning enhanced the efficiency of the data collection process 
because it allowed for the information requirements to be well specified in advance which 
shaped the nature of the data to be collected. Furthermore, the matrix output allowed patterns 
to be more easily identified. For example, identifying the test-treat pathways once the matrix 
had been developed and data charted became far easier. Using an open-ended approach to 
questioning also allowed the identification of unanticipated issues. An example is the 
observation of the use of alternative antibiotics in addition to the first-line treatment of choice. 
Also, it was possible to capture and analyse the perspectives of 51 participants working in 
different settings or locations and across different practices (rather than a few informants) to 
gain an in-depth understanding of current practice by adopting the framework approach.  
 
Furthermore, due to time and resource (money and skill) constraints, many techniques that 
might be used to elicit test-treat pathways are not feasible. For example, there are challenges 
such as the practicality of organising and running face-to-face discussions in focus groups. 
There is also the challenge of gaining the inputs of multiple clinicians with busy schedules by 
asking them to complete questionnaires in a series of rounds as in the Delphi approach. As has 
been shown in this study, framework analysis is an example of a qualitative methodology that 
is likely to be more accessible and feasible across a wide range of health economic settings. In 
principle, the framework method of analysis can be used to analyse different forms of textual 
data including interview transcripts, responses to a questionnaire, meeting minutes and field 
notes, to produce highly structured summarised data across a wide range of research areas 
(Pope et al., 2000). The appeal of the framework method of analysis to quantitative researchers 
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is that, it is deductive and allows qualitative information to be collated within pre-defined 
categories or themes by the researcher. Thus, for this method to be beneficial in any health 
economic context, it is important for the researcher to be clear from the outset the issues to be 
explored to inform the most appropriate questions to be asked during data collection. The 
researcher should be clear from the outset on issues such as the purpose of the model, the type 
of model to be developed and the elements that are heterogeneous. Once data is collected and 
converted into textual form, framework analysis can then be used to analyse the data set to 
generate outputs that may appropriately inform the model development process. It is worth 
stating that in qualitative research when reporting findings, the researcher usually describes 
and interprets quotes as without context they are not self-explanatory. However, in this study, 
because a survey rather than interviews was conducted, there was limited interpretation: this 
was due to the nature of questions asked. 
 
Clearly, the modelling process can be improved by the potential application of qualitative 
methods and those working in this field should consider the opportunities they provide. 
Qualitative investigation is a step beyond the informal discussion that modellers normally have 
with clinicians to inform the model development process. 
 
4.6 Strengths and limitations of the study 
      
The strength of this study is that, it highlights how qualitative methods can potentially assist in 
improving the model development process by facilitating the involvement of, and capturing 
and analysing the perspectives of the different types of experts knowledgeable on a topic of 
interest and working in different settings (rather than a few informants), thereby potentially 
enhancing the credibility and generalizability of models developed. Furthermore, the approach 
adopted in this study is intuitive and deductive in nature (allowing qualitative information to 
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be collated within pre-defined themes), thus, can be readily adopted by quantitative 
researchers. 
 
The limitations of this study include the fact that only clinicians and medical assistants were 
sampled. If other relevant stakeholders such as patients (van Voorn et al., 2016) and policy 
makers had been sampled, they may have held different views or added further considerations. 
Furthermore, it was not clear whether the participants understood all the questions and it was 
not possible to probe their responses because the interviews were not personally conducted. 
For example, in this study, this was a deficiency when capturing valid participants’ views about 




Having gained a greater understanding of the intricacies of the typhoid test-treat pathway(s) in 
Ghana, the next chapter (Chapter 5) is focussed on exploring the literature on economic 
evaluations of typhoid. This was to acquire knowledge specific to typhoid economic analysis 
to augment the knowledge already acquired to ensure that the most appropriate methodologies 








Chapter 5: Economic evaluation of typhoid - a review 
 
This chapter is focussed on exploring the literature on the economic evaluation of typhoid. The 
focus on typhoid economic evaluation in general was to gain a holistic understanding of the 
modelling approaches that have been adopted in this setting for the economic evaluation of 
typhoid interventions, and the circumstances under which they were adopted and utilized. The 
findings of this chapter can then contribute to informing the modelling process utilized in 




The modelling approach adopted and utilized in economic evaluations is informed by the 
natural history of the disease, care pathway(s) and the type of intervention being evaluated 
(Brennan et al., 2006). Two main types of interventions exist for typhoid fever. These are 
interventions targeted at typhoid treatment (such as test treat strategies), and interventions 
targeted at typhoid prevention (such as vaccination) (WHO, 2003). The different nature of 
these interventions imply that they will require different modelling approaches in their 
evaluation.   
 
Model-based cost-effectiveness studies involve adapting an existing model or developing a 
new model for the analysis. Identifying what has already been done in the area of interest is 
fundamental to the approach taken. Thus, in order to examine the value of the hypothetical test 
for typhoid fever in Ghana, there was the need for a review of previous typhoid economic 





5.2 Study aim 
	
The aim of the review was to explore the literature focussed on typhoid economic evaluations 
to gain insights into the types of models that have previously been adopted in this setting (with 
particular interest in test-treat evaluations), and to capture data on model inputs that may be 




For this review, the following databases were searched for studies published from inception to 
September 2017. No restrictions on language were applied. 
1. Medline 
2. Excerpta Medica dataBASE (EMBASE) 
3. Centre for Reviews and Dissemination [Database of Abstracts of Reviews of Effects 
(DARE), Heath Technology Assessment (HTA), and NHS Economic Evaluation Database 
(NHS EED)] 
4. PubMed 
A reference search was undertaken by scanning the bibliographies of the relevant articles 
finally included in the review for any additional relevant articles. The reference management 
software Endnote was used to manage the list of articles. 
 
5.3.1 Search terms 
	
The search strategy was customized for each database and searching was undertaken using the 
following terms, including truncation of terms where appropriate: economic evaluation, cost-
benefit analysis (CBA), cost-effectiveness analysis (CEA), cost-utility analysis (CUA), 
typhoid fever and enteric fever. The search strategy was developed to cover all types and forms 
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of economic evaluations to ensure that all the relevant studies were retrieved first before 
focussing on model-based studies. This approach was taken because a scoping search 
undertaken showed that there was not much literature in this field, and the intention was to 
keep the search broad enough not to miss out on any study due to the limited literature base.  
Appendix 4 shows the complete search strategy for each database.  
 
5.3.2 Inclusion criteria 
	
Studies were deemed potentially relevant to be included in the review if they were:   
1. Economic evaluations focussed on typhoid fever; or 
2. Systematic reviews of typhoid economic evaluations.  
 
5.3.3 Exclusion criteria 
	
Studies were excluded if they were: 
1. Not in English; or 
2. Not conducted in an endemic setting; or 
3. Trial protocols or commentaries; or 
4. Letters or editorials. 
 
5.3.4 Selection of articles for the review 
	
After the removal of duplicates, a two-stage approach to article selection was used. The first 
stage involved screening of abstracts and titles to identify potentially relevant articles whilst 
the second stage involved screening of the full text articles. The screening process during both 
stages was conducted against the inclusion and exclusion criteria. The screening process was 
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undertaken by two reviewers (S.F and P.B) independently and any disagreements regarding 
eligibility were resolved using the opinion of a third reviewer (C.D) where necessary. All 
studies identified after the second stage of article selection were included for data extraction. 
 
5.3.5 Data extraction 
	
A data extraction form was developed in Excel and piloted. Then data extraction was conducted 
for each study included in this review to answer the following questions: 
1. What were the interventions evaluated (test-treat strategies; vaccination)? 
2. What was the economic evaluation approach adopted (CUA or CBA or CEA) and what 
was the outcome measure? 
3. What type of model was used (static model; transmission dynamic model)? 
4. What was the impact of the intervention on the transmission of infection between 
individuals? 
 
5.3.6 Quality assessment 
	
The methodological quality of the included studies was assessed using a modelling quality 
checklist modified from Philips et al. (2006). This modelling quality checklist was adopted 
because, although the search strategies were developed to capture the different forms of 
economic evaluation, the focus of this study was to examine how typhoid interventions have 
been modelled. Thus, a modelling quality checklist was considered appropriate here. Each item 
on the checklist was rated under the categories “yes”, “no”, “unclear” and “not applicable” by 
the extent of reporting. No study was rejected on quality grounds because the focus of this 
review was to explore the models used and not to comment on the validity of results and 
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conclusions drawn from these studies. Table 5-1 below shows the quality assessment tool 
employed in this study. 
Table 5-1 Modified Philips checklist criteria for quality assessment of included studies 
 




Is the objective of the model specified and consistent with the stated decision problem? 
 
 
Is the primary decision maker specified? 
 
 
Is the perspective of the model stated clearly? 
 
 
Are the model inputs consistent with the stated perspective? 
 
Is the structure of the model consistent with a coherent theory of the health condition under evaluation? 
 
 
Are the sources of the data used to develop the structure of the model specified? 
 
Are the structural assumptions reasonable given the overall objective, perspective and scope of the model? 
 
 
Is there a clear definition of the options under evaluation? 
 
 
Have all feasible and practical options been evaluated? 
 
 
Is there justification for the exclusion of feasible options? 
 




Is the time horizon of the model sufficient to reflect all important differences between the options? 
 
Do the disease states (state transition model) or the pathways (decision tree model) reflect the underlying 
biological process of the disease in question and the impact of interventions? 
 
 
Is the cycle length defined and justified in terms of the natural history of disease? 
 
 





After the removal of duplicates, 43 unique articles were identified for title and abstract 
screening. Fifteen titles and abstracts were potentially eligible for inclusion. After full text 
screening, 8 studies were included in the review.  The PRISMA flow diagram (Fig 5-1) below 







































Fig 5-1 The PRISMA flow diagram summarising the search strategy and 
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5.4.1 Characteristics of included studies 
	
Seven primary studies (Canh et al., 2006; Cook et al., 2008; Cook et al., 2009; Lauria et al., 
2009; Musgrove, 1992; Poulos et al., 2004; Shepard et al., 1995) and a systematic review 
(Watson and Edmund, 2015) were identified. All primary studies retrieved had been included 
in the systematic review and no new primary studies were identified post the systematic review. 
The primary studies retrieved and included in this systematic review were published between 
1992 and 2009 and the systematic review was published in 2015. Table 5-2 illustrates the 
characteristics of the included studies. 
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Table 5-2 Characteristics of included studies 
study Intervention 
evaluated 
Comparator  Type of economic 
evaluation  
Outcome measure Data source Perspective  
adopted 
Canh et al., 2006 Vaccination No vaccination Cost-benefit analysis Willingness-to-pay Field studies Private sector  
Cook et al., 2008 Vaccination No vaccination Cost-utility analysis Cost/DALY averted Field studies Public sector and societal 
Cook et al., 2009 Vaccination No vaccination Cost-benefit analysis Cost-of-illness avoided & 
Willingness-to-pay 
Field studies Societal  
Lauria et al., 2009 Vaccination No vaccination Cost-effectiveness 
analysis 
Cost/case avoided Field studies Public sector 
Musgrove, 1992 Vaccination No vaccination Cost-benefit analysis &       
cost-effectiveness 
analysis 
Cost/case avoided & 
maximum cost of vaccination 
compatible with a net 




Poulos et al., 2004 Vaccination No vaccination Cost-benefit analysis Cost-of-illness avoided Field studies Public sector and societal 
Shepard et al., 1995 Vaccination No vaccination Cost-utility analysis Cost/QALY Expert 
opinion 




5.4.2 Quality assessment of included studies 
	
Quality assessment of the included studies showed that 38% of the checklist items were 
categorized as “yes”, 27% as “no” and 35% as “unclear”. No item was categorized under “not 
applicable”. The decision problem was clearly stated in all studies and the objectives of the 
model were also specified which were consistent with the stated decision problem. However, 
in all the studies, it was unclear if the economic analysis approach used was consistent with the 
intervention under evaluation. This is because even though the focus of the evaluation in all 
the studies was the cost-effectiveness of typhoid vaccination, none of the economic evaluation 
was based on transmission dynamic modelling. None of the studies gave a clear definition of 
the options under investigation, thus, it was difficult to ascertain whether all feasible and 









Table 5-3 Quality assessment of included studies 















Is there a clear statement of the decision problem? yes yes yes yes yes yes yes 
Is the objective of the model specified and consistent with the 
stated decision problem? 
yes yes yes yes yes yes yes 
Is the primary decision maker specified? unclear yes unclear yes yes unclear unclear 
Is the perspective of the model stated clearly? yes yes yes yes yes yes yes 
Are the model inputs consistent with the stated perspective? yes yes unclear yes unclear yes yes 
Is the structure of the model consistent with a coherent theory of 
the health condition under evaluation? 
unclear unclear unclear unclear unclear unclear unclear 
Are the sources of the data used to develop the structure of the 
model specified? 
yes yes unclear yes no no unclear 
Are the structural assumptions reasonable given the overall 
objective, perspective and scope of the model? 
unclear unclear unclear unclear unclear unclear unclear 
Is there a clear definition of the options under evaluation? yes yes yes yes no yes yes 
Have all feasible and practical options been evaluated? no no no no no no no 
Is there justification for the exclusion of feasible options? no no no no no no no 
Is the chosen model type appropriate given the decision problem 
and specified casual relationships within the model? 
no unclear unclear no unclear no no 
Is the time horizon of the model sufficient to reflect all important 
differences between the options? 
unclear unclear unclear unclear yes unclear yes 
Do the disease states (state transition model) or the pathways 
(decision tree model) reflect the underlying biological process of 
the disease in question and the impact of interventions? 
unclear unclear unclear unclear unclear unclear uncler 
Is the cycle length defined and justified in terms of the natural 
history of disease? 
no no no no no no no 
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5.4.3 Summary of study findings 
	
The cost-effectiveness of typhoid vaccination was the focus of all the primary studies included 
in this review and none of them was model-based. None of the studies considered typhoid test-
treat cost-effectiveness. Two studies were based on values derived from expert opinion 
(Musgrove, 1992; Shepard et al., 1995), and five studies were based on values derived from 
field studies (Canh et al., 2006; Cook et al., 2008; Cook et al., 2009; Lauria et al., 2009; Poulos 
et al., 2004). The evaluations that were based on field studies were noted to share common 
authorship through collaboration with the Disease of Most Impoverished (DOMI) program. In 
all studies, it was noted that transmission dynamic modelling was not integrated into the 
economic analyses although the studies sought to evaluate the cost-effectiveness of typhoid 
vaccination. For example, analysis by Polous et al (2004) involved dividing the cost of running 
the vaccination programme in the study population by the economic benefits of Vi Vaccine 
(which was measured as the avoided ex-ante cost of illness in the population). Using a 
contingent valuation approach, Canh et al (2006) found that a vaccination programme in Hue, 
Vietnam was more likely to be cost-effective if benefits were measured according to 
households’ willingness to pay (WTP): suggesting a potential for private sector provision of 
typhoid fever vaccines in Hue, Vietnam. Cook et al (2008) estimated the total costs of 
immunizing the study population in one year and compared these costs with the effects of 
immunization on disease burden (cases, deaths, DALYs) over 3 years (duration of the vaccine’s 
effectiveness). Lauria et al (2008) used an optimisation model to determine the vaccine user 
fees for adults and children that would maximize the number of typhoid cases avoided without 
increasing public spending. This is the only study that was noted to have included indirect 
protection (i.e., herd immunity), albeit, using hypothetical values for herd immunity rather than 
estimates from dynamic modelling. In this particular study, it was shown that vaccine cost-
effectiveness was impacted by the level of indirect protection. Whilst the importance of herd 
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immunity was acknowledged in the other studies, it was noted as having been excluded from 
their analysis. The absence of evidence was cited as the reason for exclusion. Analysis by 
Poulus et al. (2004) when conducted from the public sector perspective, showed that a 
vaccination programme targeted at children under 5 years would be cost-saving. Conducting 
the same analysis from the societal perspective showed that there were net benefits in other age 
groups if vaccine cost was moderate and vaccination was carried out in a high incidence setting. 
Two studies showed that although vaccination with Vi-polysaccharide in both adults and 
children was unlikely to be cost-effective in a general population setting from the public sector 
perspective, it would very likely be cost-effective in a high incidence setting (Musgrove, 1992; 
Shepard et al., 1995). In these studies, it was established through sensitivity analysis that the 
main drivers of cost-effectiveness were vaccine cost, vaccine duration of protection, case 
fatality rate and vaccine effectiveness. Indirect protection was not assumed in these studies: 
therefore, the effect of herd immunity on cost-effectiveness could not be appraised. It is worth 
stating that whilst vaccination programmes were predicted to reduce typhoid incidence, it is 
not easy to draw this conclusion without the studies having included some measure of herd-
immunity in the analysis. It was noted that short or medium-term vaccination programs are 
unlikely to be effective in the elimination of the disease without measures aimed at reducing 
the ongoing force of infection (the rate at which susceptible individuals become infected) such 




This review examined previous typhoid economic evaluations, with particular focus on how 
modelling for typhoid interventions had been approached. The review showed that there have 
been relatively few economic evaluations that have focussed on typhoid fever, all of which 
have focused on the cost-effectiveness of typhoid vaccination although none of them was 
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model-based. There are a number of reasons why a new systematic review may be considered. 
However, before undertaking a systematic review it is necessary to check whether there are 
already existing or ongoing reviews, and whether a new review is justified. Although a 
systematic review on the topic area was identified through the paper selection process, the 
focus of that systematic review was to examine typhoid vaccine economic evaluations for their 
potential contributions to inform disease control. This differs markedly from the focus of the 
systematic review in this thesis, thus the justification for undertaking this systematic review.   
  
Vaccination acts by stimulating the immune system of the host and operates directly by 
reducing the number of susceptible individuals in the population and indirectly via “herd 
immunity”. When evaluating typhoid vaccine effectiveness, it is key that both these effects are 
captured. Transmission dynamic models are well suited for capturing both effects: thus, they 
are appropriate when evaluating the cost-effectiveness of typhoid vaccination (Keeling and 
Rohani, 2011). However, as noted, this was not the case in the studies included in this analysis, 
consequently, indirect protection was omitted in the analysis. Therefore, it was not possible to 
appraise the indirect effect of vaccination in their analysis. The implication is that this may 
lead to an underestimation or overestimation of the true benefits of vaccination and may result 
in inappropriate decision-making. Hence, transmission dynamic modelling should be 
integrated into cost-effectiveness analysis when estimating the true value of typhoid vaccines 
for these evaluations to be useful to policy making. However, under certain circumstances, 
using a static model based on only direct protection may be a reasonable approximation. For 
example, this will be true if the new cases that are prevented as a result of vaccination make a 
relatively little contribution to the rate at which susceptible individuals acquire the disease 
(Watson and Edmund, 2015).  
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None of the studies included in this review focussed on typhoid test-treat strategies. Thus, the 
review shows that the impact of typhoid test-treat strategies has not been explored using 
modelling. A notable feature of typhoid fever is chronic carriers (1-5%) who continue to shed 
the organisms via either their stool or urine. Thus, sustaining the occurrence of the disease in 
endemic settings (WHO, 2003). Furthermore, short-term convalescent patients may also 
contribute to disease transmission through faecal shedding in an endemic setting. Early 
accurate diagnosis and treatment of a case of typhoid fever (new case, short-term convalescent, 
or chronic carrier) focused on curtailing shedding can potentially affect onward transmission. 
However, the potential benefits of treatment following early accurate diagnosis in the 
prevention of onward transmission of the infection in an endemic setting has been little studied. 
Thus, there is no evidence to inform the extent to which treatment affects transmission. 
Therefore, when evaluating the the cost-effectiveness of an intervention for typhoid fever (such 
as test-treat strategies) where the emphasis is on improving health outcomes (as is the case in 
this work) rather than benefits to the population as a result of treatment impacting on 
transmission, then a static model may suffice (Drake et al., 2016). Indeed, the role of static 
models to evaluate the cost-effectiveness of rapid diagnostic testing in resource-limited settings 
have been shown in other disease areas where the focus was to improve direct health outcomes 
without necessarily impacting disease transmission (Tawiah et al., 2016; Hansen et al., 2017). 
One parameter that has been found to be a major driver of cost-effectiveness in the field of 
typhoid economic evaluations is “incidence”. Most studies have focussed on the estimation of 
incidence thresholds to guide policy decision-making. However, it has also been shown that 
covariates such as case fatality rate, antimicrobial resistance, and access to quality health care 
are critical but uncertain parameters that drive the incidence threshold (Lo et al., 2018). Whilst 
static models have their limitations, they can certainly be used to assess the importance of these 




Under certain circumstances, a static model or a dynamic model may be appropriate in the 
evaluation of an intervention for typhoid fever. Typhoid test-treat modelling represents a grey 
area where further work is needed. The next chapter (Chapter 6) builds on this by 
demonstrating the use of static models to evaluate the potential cost-effectiveness of rapid 




















Chapter 6: An early cost-effectiveness study of a 
hypothetical rapid test for typhoid fever diagnosis in 
Ghana 
 
This chapter brings together and employs all the knowledge and findings from the previous 
chapters in an early cost-effectiveness analysis. 
  
6.1 Background   
  
In Ghana, there are some issues of concern with the diagnosis of typhoid fever (see Chapter 1, 
p. 1-2). A quick turnaround time (leading to early diagnosis and treatment), better accuracy 
and availability are some of the potential benefits that a rapid diagnostic test could offer over 
current testing strategies in Ghana (see Chapter 4, p. 82). Therefore, the development of a test 
for typhoid fever in the Ghanaian setting which has better accuracy than the current available 
tests, and which is simple and affordable with a quick turnaround time to enable prompt 
implementation of an appropriate effective treatment has an obvious attraction. The aim of this 
chapter was to examine the potential cost-effectiveness of the HT-test in Ghana, with specific 
focus on the estimation of the maximum price and the minimum test performance required for 
the HT-test to be cost-effective. In this early cost-effectiveness analysis, the HT-test is the 
index test (the test to be evaluated). The comparator interventions (in this case the reference 
standards) against which the performance of the HT-test is compared are the culture testing 
pathway and the Widal testing pathway which were identified in Chapter 4 as being the main 







The patient population considered in this analysis is made up of individuals presenting with 
symptoms suggestive of typhoid fever (diagnosis is unknown at presentation) at a health care 
facility in Ghana. A time horizon of 180 days was chosen because in this analysis all pathways 
eventually lead to successful treatment and in such cases the appropriate time horizon needs to 
be as long as the longest treatment pathway. In this instance, the longest treatment pathway 
was 34 days. Thus, 180 days was chosen to be an appropriate time over which patients will 
benefit from the effects of testing and treatment for typhoid fever (Lo et al., 2018). Also, by 
taking the time horizon to 180 days, it would allow other feasible options to be added to the 
model which could have a longer treatment time. The Ghanaian national health service 
perspective was adopted for the analysis because the health service is the direct payer for health 
care services and the aim is to support decision making for the health service (EUnetHTA, 
2015). No discounting of cost and benefits was undertaken because the time horizon did not 
exceed 12 months (Drummond et al., 2005). The findings are expressed in terms of cost, 
quality-adjusted life years (QALYs) and net-monetary benefit (NMB). Here, the NMB is 
defined for each intervention as: 
NMB = QALYs gained * willingness to pay (WTP) for a QALY – cost of intervention. 
In Ghana, a cost-effectiveness threshold of less than $104-$951/QALY is generally considered 
to be cost-effective by policy makers (Woods et al., 2016). For this analysis, the upper limit of 
the cost-effectiveness threshold value ($951/QALY) was chosen because the lower limit is 





6.2.1 Model Choice 
 
Evaluating the potential value of the HT-test (or indeed any new technology at its early stage 
of development) requires the use of models because of the lack of data describing the 
effectiveness of an intervention during its early stages of development. An important first step 
was to decide the type of model to use (static or dynamic); i.e., whether transmission of 
infection between individuals needed to be captured in the model? Although it is acknowledged 
that typhoid fever is an infectious disease and transmission dynamic modelling would be better 
suited for its evaluation, a static model rather than a dynamic model was adopted in this study. 
Underpinning this choice is the fact that, unlike vaccination where its role in reducing the 
incidence of typhoid (directly and indirectly which is best captured by a dynamic model) has 
been demonstrated (Watson and Edmunds, 2015), there is no evidence to inform the extent to 
which early diagnosis and treatment affects onward transmission as this has been little studied 
(see Chapter 5, p. 101). In the case of this analysis, the emphasis was on evaluation of the direct 
benefits of testing and treatment to an individual (i.e., survival and quality of life) rather than 
benefits to the population via prevention of onward transmission. Furthermore, all the patients 
in this model are assumed to be treated successfully, thus, they will not contribute to onward 
transmission although there is the issue with a few days’ delay (3 days) before they are cured. 
However, because the means of transmission is not direct person-to-person (Akullian et al., 
2015), even a few days’ delay will not be likely to make much difference to the overall force 
of infection. Also, when interpreting results, the fact that including transmission effects will 
only increase the health gains from treatment, any intervention shown to be cost-effective is 
even more likely to be cost-effective in real life. Thus, under these circumstances, a static 
model was considered appropriate for the analysis. 
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The type of static model to employ (i.e., decision tree or Markov model) depends on the nature 
of the clinical condition being evaluated (i.e., acute or chronic). Decision trees are used for 
“one off” decisions and are particularly suited to acute clinical conditions, once-only diseases, 
and short-term diagnostic or screening decisions whereas Markov models are more suited for 
modelling the progression of chronic disease (Drummond et al., 2005). As discussed in Chapter 
2, typhoid fever is an acute condition. Therefore, in this study, decision trees were constructed 
to undertake the evaluation. 
 
6.2.2 Structuring the model 
 
The ensuing sections outline the assumptions and the steps in constructing and analysing the 
decision trees used in this analysis.  
 
6.2.2.1 Position of HT-test on the clinical pathway  
 
In this analysis, the value of the hypothetical test in each of the two care pathways was 
considered separately due to differences in existing pathways. A key determination in test 
evaluation is the best placement and role of a new test on existing pathways. Therefore, as a 
comparator for the two current tests (i.e., the Widal care pathway and the culture care pathway 
used in Ghana), the HT-test was evaluated in three possible roles (replacement, triage or add-
on), resulting in the construction of six decision trees. In this analysis, the emphasis of the 
evaluation was to determine in each role the maximum cost of the HT-test at a given sensitivity 
and specificity pair (using threshold analysis) at which it was still cost-effective at a WTP 
threshold of $951/QALY. There was no intention to compare the different roles with each other 
in the same pathway. The index test (the HT-test) can only appear in the comparisons once. 
Thus, there could be multiple current practice options but only one hypothetical testing strategy 
which explains why six different trees were constructed and not two (one of the two current 
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tests and one of the three possible roles of the new tests in each one). This was done to provide 
the policy maker (Government of Ghana) with a complete analysis of the potential benefits of 
the HT-test in each of the two pathways and in each of the different roles to support informed 
decision-making. Each model has two arms (current practice and the hypothetical testing 
strategy). The current practice arm is the same in all three scenarios in both pathways, but the 
hypothetical testing strategy arm differs depending on the role of the test on the test-treat 
pathway (replacement, triage or add-on). The test-treat pathway for a suspected typhoid case 
is as shown in the different decision trees. In the replacement role, the HT-test is a potential 
substitute for current tests. In the triage role, the HT-test is used to decide who should receive 
further testing with current tests, while in the add-on role the HT-test provides additional 
diagnostic information following the current test. Fig 6-1 shows the model for the HT-test vs. 
Widal test in the replacement Role. The other five models are shown in Appendix 5. Fig 6-2 
shows the Model structure showing the comparison between HT-test vs. Widal test in the 
different roles.
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Fig 6-1 Model structure for evaluating the HT-test vs. Widal test in the replacement role 
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Fig 6-2 Model structure showing the comparison between HT-test vs. Widal test in the different roles 
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6.2.2.2 Test accuracy 
 
In this analysis, each test is considered to provide either a positive or negative test result. This 
allows the application of sensitivity and specificity values to be considered in the analysis. The 
resulting possible test statuses for patients following the different pathways are shown in Table 
6-1 below. 
 
Table 6-1 Description of the application of test statuses used in the models 
 
Status Description 
TP True Positive (has typhoid and tests positive for it) 
TN True Negative (does not have typhoid and tests negative for it)  
FP False Positive (does not have typhoid but tests positive for it) 
FN False Negative (has typhoid but tests negative for it) 
 
Given that the HT-test is a hypothetical test, there was no information on the sensitivity and 
specificity of the test. For the Widal test and blood culture, following a detailed search of the 
literature, a meta-analysis study of typhoid diagnostic accuracy studies was found and used to 
inform their test accuracy parameters as shown in Table 6-2 below.  
 
Table 6-2 Sensitivity and specificity values for Widal test and blood culture 
 
Parameter Estimate Data source 
Sensitivity of Blood culture (CI) 0.68 (0.52 - 0.81) Storey et al., (2015) 
Specificity of Blood culture (CI) 0.75 (0.35 – 0.94) Storey et al., (2015) 
Sensitivity of Widal test (CI) 0.69 (0.61- 0.75) Storey et al., (2015) 
Specificity of Widal test (CI) 0.83 (0.77- 0.88) Storey et al., (2015) 
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6.2.2.3 Model assumptions 
 
In order to implement the models, the following assumptions were made: 
§ For a patient presenting with suspected typhoid, if the patient does not have typhoid, then 
it is assumed they have malaria. Underpinning this assumption is the fact that, the 
presenting symptoms for both conditions are similar (Wain et al., 2015) and the most 
common differential diagnosis for typhoid fever is malaria (see Chapter 4, p. 81). This is 
the fundamental assumption of the model. 
§ Test results obtained from retesting a person who has had treatment failure with the same 
test, are independent of those from the first test. Underpinning this assumption is the fact 
that, as part of the typhoid test-treat protocol in Ghana, patients are retested with the same 
test on their review appointments and further treatment decisions are made based on the 
test results (see Chapter 4, P. 81).  Thus, the implicit assumption that errors are purely 
random in second test. 
§ If the first round of typhoid treatment fails in individuals who actually have typhoid, then 
the second round will always be successful. Underpinning this assumption is the fact that, 
ciprofloxacin has been found to be highly active against Salmonellae in vivo and repeated 
treatment is usually associated with a 100% cure rate (Alam et al., 1995).    
§ For any patient that has malaria, malaria treatment is successful. This is justified because 
artemisinin-based combination treatments (ACTs) (the first line drug for uncomplicated 
malaria in Ghana) are rapid and effective (effectiveness usually exceeds 95%) (Nosten and 
White, 2007). 
§ There is no uncertainty about the length of treatment for typhoid and malaria (14 days and 
3 days respectively). These are informed by the standard treatment guidelines in Ghana 
(GNDP, 2014).  
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§ All patients experiencing treatment failure return for retesting immediately after 
completion of a treatment course. Underpinning this assumption is the fact that as part of 
the clinical practice in Ghana, patients are given review dates which falls on the last day of 
a treatment course and are highly encouraged to return for reassessment and this seems to 
be the case (see Chapter 4, page 81). Thus, the implicit assumption made. 
§ Delays on the test-treat pathway (i.e., delay receiving test results, delay receiving treatment) 
are negligible. Underpinning this assumption is the fact that there are available tests and 
treatments for typhoid fever in Ghana (GNDP, 2014), thus, once patients have reported to 
the healthcare facility they are tested and an appropriate treatment is given (see Chapter 4, 
p 81).   
§ Patients experience the same utility at the different phases of treatment but return to perfect 
health once treatment has been completed. This assumption was made because of the 
paucity of evidence in the literature on utility estimates to inform the different phases of 
treatment. 
§ Utility when experiencing typhoid symptoms is the same as when experiencing malaria 











6.2.2.4 Individuals tested who have typhoid 
 
Any action taken is dependent on the information available to the clinician at that point in time 
(i.e. test results and response to treatment). For example, as shown in the current practice arm 
(Fig 6-1), individuals presenting with symptoms suggestive of typhoid who test positive and 
actually have typhoid (True positive - TP) are given a first round of typhoid treatment, some 
of whom will be successfully treated and others not. TPs experiencing treatment failure are 
retested and re-test TPs are given a second round of typhoid treatment which in the model is 
assumed to be successful. Retested negatives (re-test FN) will be given malaria treatment on 
the basis that typhoid treatment has been unsuccessful. However, because re-test FN patients 
actually have typhoid, the malaria treatment will be ineffective. They are then given a second 
round of typhoid treatment following the malaria treatment and this second round of treatment 
is assumed to be successful.  
 
6.2.2.5 Individuals tested who do not have typhoid 
 
As shown in the current practice arm (Fig 6-1), individuals presenting with symptoms 
suggestive of typhoid who test negative and do not have typhoid (and assumed to have malaria) 
(True negative - TN) are given treatment for malaria which in the model is assumed to be 
successful. Individuals presenting with symptoms suggestive of typhoid who test positive but 
do not have typhoid (False positive - FP) are treated for typhoid based on their test results. 
However, because they do not have typhoid, typhoid treatment will be ineffective and the 
patients are retested. Test positive patients as a result of a re-test (re-test FP) are given a second 
round of typhoid treatment which will be ineffective for the same reason. Based on two typhoid 
treatment failures, they are given treatment for malaria which is assumed to be successful. Test 
negative patients as a result of a re-test (re-test TN) are given treatment for malaria which is 




A range of secondary sources was utilized to parameterize the model. These secondary sources 
were identified through extensive searching of published literature, websites of government 
departments in Ghana, and medical records in Ghana. Table 6-3 shows the probabilities used 
in the economic analysis along with the data source.  
 
Table 6-3 Probability estimates utilized in the economic analysis 
 
Parameter Estimate Data source 
Probability of successful first typhoid 
treatment 
0.95 Chandey and Multani, (2012) 
Prevalence of typhoid in the patient 
population presenting  
0.48 Afoakwah et al., (2011) 
 
Given that this is an early economic evaluation, there was a lack of data to inform estimates of 
the parameters describing the characteristics of the HT-test, thus these parameters were subject 
to extensive sensitivity analysis to draw conclusions about the characteristics of this test 
necessary for it to be cost-effective. 
 
6.2.3.1 Measurement of effects 
 
The primary outcome measure was the QALY. Total QALYs were estimated for each branch 





Table 6-4 Parameter estimates used to inform QALY values 
 
Item Estimate Source 
Utility when experiencing typhoid 
symptoms (CI) 
0.867 (0.81-0.912) Lo et al., (2018) 
Perfect health utility 1 By definition: Drummond 
et al., (2005) 
Time horizon of model (days) 180 Lo et al., (2018) 
Number of days per typhoid treatment 14 GNDP, (2014) 
Mean recovery time for successful typhoid 
treatment (SD) 
3.68 (0.92) Chandey and Multani, 
(2012) 
Number of days per malaria treatment 3 GNDP, (2014) 
Mean recovery time for successful malaria 
treatment (SD)  
1.83 (0.95) Grynberg et al., (2015) 
 
For every round of unsuccessful treatment, the total number of days per treatment is included 
in the estimation, and for every successful treatment, the mean recovery time for successful 
treatment is also included. For example, total QALYs for a branch where a patient receives two 
rounds of typhoid treatment (i.e., one unsuccessful and one successful) was calculated as, 
(U1T1) + (U1T2) + (U2T3) / 365 days.  
Where U1 is the utility when experiencing typhoid symptoms. 
T1 is number of days per typhoid treatment. 
T2 is mean recovery time for successful typhoid treatment. 
U2 is perfect health utility. 
T3 is the number of days in perfect health after two typhoid treatments. 
The time horizon (TH) has been incorporated into the above calculation as follows:  
T3 = TH – (T1+T2)   
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6.2.3.2 Measurements of cost 
 
Total cost for each branch was estimated based on the perspective of the Ghanaian national 
health service and for the 2018 cost year. All costs were converted to US dollars by using the 
exchange rate (Gh₵1 = $0.225) adopted from the website of the Bank of Ghana at the time of 
analysis (29/03/2018) (BoG, 2018). Table 6-5 shows the costs used in the economic analysis. 
 
Table 6-5 Cost parameters and references 
 
Item Unit cost (Gh₵) Unit cost ($) Data source 
Widal test 5.67 1.28 NHIS tariffs, (2016) 
Blood culture 10.18 2.29 NHIS tariffs, (2016) 
Ciprofloxacin 6 1.35 NHIS tariffs, (2016) 
Artemether/Lumefantrine 3.5 0.79 NHIS tariffs, (2016) 
OPD tariff per visit 16.07 3.62 NHIS tariffs, (2016) 
 
Ciprofloxacin and Artemether/Lumefantrine are the first line drugs of choice for typhoid and 
malaria treatment respectively in Ghana. The total cost for a branch where a patient has visited 
the health facility once, received the Widal test and then typhoid treatment is estimated as 
follows: 
cost of Widal test + cost of ciprofloxacin + OPD tariff per visit = $ 6.25  
The OPD tariff is an amount reimbursable to the service provider per visit to cover other costs 
like staff time and consultation. On any pathway where initial treatment is unsuccessful, there 
will be more than one visit and, in such instances, the OPD tariff is multiplied by the number 
of visits and added to the other costs incurred in order to estimate the total cost for that branch. 
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6.2.4 Analysing the decision tree 
 
After the model had been populated, the decision tree was averaged out and “rolled-back” to 
obtain the expected costs and QALYs gained for each strategy. These are the sum of the 
products of the estimates of the probability of events and their outcomes. 
 
6.2.5 Dealing with uncertainty 
 
Sensitivity analyses were conducted to test the robustness of parameter estimates, determine 
the range of parameters which have the greatest impact on cost-effectiveness, and determine 
how sensitive the results are to changes in model structure. Given that this is an early economic 
evaluation of a hypothetical test, there was no information on test accuracy or cost of the new 
test. Thus, each of these parameters was a separate focus of sensitivity analysis. Headroom 
analysis (i.e., maximum cost at which the new technology is still cost-effective at a given 
willingness-to-pay threshold) using NMB was conducted. The price at which the NMB of using 
the HT-test equals the NMB of using each of the comparator tests gives information on the 
headroom price of the HT-test compared to each of the comparator tests. Furthermore, 
sensitivity and specificity pairs for the HT-test were varied and the headroom price for each 
pair determined. This analysis gave information on how good the test needs to be (in terms of 
accuracy), and at what price, for it to be cost-effective. By varying accuracy pairs for the HT-
test, the incremental effectiveness for each accuracy pair could be determined and information 
on which accuracy pairs provide the most benefit to patients within cost-effectiveness 
constraints could be identified. 
 
Probabilistic sensitivity analysis (PSA) was also conducted. A probability distribution was 
defined for each uncertain parameter (i.e., sensitivity and specificity of Widal test, sensitivity 
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and specificity of culture, prevalence of typhoid fever in the patient population presenting, 
probability of successful first typhoid treatment, mean recovery time for successful typhoid 
treatment and mean recovery time for successful malaria treatment). A beta distribution was 
assigned to all uncertain parameters except the test accuracy parameters of the comparator tests. 
Table 6-6 shows the beta distributions assigned to each of the uncertain model parameters. 
Table 6-6 Parameters of beta distribution  
 
Model parameters with uncertainty Parameters of beta distribution 
a b 
Mean recovery time for successful typhoid treatment 
(This is a fraction of the length of treatment for typhoid)  
9.95 28.32 
Mean recovery time for successful malaria treatment 
(This is a fraction of the length of treatment for malaria)  
0.85 0.55 
Prevalence of typhoid in the patient population 
presenting 
22 24 
Probability of successful first typhoid treatment  38 2 
Utility when experiencing typhoid symptoms  145.48 22.32 
 
 
 Sensitivity and specificity are correlated and therefore required a different method that 
accounts for the correlation between these parameters (Harbord and Whiting, 2009). Data from 
a meta-analysis of typhoid diagnostic accuracy studies (Storey et al., 2015) was utilized to 
obtain the hierarchical summary receiver operating characteristic (HSROC) curves for Widal 
test and blood culture. Using the Stata function metandi to obtain the HSROC curve and the 
following equation that links sensitivity to any given specificity, it was possible to take a value 
of specificity and calculate a corresponding sensitivity along the HSROC curve. 
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Where	lambda	(,) is the mean of the accuracy parameter. 
Beta	(/) is the shape parameter. 
 
For the PSA, lambda and beta were described by a normal distribution using the mean and 
standard error described in the Stata output. These distributions were then sampled for the PSA. 
The model was run 1000 times, each time randomly selecting a value for each parameter from 
their respective distributions. Mean costs and mean QALYs were calculated by averaging 
across all 1000 simulations. Cost-effectiveness acceptability curves (CEACs) were drawn to 
gain a greater understanding of realistic price and test accuracy parameters.  
  
6.2.6 Value of information (VOI) analysis 
 
VOI analysis was conducted to provide insights into the value of conducting further research 
from the perspective of the health care provider in Ghana. In the absence of information on test 
accuracy parameters of the HT-test and specific guidance on VOI analysis at this early stage 
of analysis, the assumption was made that the HT-test has the same accuracy characteristics as 
the Widal test (the better of the two comparator tests in terms of accuracy). This approach was 
taken in order to reflect in the results some sense of the value of resolving this uncertainty as 
the accuracy of the HT-test is unknown. Thus, the accuracy parameters for the Widal test (i.e., 
sensitivity of 0.69 and specificity of 0.83 with their associated uncertainty) were used to inform 
the test accuracy of the HT-test in both comparisons (i.e., the HT-test vs. Widal test and the 
HT-test vs. blood culture). The VOI analysis was repeated for different prices in each role as 
informed by the results of the headroom analysis. The assumed sensitivity and specificity of 
the HT-test were incorporated into the PSA to capture the variations around the HT-test 
accuracy characteristics in the analysis. To do this, the distributions for the Widal test were 
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sampled 2,000 times. The first 1,000 samples were used to describe the uncertainty around the 
Widal test characteristics (sensitivity and specificity) and the second set of 1,000 samples for 
uncertainty around the HT-test characteristics. When thinking about the overall value of 
removing decision uncertainty, one needs to consider the number of people affected by the 
decision annually and how long the current comparison will remain relevant. Kim et al (2017) 
reports that the annual incidence of typhoid in Ghana in 2016 was 60,892, thus, in this analysis, 
the number of people considered to be affected by the decision annually was 60,000. Also, it 
is assumed that the HT-test is likely to be relevant for five years before new technologies 
become available, thus, a decision relevant time horizon of 5 years was adopted in this analysis. 
In the absence of an accepted discounting rate in Ghana, a discounting rate of 3.5% (as applied 
in the UK) was adopted in this analysis to estimate the present value of the overall value of 
removing decision uncertainty over the specified decision relevance time horizon of 5 years. 
The formula below was used to estimate the total discounted incidence over 5 years. This value 
was multiplied by the expected value of perfect information (EVPI) per person in each scenario 
to obtain the overall value of removing decision uncertainty over 5 years.  
N * (1+ 1/(1+r) + 1/(1+r)2 + 1/(1+r)3 + 1/(1+r)4) 
Where N is the annual incidence (in the case of this analysis N= 60,000) 
r is the discounting rate (in the case of this analysis r = 0.035)  
The total discounted incidence used in this analysis is 280,385.	
	
	
 In VOI analysis, one may also want information on the parameters causing most of the decision 
uncertainty and the potential value of reducing the uncertainty by collecting more data. This is 
known as expected value of partial perfect information (EVPPI). In this study, EVPPI was 
estimated using the Sheffield Accelerated Value of Information (SAVI) software (Strong et al., 
2014). Information about the model (i.e., model name, WTP threshold, number of patients 
affected by the decision each year, decision relevance time horizon, units used for cost and 
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benefits and name of jurisdiction/country) were inputted into the software. Then, the PSA 
samples of parameters, costs and effects were imported into the software as three csv files and 
the software was run to generate a report on the EVPPI. The potential limitation of using the 
SAVI software is that, it does not incorporate a discounting rate and therefore, the estimated 
EVPPI over the relevance time horizon is a direct multiplication of the per person EVPPI by 
the time horizon. This is inappropriate and a discounting rate needs to be introduced into this 
calculation in order to estimate the actual EVPPI value over the relevant time horizon. This 
particular limitation was not considered applicable in this analysis because, it was identified 
from the outset and the overall EVPPI for the relevant time horizon was calculated by 
multiplying the per person EVPPI with the estimated total discounted incidence over 5 years 


















The results are presented in two parts. The results of HT-test vs. Widal test are presented first, 
followed by the results of the HT-test vs. blood culture. In each case, the results are presented 
in the following order. First, graphs of NMB of the HT-test and each of the comparator tests 
(which gives information on headroom price) are presented. These are followed by tables of 
incremental effectiveness and the maximum price at which the HT-test is still cost-effective (at 
a threshold of $951/QALY) at each sensitivity and specificity pair for the HT-test against each 
of the comparator tests. Then CEACs and a table summarising the results for the comparisons 
between the HT-test and each of the comparator tests is presented. Finally, VOI analysis results 
















6.3.1 Comparisons of the HT-test vs. Widal test 
 
6.3.1.1 Headroom analysis using NMB (the HT-test vs. Widal test) 
 
Taking all parameters at baseline and using NMB for each intervention at a WTP for a QALY 
of $951, the NMB for the HT-test and Widal test with variation in the price for the HT-test in 
the replacement role is shown in Fig 6-3. As shown in Fig 6-3, at a WTP of $951 for a QALY, 
the HT-test can be priced up to $3.85 and still be cost-effective against the Widal test in the 
replacement role. The maximum prices at which the HT-test can be priced and still be cost-
effective against the Widal test in the triage and add-on roles are $1.94 and $1.47 respectively. 
The figures showing NMB for triage and add-on roles are presented in Appendix 6. 

































6.3.1.2 Incremental effectiveness (QALYs) varying sensitivity and specificity 
pairs for the HT-test vs. Widal test  
 
The following set of tables show the incremental effectiveness and the maximum price at which 
the HT-test is still cost-effective (at $951/QALY) at each sensitivity and specificity pair for the 
HT-test vs. Widal test in the replacement role. The tables for the triage and add-on roles are 
presented in Appendix 7. When examined together, these tables provide valuable and useful 
information critical to the understanding of how accurate the HT-test needs to be, and at what 
price, for it to be cost-effective.  
 
NV in the tables represent negative values for price and implies that the HT-test cannot be cost-
effective at these sensitivity and specificity pairs and the end user of the test would have to be 
paid for using the test. Shaded black cells represent cases where either the test is completely 















Table 6-7 Incremental effectiveness (QALYs) at each sensitivity and specificity pair for 
the HT-test vs. Widal test (Replacement role)  
 
 
            
 100 0.0010 0.0007 0.0004 0 -0.0005 -0.001 -0.0016 -0.0022 -0.0029 -0.0036   
 90 0.0010 0.0007 0.0003 -0.0001 -0.0005 -0.0011 -0.0016 -0.0022 -0.0029     
 80 0.0009 0.0006 0.0003 -0.0001 -0.0006 -0.0011 -0.0017 -0.0023       
Sensitivity 70 0.0009 0.0006 0.0002 -0.0002 -0.0007 -0.0012 -0.0017         
 60 0.0008 0.0005 0.0002 -0.0003 -0.0007 -0.0012           
 50 0.0007 0.0004 0.0001 -0.0003 -0.0008             
 40 0.0007 0.0004 0 -0.0004               
 30 0.0006 0.0003 0                 
 20 0.0006 0.0003                   
 10 0.0005                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
     Specificity       
 
 
Table 6-8 Maximum price ($) at which the HT-test is still cost-effective at each sensitivity 
and specificity pair for the HT-test vs. Widal test (Replacement role) 
 
 
            
 100 3.85 3.13 2.40 1.64 0.86 0.06 NV NV NV NV   
 90 3.59 2.89 2.16 1.41 0.64 NV NV NV NV     
 80 3.33 2.64 1.92 1.18 0.42 NV NV NV       
Sensitivity 70 3.07 2.39 1.69 0.95 0.2 NV NV         
 60 2.82 2.15 1.45 0.73 NV NV           
 50 2.56 1.91 1.22 0.5 NV             
 40 2.31 1.67 0.99 0.28               
 30 2.06 1.43 0.76                 
 20 1.81 1.19                   
 10 1.56                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
 
Values in bold format represents values of price at sensitivity and specificity pairs at which the HT-test is still 
cost-effective and has a positive incremental effect, and would normally be of interest to a decision maker. 
 
Values in italic format represent values of price at sensitivity and specificity pairs at which the HT-test is still 
cost-effective but is slightly less effective than the Widal test. 
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As shown in the set of tables (Tables 6-7 & 6-8), the HT-test can be priced up to $3.85 and still 
be cost effective against the Widal test in the replacement role when the HT-test has both 
sensitivity and specificity of 100%. In this case, the incremental effectiveness is 0.0010. When 
the HT-test has both sensitivity and specificity of 70%, it can be priced up to $0.95 and still be 
cost-effective, however, here the incremental effectiveness is -0.0002. This means that as the 
accuracy of the HT-test decreases, the maximum price of the HT-test for it to be cost-effective 
against the Widal test in the replacement role reduces with a decrease in incremental 


















6.3.1.3 Cost-effectiveness acceptability curves for the HT-test vs. Widal test 
(replacement role) 
 
Using a reasonable price range for the HT-test of $1.00 to $4.00 that was informed by findings 
shown in Table 6-7 and Table 6-8, the CEACs for the PSA of the HT-test vs. Widal test in the 
replacement role are presented below. The set of figures for the triage and add-on roles are 
presented in Appendix 8. In the CEACs, the price is fixed whereas sensitivity and specificity 
are varied using the following pairs of values (1:1; 0.6:1; 1:0.6; 0.9:0.9; 0.7:0.9; 0.9:0.7; 
0.8:0.8; 0.7:0.7).  
 
Fig 6-4 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




Curves for the other sensitivity and specificity pairs are not shown because at a price of $4, only the (1,1) pair has any 

























P(HT-test, 1:1) Threshold ($951) 
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Fig 6-5 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




The curve for the (0.7:0.7) sensitivity and specificity pair is not shown because it never goes above zero 
 






The results show that specificity is a major driver of the probability of the HT-test being cost-
effective at the threshold value of $951 per QALY. For any price above the estimated 
headroom, the HT-test was always less than 50% likely to be cost-effective at the WTP 
threshold even for the most optimistic scenario for the HT-test (i.e., both sensitivity and 
specificity of 100%). For example, the headroom price for the HT-test in the replacement role 
as shown in Table 6-8 is $3.85. From Fig 6-4, at a price of $4 (which is above the headroom), 
the HT-test is less than 50% likely to be cost-effective even when both sensitivity and 
specificity are 100%. The results further show that when the price is low (below the price of 
the Widal test) (in this case $1), then all the pairs with positive expected incremental 
























P(HT-test, 1:1) P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) Threshold ($951)
P(HT-test, 0.7:0.90) P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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6.3.1.4 Results for the VOI analysis (the HT-test vs. Widal test)   
 
Using sensitivity and specificity for the HT-test sampled from the same distribution for the 
Widal tests and a price of $1.00 informed by the CEACs, the results of the VOI analysis for 
the HT-test vs. Widal test in the replacement role are presented below. The results for the triage 
and add-on roles are presented in Appendix 9.  
 
 







As shown in Fig 6-6, at a WTP threshold of $951/QALY, the overall EVPI for the specified 
























In VOI analysis, one may also want information on the parameters causing most of the decision 
uncertainty and the potential value of reducing the uncertainty by collecting more data. This is 
known as expected value of partial perfect information (EVPPI). Table 6-9 shows the EVPPI 
for each of the uncertain model parameters at a WTP threshold of $951/QALY. 
Table 6-9 Single parameter EVPPI 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0 0 0.00 
Mean recovery time for successful malaria 
treatment 
0 0 0.00 
Prevalence of typhoid in the patient 
population presenting 
0 0 0.00 
Probability of first successful typhoid 
treatment 
0 0 0.00 
Utility when experiencing typhoid 
symptoms 
0 0 0.00 
Specificity of Widal test 0.000222 0 62 
Sensitivity of Widal test 0 0 0.00 
Specificity of the HT-test 0.001010 
 
0 283 
Sensitivity of the HT-test 0 0 0.00 
 
The standard error shows whether there have been enough replications in the model.   
 
 
As shown in Table 6-9, specificity of the HT-test and Widal test are the two parameters causing 
most of the decision uncertainty. The standard error values also indicate that in this analysis, 









Role Price ($) Percentage likelihood of being cost-effective at threshold for the following accuracy pairs (sensitivity, specificity)  
 
Replacement (1,1) (0.6,1) (1,0.6) (0.9,0.9) (0.7,0.9) (0.9,0.7) (0.8,0.8) (0.70.7) 
 4.00 0%        
 3.00 72% 0% 0% 0% 0% 0% 0% 0% 
 2.00 100% 63% 0% 89% 7% 0% 0% 0% 
 1.00 100% 100% 2% 100% 100% 19% 95% 0% 
          
Triage  2.00 3%        
 1.00 100% 63% 0% 52% 7% 0% 0% 0% 
 0.50 100% 100% 1% 99% 91% 7% 33% 0% 
          
Add-on 2 2%        
 1.00 76% 11% 0% 5% 0% 0% 0% 0% 







Role Headroom price ($) Incremental Effectiveness (QALYs) (positive range)  Price range ($) (across range of positive 
incremental effectiveness) 
Replacement 3.85 0 to 0.0010 (Specificity at least 70%) 1.64-3.85 (Specificity at least 70%) 
Triage 1.94 0 to 0.0003 (Specificity at least 90%) 0.34-1.94 (Specificity at least 90%) 
Add-on 1.47 0 to 0.0002 (Specificity at least 90%) 0.76-1.47 (Specificity at least 90%) 
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Table 6-11 Summary of VOI analysis for the HT-test vs. Widal test 
Role Price ($) EVPI per person ($) Overall EVPI ($) for the decision relevant time horizon `(5yrs) 
Replacement 2.00 0.00 0.00 
 1.00 0.011723 3287 
    
Triage 1.00 0.001029 289 
 0.50 0.066283 18585 
    
Add-on 1.00 0.000082 23 
 0.50 0.001449 406 
 




























of Widal test 
Sensitivity 







Replacement 2.00          





           
Triage 1.00   0.000109 
(30.68) 
      











           
Add-on 1.00          
 0.50   0.000307 
(86) 




Table 6-10 shows the percentage likelihood of the HT-test being cost-effective compared to 
the Widal test at a given price and accuracy pair for the HT-test at the WTP threshold value of 
$951 per QALY. For example, it can be seen from the table that at a price of $2 and test 
accuracy parameters of sensitivity 60% and specificity 100%, the HT-test is 63% likely to be 
cost-effective in a replacement role compared to the Widal test. The results also show that, as 




Table 6-11 shows that for the assumptions made about the HT-test, the EVPI per person is 
$0.00 when the HT-test is $2.00, thus, the overall EVPI for 5 years is also 0.00. This indicates 
that research into other parameters to resolve uncertainty is not worth doing based on the 
assumptions made about the HT-test. The EVPPI results also shows that at this price ($2.00), 
there is no uncertainty associated with the individual model parameters as an inevitable 
consequence of the overall EVPI being zero.  
 
The results further show that, regardless of the scenario, mean recovery time for successful 
typhoid treatment, mean recovery time for successful malaria treatment, probability of 
successful first typhoid treatment and the sensitivity of the HT-test do not contribute to the 
decision uncertainty. Overall, the prevalence of typhoid in the patient population, the 
specificity of the Widal test and the specificity of the HT-test can be seen to be the parameters 









6.3.2 Comparisons of the HT-test vs. blood culture 
 
6.3.2.1 Headroom analysis using NMB (the HT-test vs. blood culture) 
 
Taking all the parameters at baseline and using NMB for each intervention at a WTP for a 
QALY of $951, the NMB for the HT-test and blood culture with variation in the price for the 
HT-test in the replacement role is shown in Fig 6-7. As shown in Fig 6-7, at a WTP of $951 
for a QALY, the HT-test can be priced up to $9.56 and still be cost-effective vs. blood culture 
in the replacement role. The maximum prices at which the HT-test can be priced and still be 
cost-effective vs. blood culture in the triage and add-on roles are $7.14 and $10.08 respectively. 
The graphs for the triage and add-on roles are presented in Appendix 10.   
 




























Headroom analysis (sensitivity and specificity of the HT-test; 1,1)
NMB (HT-test) NMB (Blood culture)
9.56
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6.3.2.2 Incremental effectiveness (QALYs) varying sensitivity and specificity 
pairs for the HT-test vs. blood culture (Replacement role) 
 
The following set of tables show the incremental effectiveness and the maximum price at which 
the HT-test is still cost-effective (at $951/QALY) at each sensitivity and specificity pair for the 
HT-test vs. blood culture in the replacement role. The set of tables for the triage and add-on 
roles are presented in Appendix 11. 
 
The results show a similar observation made in the comparison between the HT-test and Widal 
test. That is, as the accuracy of the HT-test decreases, the maximum price of the HT-test for it 
to be cost-effective against blood culture reduces with a decrease in incremental effectiveness 



















Table 6-12 Incremental effectiveness (QALYs) at each sensitivity and specificity pair for 
the HT-test vs. blood culture (Replacement role)  
 
 
      
             
 100 0.0010 0.0007 0.0004 0 -0.0005 -0.0010 -0.0016 -0.0022 -0.0029 -0.0036   
 90 0.0010 0.0007 0.0003 -0.0001 -0.0005 -0.0011 -0.0016 -0.0022 -0.0029     
 80 0.0009 0.0006 0.0003 -0.0001 -0.0006 -0.0011 -0.0017 -0.0023       
Sensitivity 70 0.0009 0.0006 0.0002 -0.0002 -0.0007 -0.0012 -0.0017         
 60 0.0008 0.0005 0.0002 -0.0003 -0.0007 -0.0012           
 50 0.0007 0.0004 0.0001 -0.0003 -0.0008             
 40 0.0007 0.0004 0 -0.0004               
 30 0.0006 0.0003 0                 
 20 0.0006 0.0003                   
 10 0.0005                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
     Specificity       
 
Table 6-13 Maximum ($) price at which the HT-test is still cost-effective at each sensitivity 
and specificity pair for the HT-test vs. blood culture (Replacement role) 
 
    
             
 100 9.56 8.57 7.58 6.59 5.6 4.62 3.63 2.64 1.65 0.66   
 90 9.31 8.33 7.35 6.37 5.39 4.41 3.43 2.45 1.46     
 80 9.07 8.1 7.13 6.16 5.18 4.21 3.23 2.26       
Sensitivity 70 8.82 7.86 6.9 5.94 4.97 4.01 3.04         
 60 8.58 7.63 6.68 5.72 4.76 3.8           
 50 8.34 7.4 6.46 5.51 4.56             
 40 8.1 7.17 6.24 5.3               
 30 7.87 6.95 6.02                 
 20 7.63 6.72                   
 10 7.4                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
 
Values in bold format represents values of price at sensitivity and specificity pairs at which HT-test is still cost-
effective and has a positive incremental effect and would normally be of interest to a decision maker. 
 
Values in italic format represent values of price at sensitivity and specificity pairs at which the HT-test is still 
cost-effective but is slightly less effective than blood culture. 
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6.3.2.3 Cost-effectiveness acceptability curves for the HT-test vs. blood 
culture (replacement role) 
 
Using a reasonable price range for the HT-test of $6.00 to $10.00, which was informed by 
findings shown in Table 6-12, and Table 6-13, the CEACs for the PSA of the HT-test vs. blood 
culture in the replacement role are presented below. The set of graphs for the triage and add-
on roles are presented in Appendix 12. In the CEACs, the price is fixed whereas sensitivity and 
specificity are varied using the following pairs of values (1:1; 0.6:1; 1:0.6; 0.9:0.9; 0.7:0.9; 
0.9:0.7; 0.8:0.8; 0.7:0.7).  
 
Fig 6-8 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




Curves for the other sensitivity and specificity pairs are not shown because at a price of $10.00, only the (1,1) pair 



























Fig 6-9 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 







The results showed a similar trend as observed with the HT-test vs. Widal test comparison. 
That is, specificity is a major driver of the probability of HT-test being cost-effective at the 
threshold value for cost-effectiveness of $951 per QALY. For any price above the estimated 
headroom, the HT-test was always less than 50% likely to be cost-effective at the WTP 
threshold even for the most optimistic scenario for the HT-test (i.e., both sensitivity and 
specificity of 100%) (Fig 6-8). The results also show that as the price drops, more and more 



























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)
P(HT-test, 0.7:0.90) P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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6.3.2.4 Results for the VOI analysis (the HT-test vs. blood culture) 
 
Using sensitivity and specificity for the HT-test sampled from the same distribution for the 
Widal tests and a price of $6.00 informed by the CEACs, the results of the VOI analysis for 
the HT-test vs. blood culture in the replacement role are presented below. The results for the 
triage and add-on roles are presented in Appendix 13.  
 









As shown in Fig 6-10, at a WTP threshold of $951/QALY, the overall EVPI for the specified 






















Table 6-14 shows the EVPPI for each of the uncertain model parameters at a WTP threshold 
of $951/QALY. 
Table 6-14 Single parameter EVPPI 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0.00 0 
Mean recovery time for successful malaria 
treatment 
0.00 0.00 0 












Utility when experiencing typhoid 
symptoms 
0.00 0.00 0 




Sensitivity of blood culture 0.061716 0.01 17304 
 
Specificity of the HT-test 0.00 0.00 0 
Sensitivity of the HT-test 0.00 0.00 0 
 
The standard error shows whether there have been enough replications in the model.   
 
As shown in table 6-14, the parameters causing most of the decision uncertainty are prevalence 
of typhoid in the patient population, probability of first successful typhoid treatment, sensitivity 








Role Price ($) Percentage likelihood of being cost-effective at threshold for the following accuracy pairs (sensitivity, specificity)  
 
Replacement (1,1) (0.6,1) (1,0.6) (0.9,0.9) (0.7,0.9) (0.9,0.7) (0.8,0.8) (0.70.7) 
 10.00 39%        
 9.00 64% 39% 1% 33% 23% 4% 11% 2% 
 8.00 86% 65% 6% 59% 46% 15% 29% 8% 
 7.00 97% 88% 20% 83% 74% 35% 54% 25% 
 6.00 100% 98% 42% 96% 92% 60% 79% 49% 
          
Triage  8.00 26%        
 7.00 55% 31% 4% 30% 22% 7% 13% 4% 
 6.00 83% 64% 14% 61% 49% 24% 35% 18% 
 5.00 97% 88% 34% 87% 79% 50% 65% 40% 
          
Add-on 11.00 40%        
 10.00 51% 45% 24% 41% 39% 28% 32% 26% 






Role Headroom price ($) Incremental Effectiveness (QALYs) (positive range)   Price range ($) (across range of positive 
incremental effectiveness) 
Replacement 9.56 0 to 0.0010 (Specificity at least 70%) 6.59-9.56 (Specificity at least 70%) 
Triage 7.14 0 to 0.0003 (Specificity at least 90%) 5.06-7.14 (Specificity at least 90%) 
Add-on 10.08 0 to 0.0002 (Specificity at least 90%) 9.37-10.08 (Specificity at least 90%) 
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Table 6-16 Summary of VOI analysis for the HT-test vs. blood culture 
Role Price ($) EVPI per person ($) Overall EVPI ($) for the decision relevant time horizon `(5yrs) 
Replacement 7.00  0.561838 
 
157531 
 6.00  0.184085 
 
51615 
    
Triage 6.00  0.434218 
 
121748 
 5.00  0.337717 
 
94691 
    
Add-on 10.00  0.546230 
 
153154 
































































           


















           
Add-on 10.00   0.234678 
(65800) 















Table 6-15 shows the percentage likelihood of the HT-test being cost-effective compared to 
blood culture at a given price and accuracy pair for the HT-test at the WTP threshold value of 
$951 per QALY. For example, it can be seen from the table that at a price of $6.00 and test 
accuracy parameters of sensitivity 90% and specificity 90%, the HT-test is 96% likely to be 
cost-effective in a replacement role compared to blood culture. The results also show that, as 




Table 6-16 shows that regardless of the scenario, mean recovery time for successful typhoid 
treatment, mean recovery time for successful malaria treatment and utility when experiencing 
typhoid symptoms do not contribute to the decision uncertainty. Overall, the prevalence of 
typhoid in the patient population presenting, probability of first successful typhoid treatment, 
specificity and sensitivity of blood culture seem to be the parameters contributing to most of 
the decision uncertainty in the HT-test vs blood culture comparison.   
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6.4 Discussion  
 
Using a model-based economic evaluation with the outcome measure of the QALY, this 
chapter examined the potential cost-effectiveness of a hypothetical typhoid test (the HT-test) 
in Ghana. In this early cost-effectiveness analysis, the HT-test was the index test (the test to be 
evaluated). The comparator interventions (in this case the reference standards) against which 
the performance of the HT-test was compared were the culture testing pathway and the Widal 
testing pathway identified as being the main diagnostic tests used for typhoid fever in Ghana. 
The evaluation was conducted by varying the position of the HT-test on each of the two testing 
pathways. 
 
The headroom analysis (where the assumption is made that the HT-test is 100% accurate) 
shows that the HT-test can be priced up to $3.85 and still be cost-effective against the Widal 
test in the replacement role. The maximum prices at which the HT-test can be priced and still 
be cost-effective against the Widal test in the triage and add-on roles are $1.94 and $1.47 
respectively. The implication of these results is that depending on the number of tests that are 
likely to be administered over the lifetime of the HT-test, if it is not possible to develop the 
HT-test so that it can be sold below these prices and make a profit, then resources should not 
be committed to its further development. It is worth stating that although a higher price allows 
for a greater chance of a return on investment, it also increases the possibility of rejection on 
budget impact grounds.  
 
Examining the headroom room prices for all the different roles together also gives an indication 
about the likely placement of the HT-test on the current testing pathway. For example, looking 
at the values $3.85, $1.94 and $1.47, which represents replacement, triage and add-on 
respectively, it can be concluded that the test has more value in a replacement role rather than 
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as a triage or add-on to the current testing pathway. That is, if realistically the headroom prices 
for the triage and add-on roles are too low and it not possible to develop and sell the HT-test at 
these prices, then this indicates that producing the test to replace the Widal test might be the 
more viable option. The same principle of reasoning as already described can be applied to the 
HT-test vs. blood culture comparison. In this comparison, a similar conclusion is made that the 
HT-test is likely to have more value in a replacement role rather than as a triage or add-on to 
blood culture.   
 
Acknowledging that the headroom price (when the HT-test is 100% accurate) is probably going 
to be unrealistic, the focus turns to how accurate the HT-test needs to be to be cost-effective. 
Additional information on the value of the HT-test compared to each of the comparator tests 
and in each of the roles was considered based on effectiveness (QALYs) and headroom prices. 
These results provide provide insights into how good the HT-test needs to be (in terms of 
accuracy), and at what price, for it to be cost-effective. For example, it is shown that the HT-
test can be priced up to $3.85 and still be cost effective against the Widal test in the replacement 
role when the HT-test has sensitivity and specificity of 100%. In this case, the incremental 
effectiveness is 0.0010. When the HT-test has a sensitivity and specificity of 70%, the 
maximum price at which it can still be cost-effective is $0.95 and at an incremental 
effectiveness of -0.0002. This indicates that as the accuracy of the HT-test decreases, the 
maximum price at which the HT-test can be priced and still be cost-effective against the Widal 
test in the replacement role must also decrease. This implies that greater potential returns on 
investment are possible with a better test. Although care must be taken when recommending a 
test with characteristics that lead to a negative effectiveness, as further factors beyond cost-
effectiveness may need to be considered for the test to be acceptable to decision makers (e.g., 
small decrease in effectiveness coupled with large cost savings). The maximum price at which 
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the test can be sold at post development when both sensitivity and specificity are 100% is far 
greater and more attractive to investors compared to when both parameters are 70% ($3.85 
compared to $0.95) and the incremental effectiveness is also more attractive from the patient 
perspective (i.e., 0.0010 compared to -0.0002). Similar conclusions can be drawn for the other 
roles of the HT-test vs. Widal test and for the HT-test vs. blood culture. 
 
The PSA revealed the impact of the uncertainty in the parameters on the model results. This 
shows the probability of the HT-test being cost-effective at different accuracy pairs at a WTP 
of $951/QALY. The PSA shows that as the price of the HT-test drops, more and more pairs of 
sensitivity and specificity become cost-effective (i.e., the PSA supports the main findings). The 
PSA results help to provide a greater understanding of a realistic price and test accuracy 
parameters for the HT-test to be cost-effective. For example, in the comparison between the 
HT-test and Widal test (in the replacement role) the headroom price is $3.85, however, at this 
price the PSA reveals that the HT-test is likely to be cost-effective only when both sensitivity 
and specificity are 100%. Acknowledging the fact that no test is likely to be 100% accurate, 
this indicates that it is not realistic for investors to invest in the development of a new test at 
this price and accuracy pairs.  
 
The PSA results also showed that specificity (at least 70%) is a major driver of the probability 
of the HT-test being cost-effective at the threshold value for cost-effectiveness of $951 per 
QALY. This observation is explained by the prevalence of typhoid in the patient population 
and what happens to FPs and FNs following the test-treat pathway for a suspected typhoid case 
as shown in the different decision trees. From the models, being FP is worse for patients than 
being FN because of the extra testing and treatments they undergo before they are eventually 
cured. Thus, a high specificity is required in order to avoid the unnecessary testing and 
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treatment associated with these pathways. This observation was common to the analyses for 
both pathways (i.e., the HT-test vs. Widal test and the HT-test vs. blood culture). 
 
It is shown in the VOI analysis (the HT-test vs. Widal test in the replacement role) that for the 
specified decision relevance time horizon of 5 years, and for the annual incidence of 60, 000 
used in this analysis, the overall expected value of removing decision uncertainty when the 
HT-test is $1.00 would in total be $3,287 for the assumptions made about the HT-test. This 
implies that research or data collection exercises costing more than this amount would not be 
a cost-effective use of resources to resolve this decision uncertainty. This is because the cost 
of making a wrong decision by decision maker as measured by the cost savings of enabling 
decision-maker’s ability to switch and select other strategies when evidence obtained reduces 
decision uncertainty, is expected to be no higher than the figure of $3,287. From this value, it 
can be concluded that there might be no value in resolving this uncertainty as any research 
studies on further data collection are likely to cost more that this amount.  
 
The VOI analysis further shows that depending on the comparison (i.e., the HT-test vs. Widal 
test or the HT-test vs. blood culture) different parameters contribute to the decision uncertainty. 
For example, in the HT-test vs. Widal test comparison, the prevalence of typhoid in the patient 
population, the specificity of the Widal test and the specificity of the HT-test are the parameters 
seen to contribute to the decision uncertainty. Whereas in the HT-test vs. blood culture 
comparison, the prevalence of typhoid in the patient population, probability of first successful 
typhoid treatment, specificity and sensitivity of blood culture are the parameters seen to 
contribute to the decision uncertainty. This implies that the focus of any further research to 
resolve uncertainty in the two comparisons will differ. These results will be of interest to a 
technology developer as it shows where future research should be focussed. 
 152	
It is worth mentioning that in this analysis it was assumed that all patients are treated 
successfully because of the high efficacy of the treatments for typhoid fever and malaria. 
However, a further consideration in this analysis could have been the inclusion of mortality 
effects in the model. The implications of including such an effect in the model is that, it may 
have led to an opposite conclusion as to what was drawn in this study. That is, it may have led 
to the conclusion that sensitivity is more important than specificity. Furthermore, in this model 
a value of 1 was assigned to perfect health utility when estimating total QALYs for each branch. 
Ideally, the baseline health state utility values would be derived from people without specific 
condition(s) using definitions of health states in the model. However, these data are rarely 
available (Ara and Brazier, 2011) (as was the case in this analysis), thus, a baseline of full 
health was assumed. But, because the average person still has other health problems, this 
assumption (i.e., perfect health utility = 1) may overestimate the benefits of an intervention (in 
this case, the true value of the HT-test) and thus distort policy decisions (Ara and Brazier, 
2011).   
 
An important issue that has been highlighted in this thesis is the inclusion of issues relevant to 
the patient on the test-treat pathway. Although it is acknowledged that capturing this may have 
a significant impact on the conclusions drawn from models, in this analysis, the patient’s 
perspective was not captured. This was due to resource constraints (time and money), lack of 
clear guidance on how this could be done and the methodological complexities associated with 
capturing these effects (Lee et al., 2010). This highlights the need for concerted efforts to 
develop methodologies in this field if such effects are to be appropriately measured and valued 
to be included in economic evaluations. Plausible ways of doing this may include adapting or 
developing patient preference elicitation methods to collect as much information of users’ 
preference as possible. 
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6.5 Strengths and limitations of the study 
	
The strengths of this analysis are that extensive sensitivity analysis has been conducted to 
identify the impact of key parameters on the conclusions drawn from the models. It also 
highlights the usefulness of early cost-effectiveness modelling embedded within the test 
development pathway. Furthermore, the models used in this analysis were informed by a 
formal qualitative approach (different from what normally happens), thus, potentially 
improving the validity as well as the generalizability and the credibility of the models. The 
models developed in this study are the first of their type.     
 
A limitation of this analysis is that there was no specific guidance on the best approach to VOI 
analysis at such an early stage of development to be adopted and how to manage parameters 
when they are completely unknown and hypothetical. Thus, the approach to VOI analysis 
adopted in this study may not be the most appropriate. Furthermore, the assumption that 
patients experience the same utility at the different phases of treatment but return to perfect 
health once treatment has been completed might be an oversimplification. The assumption of 
a perfect health utility value of 1 may overestimate the true value of the HT-test and the 
exclusion of mortality effects from the model may have led to an opposite conclusion being 
drawn from the analysis.  Another limitation of this study is the completely hypothetical nature 
of the test. Having some form of data on the new test would have been far better than not having 





This evaluation has presented a complete analysis of the potential benefits of the HT-test 
compared to two alternative tests and in each of three different roles. The analysis shows that 
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at certain prices and accuracy pairs for the HT-test, the HT-test has potential to be more 
effective compared to current tests in terms of QALYs gained and cost-effectiveness when 
introduced into current practice in Ghana. A high specificity (at least 70%) is a key test 
characteristic requirement for the HT-test to be able to improve current practice. In both 
pathways, the HT-test is likely to improve current practice when it used to replace the currently 
used tests.  
 155	
Chapter 7: Discussion 
 
This chapter discusses the findings of the thesis, its relevance as a valuable source of 
information to policy makers in Ghana and technology developers, and its wider implications 




The need for the development of a rapid diagnostic test for typhoid fever in Ghana has never 
been greater because of the serious implications it has both for the health of Ghanaians and on 
the economy of Ghana. The overall aim of this thesis was to identify the test characteristics of 
a hypothetical typhoid test such that it would meet cost-effectiveness criteria in the Ghanaian 
context. To achieve this aim, the thesis addressed four research objectives that are presented in 
Chapters 3, 4, 5 and 6. The aim of this chapter is to bring together the methodological and 
empirical work contained in this thesis. The first section provides and overview of the key 
findings from the study. The next section then considers the strengths and limitations of the 
thesis. Finally, implications of the findings for policy and future research are presented.  
 
 
7.2 Issues addressed in this thesis 
 
The ensuing sections provide an overview of the issues addressed in this thesis. 
 
7.2.1 How have economic evaluations conducted at the early phases 
of test development been done to date?     
 
Whilst several studies have indicated the importance of an iterative use of economic 
evaluations during the early phases of development of medical devices to support and guide 
decision-making under conditions of high uncertainty, there is little specific guidance on their 
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implementation (Buisman et al., 2016). It was found in Chapter 3 that despite this increased 
interest, there are few published studies that describe the early economic evaluation of medical 
tests and there is a general lack of clarity on the methods used. Possible explanations for the 
few studies published in this area include the following: The nature of early economic analysis 
(i.e., they are primarily used for internal decision-making) implies that this is what makes them 
less likely to be published. Perhaps because early economic evaluations are not as robust as 
economic evaluations conducted at the later stages of technology development, that is why they 
are not considered publishable. Furthermore, test-treat RCTs capturing the downstream health 
outcomes arising from decisions made based on the test results are not feasible and are rare, 
thus, the economic evaluation of medical tests involve extensive modelling. This is a difficult 
thing to do for an established test, but for a new test, it is an even more complex and difficult 
undertaking as care pathways may not be clearly defined at that early stage of analysis and 
there is a lack of data.  
 
The key issue emerging from Chapter 3 is that, the tools available to modellers that can 
demonstrate the value of conducting further research and product development (i.e., VOI 
analysis, headroom analysis) should be better utilized. The findings of the review conducted 
here highlights the need for concerted efforts to develop rigorous methodology in this growing 
field to maximize the value and quality of such analysis. With the limited guidance available 
on the implementation of early cost-effectiveness analysis, it is expected that the lack of clarity 
on the appropriate methods to use will continue. However, with the publication of more studies 
highlighting the need for the development of rigorous methodology in this growing field, there 
will be an increased awareness on the subject. This is expected to lead to an increase in the 
effort to develop specific guidance for the proper conduct of such analysis.  
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7.2.2 Are there any variations in existing test-treat pathways for 
typhoid fever diagnosis in Ghana? 
 
It was found from Chapter 4 that there is so much variation in practice in terms of typhoid 
testing and treatment in Ghana. The issue here is that, the quality of care that patients receive 
is likely to differ depending on the setting in which they find themselves. This situation 
highlights the need for standardisation of the the test-treat protocol for typhoid fever in Ghana 
to ensure equitable standards in the quality of care that patients receive regardless of their 
setting.  
 
Another key issue identified in Chapter 4 was the incorrect use of alternative antimicrobials in 
addition to the first line treatment of choice for typhoid fever. This situation demonstrates the 
potential for waste in current practice, highlighting the need for standardisation in, or adherence 
to, the treatment guidelines for typhoid fever patients. This will promote efficiency in the 
healthcare delivery system by containing costs associated with the use of additional 
antimicrobials. Monies saved can be used elsewhere to improve the health of Ghanaians. It will 
also ensure that patients do not suffer from the side effects associated with unnecessary 
antimicrobial therapy. Managing these side effects is also associated with a cost, which 
represents a further waste of limited available resources. 
 
Moreover, there seemed to be a lack of understanding by health professionals (clinicians and 
medical assistants) in Ghana on test characteristics to make the link between test accuracy and 
the role of a new test on a care pathway. Clinicians and medical assistants are key stakeholders 
when delineating test-treat pathways (a key requirement for test evaluation), thus, their lack of 
understanding of these matters raises issues of concern because this might lead to 
misinformation on important parameters to capture when modelling test-treat pathways. This 
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highlights the need for further education on this topic area.  
 
7.2.3 How have economic evaluations focussed on typhoid 
interventions been modelled? 
 
This issue was addressed in Chapter 5. One of the key findings in this chapter is that there have 
been relatively few economic evaluations that have focussed on typhoid fever, all of which 
have focused on the cost-effectiveness of typhoid vaccination. 
 
Another key finding is that transmission dynamic modelling has not yet been incorporated into 
economic evaluations of typhoid vaccine cost-effectiveness. Thus, there is no economic 
evaluation of typhoid vaccine cost-effectiveness that will meet the current gold standards for 
economic evaluation which requires both the direct and indirect benefits of vaccination to be 
captured when evaluating vaccine cost-effectiveness (Watson and Edmunds, 2015).     
 
 
7.2.4 What is the potential cost-effectiveness of a hypothetical test 
for typhoid fever in a Ghanaian context compared to current tests? 
 
The key finding from Chapter 6 is that, the HT-test has potential to perform better than the 
current available tests in terms of QALYs gained and cost-effectiveness at certain prices and 
accuracy pairs for the HT-test. However, a high specificity (at least 70%) is required for this to 
be achieved. 
 
Another key finding as noted from the PSA is that at higher threshold values, the probability 
of the HT-test being cost-effective increased. However, one of the main issues identified in 
Chapter 6 is the very low cost-effectiveness threshold used ($951) in this analysis. This greatly 
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influenced the probability of the HT-test being cost-effective. The implications of this low 
threshold value to a test developer is that it greatly limits the headroom price for the new 
technology, thus, there may not be much market potential for new entrants to make profit.   
 
Another key finding from Chapter 6 that confirms the findings from an earlier chapter is that, 
the techniques for early cost-effectiveness analysis are not well developed. Particularly in this 
chapter, there was the issue with the most appropriate approach to adopt in VOI analysis. In 
the traditional VOI analysis, there is always some form of data available to inform estimates 
of the new technology to enable the assessment of any value in further research. The difficulty 
in this analysis was that there was no information on the hypothetical test and in the absence 
of any specific guidance, there was no clear direction as to what to do. It is acknowledged that 
although the approach adopted in this study (the assumption was made that the HT-test has the 
same accuracy characteristics as the Widal test) might not be the most appropriate, it certainly 
highlights an area requiring further research. The difficulty in conducting VOI analysis at the 
early stages of development could be a possible explanation of their omission from studies as 
noted in Chapter 3.  
    
7.3 Strengths of the research  
 
One of the major strengths of this thesis is that it systematically reviewed previous early 
modelling studies and typhoid studies to enable the most robust methodologies to the early 
modelling approach to be adopted in this thesis.  
 
A formal qualitative methodology was used to capture and analyse the perspectives of 51 
participants working in different settings (rather than a few informants) to delineate the existing 
test-treat pathway for typhoid fever which then assisted in model structure conceptualisation 
 160	
(i.e., primary data was used to inform the model structures used in the analysis). Capturing 
variability could potentially assist in improving the validity as well as the generalizability and 
credibility of the models used in this thesis. 
 
Extensive sensitivity analysis was conducted to identify the the impact of key parameters on 
the conclusions drawn from the models.  
 
Finally, the thesis also has the strength of highlighting the usefulness of early cost-effectiveness 
modelling embedded within the test development pathway. 
 
7.4 limitations of the research 
  
Although this thesis has addressed some important issues, like any other study, it has its own 
limitations. 
 
The lack of a transmission model in this analysis may mean that the impact of a better test may 
be underestimated. Furthermore, the lack of specific guidance on the best approach to VOI 
analysis at such an early stage to be adopted for the analysis implies that the approach utilized 
may not be the most appropriate.  
 
Another limitation is that only the perspectives of clinicians and medical assistants were 
captured and in only one region when delineating the existing care pathways for typhoid fever 
in Ghana. If other relevant stakeholders such as patients (van Voorn et al., 2016) and policy 
makers had been sampled, they may have held different views or added further considerations. 
Finally, it was not possible to probe the responses of participants (clinicians and medical 
assistants) because the interviews were not personally conducted. For example, in this thesis, 
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this was a deficiency when capturing valid participants’ views about the anticipated role of a 
new test. 
 
7.5 Implications for future research 
 
This thesis has shown that the techniques for early economic evaluation are not well developed; 
particularly, there is no specific guidance on how to conduct VOI analysis at the early stages 
of test development. This highlights the need for future research in this field to develop robust 
methodologies if the value of such analysis is to be maximized. 
 
7.6 Relevance of study findings to policy makers in Ghana 
 
The findings from this thesis provide valuable information to policy makers in Ghana to make 
policy changes that will greatly improve the delivery of care for typhoid fever patients in 
Ghana. 
The study findings showed that some clinicians and medical assistants in Ghana presumptively 
treat typhoid fever (although in the minority) for valid reasons such as delays in diagnosis or 
concerns about accuracy of test or lack of availability. These circumstances reflect the 
characteristics of current practice in Ghana and the implication to policy makers is that, when 
making the decision to introduce a new test into current practice, the test would need to be 
“better” in these respects for healthcare professionals in Ghana to use. The new test should be 
accessible with a quick turnaround time and be at least as accurate as both tests.  
 
Furthermore, the use of alternative antibiotics in addition to ciprofloxacin demonstrates the 
potential for waste in current practice. The implication to policy makers is that, more education 
is needed to ensure the standardisation in, or adherence to, the treatment regimen for typhoid 
fever patients. This will not only promote efficiency in the healthcare delivery system but will 
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also ensure that, patients do not suffer from the side effects associated with unnecessary 
antimicrobial therapy (the management of which is also associated with a cost to the healthcare 
system). Monies saved could be used elsewhere to improve the health of Ghanaians.  
  
The preliminary results of the early cost-effectiveness analysis showed the potential for the 
HT-test to be more effective compared to current tests in terms of QALYs gained and cost-
effectiveness when introduced into current practice in Ghana. The implication to policy makers 
is that, it provides them with valuable information that will guide their decision to fund the 
further development of the HT-test. This could help allocate limited budgets more efficiently.  
  
7.7 Relevance of study findings to technology developers 
 
 
The findings of this thesis provide technology developers with information about the market 
potential of developing the HT-test. It provides information to the technology developer on the 
headroom prices and test characteristics at which the HT-test can be produced for it to be cost-
effective and be able to make profit on any investments that would be made in the further 
development of the test. It also provides information to the test developer on overall EVPI and 




The aim of the research undertaken within this thesis was to examine the methodologies and 
tools that have been employed in the early economic evaluation of medical tests, to explore the 
variations in existing test-treat strategies for typhoid fever in Ghana to delineate the care 
pathway for typhoid fever, to explore the types of models that have been adopted for test-treat 
evaluations of typhoid fever and to design an economic model to estimate the maximum price 
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and the minimum test performance required for the HT-test to be cost-effective in the Ghanaian 
setting.  
 
The findings of this research have wider implications for the early economic evaluation of tests. 
This research has made a number of important contributions to the early economic evaluation 
literature, both methodologically, and in terms of its recommendations for further research. 
This thesis therefore provides valuable information relevant to developing guidance in the 
implementation of early cost-effectiveness analysis. It has been noted that there is a general 
lack of clarity on the methods used in early economic evaluations, hence, it has been 
recommended that there is the need to develop robust methodologies in this field if the value 
of such analysis is to be maximized. This research further recommends that to maximize the 
value of early economic evaluations, the methods available to modellers that can demonstrate 
the value of conducting further research and product development (i.e., value of information 
(VOI) analysis, headroom analysis) should be better utilized. Furthermore, it has been 
recommended that extensive sensitivity analysis should be incorporated into such analysis 
because of the nature of early economic evaluations (i.e., associated with limited data and high 
uncertainty), to make them useful and relevant to policy making. There is no specific guidance 
on VOI analysis at this early stage of analysis and it is recommended here that, further research 
is needed in this field.  
 
 
To the author’s knowledge, the models developed in this study are the first of their type. The 
research has used a robust qualitative approach and demonstrated the benefits associated with 
integrating formal qualitative methods in the model development process. This thesis therefore 
provides a rigorous methodology for those wanting to undertake further research to improve 
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the methods used in modelling processes and/or to develop modelling guidance. It also 
provides a simple but rigorous methodology that appeals to quantitative researchers who would 
want to employ formal qualitative approaches in their research.    
 
The contribution of this research is also important in the context of improving typhoid testing 
and treatment not only in Ghana, but also in other resource-limited settings where this is a 
problem. It has been demonstrated here that, for a hypothetical test to perform better than the 
current available tests in Ghana in terms of QALYs gained and cost-effectiveness, it is 
necessary that it has a high specificity (at least 70%) and should not be priced more than $10. 
The findings of this thesis also provide valuable information to test developers about the market 
potential of developing a new test for typhoid fever that can be applied in the Ghanaian setting 
and the focus of any further research to resolve uncertainty.    




Appendix 1: Search strategy in Medline 
 
 Table A1-1 Search strategy in Medline  
# Searches Results 
1 ((new or novel or emerging or innovati* or early) adj4 test*).tw. 43724 
2 ((earl* or mid* or develop* or formative* or determinative* or design* or concept* or 
investigation*) adj2 (phase* or stage* or process* or "life cycle" or lifecycle) adj4 test*).tw. 
1971 
3 ((nascent or original or "ground breaking" or groundbreaking or promising or "cutting edge" 
or "cutting-edge" or seminal or "recently introduced") adj3 test*).tw. 
3534 
4 1 or 2 or 3    48091 
5 (new or innovat* or emerging* or novel* or nascent or original or "ground breaking" or 
groundbreaking or promising or "cutting edge" or "cutting-edge" or seminal or "recently 
introduced").tw. 
2670140 
6 exp "diagnostic test"/ 8662 
7 exp screening/ 109672 
8 exp prognosis/ 1267953 
9 exp "predisposition test"/ 30098 
10 6 or 7 or 8 or 9 1405426 
11 5 and 10   180738 
12 (early adj3 (valuation* or evaluation* or assessment* or model*)).tw. 13183 
13 (early-stage adj3 (valuation* or evaluation* or assessment* or model*)).tw. 417 
14 (early adj2 (economic or estimate*)).tw. 474 
15 12 or 13 or 14 13702 
16 15 and (4 or 11)  733 
17 (headroom or "head room").tw. 34 
18 models, economic/ or models, econometric/ 11782 
19 markov chain/ 11322 
20 Decision Trees/ 9553 
21 decision support techniques/ 15041 
22 (discrete event* adj8 model*).tw. 361 
23 (decision* adj5 model*).tw. 9742 
24 (model* adj5 markov*).tw. 8787 
25 ((econom* or cost or costs) adj model*).tw. 2837 
26 decision making/ 76162 
27 cost benefit analysis/ 66482 
28 technology assessment, biomedical/ 8612 
29 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 188046 









































31 16 and 29  27 
32 11 and 29  4121 
33 method*.tw. 4035419 
34 32 and 33  2131 
35  16 or 30 or 31 or 34 2866 
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Appendix 2: Typhoid fever diagnosis and treatment questionnaire 
The following is the exact text of the questionnaire used  
 
Please take a few minutes of your time to read and fill out this questionnaire to the best of your 
ability. Your responses will be treated as highly confidential.  
 
1. What are the signs and symptoms typhoid fever patients present with? 
 
 
2. What are your views on applying presumptive treatment to typhoid fever? 
 
 








5. Why do you use the test(s) you mentioned in 4 above? 
 
 
6. In the absence of a perfectly accurate test, there always exist a trade-off between the 
sensitivity and specificity of a test. Which is more important to you: correctly identifying 
patients with typhoid fever (sensitivity) or avoiding unnecessary typhoid treatment for 
patients that don’t have the disease (specificity) and why? 
 
 




8. If there was a new test with the properties you have stated in questions 6 & 7 above, would 





























11. What are the options of antimicrobials available to you to decide a treatment plan for 
typhoid test positive OPD patients? 
 
 




13. Do you prescribe the same antimicrobial for every typhoid test positive OPD patient (in 






















To test patients first to decide on who should receive further testing with the test you use 
now 
 
As the main investigative tool without any further testing with the test you use 
now 
 




	Appendix 3: The “analytical framework matrix” 
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culture                                   
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Tb Ciprofloxacin 500mg 
bd* 7-14 days 

















Tb Ciprofloxacin 500mg 
bd* 7 days 














Tb Ciprofloxacin 500mg 




















Tb Ciprofloxacin 500mg 



















Ciprofloxacin              
IV Ceftriaxone 
Tb Ciprofloxacin 500mg 
bd* 7 days 







Can be started 
since cultures 
takes 72 hrs 
Blood 









Tb Ciprofloxacin 500mg 
bd* 7-10 days 

















Tb Ciprofloxacin 500mg 










Appendix 4: Search strategy for each database used in Chapter 5 
 
Database(s): Ovid MEDLINE(R)  
Search Strategy: 
# Searches Results 
1 Cost-Benefit Analysis/ or economic evaluation*.mp. 74470 
2 typhoid fever.mp. or Typhoid Fever/ 11571 
3 enteric fever.mp. or Typhoid Fever/ 10913 
4 2 or 3 11819 
5 1 and 4 30 
 
 
Database(s): Embase  
Search Strategy: 
# Searches Results 
1 "cost effectiveness analysis"/ or economic evaluation/ or economic 
evaluation*.mp. 
141701 
2 typhoid fever.mp. or typhoid fever/ 12727 
3 enteric fever.mp. or typhoid fever/ 12126 
4 2 or 3 13014 
5 1 and 4 95 
6 limit 5 to (exclude medline journals and yr="1948 - 2017") 9 
 
Database: DARE, HTA, NHS EED 
1 (economic evaluation) IN DARE, NHSEED, HTA 18521 
2 (typhoid fever) IN DARE, NHSEED, HTA 15 




("typhoid fever"[MeSH Terms] OR ("typhoid"[All Fields] AND "fever"[All 
Fields]) OR "typhoid fever"[All Fields])  
AND  
("cost-benefit analysis"[MeSH Terms] OR ("cost-benefit"[All Fields] AND 
"analysis"[All Fields]) OR "cost-benefit analysis"[All Fields] OR 










Appendix 5: Models for the economic analysis 




 Where CT refers to comparator test (Widal test)  Where IT refers to Index test (the HT-test) 
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Fig A5-2 Model comparing the HT-test vs. Widal test in the add-on role 
 
 
Where CT refers to comparator test (Widal test)   Where IT refers to Index tests (the HT-tests) 
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Fig A5-3 Model comparing the HT-test vs. blood culture in the replacement role 
 
 
Where CT refers to comparator test (blood culture)   Where IT refers to Index test (the HT-test) 
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Fig A5-4 Model comparing the HT-test vs. blood culture in the triage role 
 
 
Where CT refers to comparator test (blood culture)   Where IT refers to Index test (the HT-test) 
 182	




Where CT refers to comparator test (blood culture)   Where IT refers to Index test (the HT-test)
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Appendix 6: Headroom analysis (the HT-test vs. Widal test) 
 
Fig A6-1 Headroom of the HT-test vs. Widal test at a WTP of $951/QALY (Triage role) 
 
 

























































Appendix 7: Incremental effectiveness (QALYs) and headroom 
(the HT-test vs Widal) 
 
Table A7-1 Incremental effectiveness (QALYs) at each sensitivity and specificity pair for 
the HT-test vs. Widal test (Triage Role) 
             
 100 0.0003 0.0001 -0.0002 -0.0005 -0.0009 -0.0013 -0.0018 -0.0024 -0.0030 -0.0036   
 90 0.0003 0.0001 -0.0002 -0.0005 -0.0009 -0.0014 -0.0019 -0.0024 -0.0030     
 80 0.0003 0.0001 -0.0002 -0.0005 -0.0009 -0.0014 -0.0019 -0.0024       
Sensitivity 70 0.0003 0.0001 -0.0002 -0.0006 -0.0010 -0.0014 -0.0019         
 60 0.0003 0 -0.0002 -0.0006 -0.0010 -0.0014           
 50 0.0002 0 -0.0003 -0.0006 -0.0010             
 40 0.0002 0 -0.0003 -0.0006               
 30 0.0002 0 -0.0003                 
 20 0.0002 0                   
 10 0.0002                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       
Specificity 
 
     
 
Table A7-2 Maximum price ($) at which the HT-test is still cost-effective at each 
sensitivity and specificity pair for the HT-test vs. Widal test (Triage role) 
             
 100 1.94 1.5 1.01 0.48 NV NV NV NV NV NV   
 90 1.78 1.35 0.87 0.34 NV NV NV NV NV     
 80 1.63 1.2 0.73 0.20 NV NV NV NV       
Sensitivity 70 1.47 1.06 0.58 0.07 NV NV NV         
 60 1.32 0.91 0.44 NV NV NV           
 50 1.17 0.77 0.31 NV NV             
 40 1.02 0.62 0.17 NV               
 30 0.88 0.48 0.03                 
 20 0.73 0.34                   
 10 0.59                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
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Table A7-3 Incremental effectiveness (QALYS) at each sensitivity and specificity pair for 
the HT-test vs. Widal test (Add-on role) 
             
 100 0.0002 0 -0.0002 -0.0004 -0.0006 -0.0008 -0.0010 -0.0013 -0.0015 -0.0017   
 90 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009 -0.0011 -0.0013 -0.0015     
 80 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009 -0.0011 -0.0013       
Sensitivity 70 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009 -0.00109709         
 60 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009           
 50 0.0001 -0.0001 -0.0003 -0.0005 -0.0007             
 40 0.0001 -0.0001 -0.0003 -0.0005               
 30 0 -0.0002 -0.0004                 
 20 0 -0.0002                   
 10 0                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       
Specificity 
     
 
Table A7-4 Maximum price ($) at which HT-test is still cost-effective at each sensitivity 
and specificity pair for the HT-test vs. Widal test (Add-on role) 
 
             
 100 1.47 0.76 0.05 NV NV NV NV NV NV NV   
 90 1.32 0.61 NV NV NV NV NV NV NV     
 80 1.17 0.46 NV NV NV NV NV NV       
Sensitivity 70 1.03 0.32 NV NV NV NV NV         
 60 0.88 0.17 NV NV NV NV           
 50 0.73 0.02 NV NV NV             
 40 0.59 NV NV NV               
 30 0.44 NV NV                 
 20 0.29 NV                   
 10 0.15                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
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Appendix 8: CEACs of the HT-test vs. Widal test 
Fig A8-1 CEAC (with variations in the sensitivity and specificity of the HT-test at a 
fixed price of $3.00) at WTP of $951 (Replacement role: the HT-test vs. Widal tests) 
 
Curves for the (1:0.6; 0.9:0.7; 0.8:0.8; 0.7:0.7) sensitivity and specificity pairs are not shown because they never 
go above zero 
 
 
 Fig A8-2 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 
price of $2.00) at a WTP of $951 (Replacement role: the HT-test vs. Widal test)  
 
Curves for the (1:0.6; 0.9:0.7; 0.7:0.7) sensitivity and specificity pairs are not shown because they never go above 
zero 
 























P(HT-test, 1:1) P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) Threshold























P(HT-test, 1:1) P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) Threshold
P(HT-test, 0.7:0.90) P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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Fig A8-3 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 
price of $0.50) at a WTP of $951 (Triage role: the HT-test vs. Widal test) 
 
 
Curves for the (1:1; 0.6:1) sensitivity and specificity pairs are not shown because they never go below one 
 
 
Fig A8-4 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 





Curves for the (1:0.6; 0.9:0.7; 0.8:0.8; 0.7:0.7) sensitivity and specificity pairs are not shown because they never 
go above zero 

























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)























P(HT-test, 1:1) P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) P(HT-test, 0.7:0.90)
P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7) Threshold
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Fig A8-5 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 
price of $2.00) at a WTP of $951 (Triage role: the HT-test vs. Widal test)  
 
 
Curves for the other sensitivity and specificity pairs are not shown because at a price of $4, only the (1,1) pair has 
any chance of cost-effectiveness, and even then only above the current threshold.  
 
 
Fig A8-6 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




Curves for the (1:0.6; 0.9:0.7; 0.7:0.7) sensitivity and specificity pairs are not shown because they never go above 
zero 















































P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)
P(HT-test, 0.7:0.90) P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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Fig A8-7 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 
price of $1.00) at a WTP of $951 (Add-on role: the HT-test vs. Widal test) 
 
 
Curves for the (1:0.6; 0.9:0.7; 0.7:0.7) sensitivity and specificity pairs are not shown because they never go above 
zero: (1:0.6; 0.9:0.7; 0.7:0.7) 
The curve for the (1:1) sensitivity and specificity pair is not shown because it never goes below one 
 
 
Fig A8-8 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




Curves for the other sensitivity and specificity pairs are not shown because at a price of $2, only the (1,1) pair 























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)

























Appendix 9: VOI analysis (the HT-test vs. Widal test) 
Fig A9-1 VOI analysis of the HT-test vs. Widal test in the replacement role at a price of 




As shown in Fig A9-1, at a WTP threshold of $951/QALY, the overall EVPI for the specified 
decision relevance time horizon of 5 years is $0.00. 
 
Table A9-1 Single parameter EVPPI when the HT-test is $2.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0.00 0 
Mean recovery time for successful malaria 
treatment 
0.00 0.00 0 
Prevalence of typhoid in the patient 
population presenting 
0.00 0.00 0 
Probability of first successful typhoid 
treatment 
0.00 0.00 0 
Utility when experiencing typhoid 
symptoms 
0.00 0.00 0 
Specificity of Widal test 0.00 0.00 0 
Sensitivity of Widal test 0.00 0.00 0 
Specificity of the HT-test 0.00 0.00 0 
Sensitivity of the HT-test 0.00 0.00 0 
 
Table A9-1 shows that none of the parameters contribute to decision uncertainty as the EVPI 
























As shown in Fig A9-2, at a WTP threshold of $951/QALY, the overall EVPI for the specified 
decision relevance time horizon of 5 years is $289. 
 
Table A9-2 Single parameter EVPPI when the HT-test is $1.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0 0 0.00 
Mean recovery time for successful malaria 
treatment 
0 0 0.00 
Prevalence of typhoid in the patient 
population presenting 
0.000109 0 31 
Probability of first successful typhoid 
treatment 
0 0 0.00 
Utility when experiencing typhoid 
symptoms 
0 0 0.00 
Specificity of Widal test 0 0 0.00 
Sensitivity of Widal test 0 0 0.00 
Specificity of the HT-test 0 0 0.00 
Sensitivity of the HT-test 0 0 0.00 
 
 
Table A9-2 shows that prevalence of typhoid in the patient population presenting is the 

























Fig A9-3 VOI analysis of the HT-test vs. Widal test in the triage role at a price of $0.5 




As shown in Fig A9-3, at a WTP threshold of $951/QALY, the overall EVPI for the specified 
decision relevance time horizon of 5 years is $18585. 
Table A9-3 Single parameter EVPPI when the HT-test is $0.5 
 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0 0.000 
Mean recovery time for successful malaria 
treatment 
0.00 0 0.000 






Probability of first successful typhoid 
treatment 
0.00 0 0.000 






Specificity of Widal test 0.000040 0 11 
Sensitivity of Widal test 0.000265 0 74 
Specificity of the HT-test 0.010029 0 2812 
Sensitivity of the HT-test 0.00 0 0.000 
 
Table A9-3 shows that the prevalence of typhoid in the patient population presenting, utility 
when experiencing typhoid symptoms, specificity and sensitivity of Widal test and the 




























As shown in Fig A9-4, at a WTP threshold of $951/QALY, the overall EVPI for the specified 
decision relevance time horizon of 5 years is $23. 
Table A9-4 Single parameter EVPPI when the HT-test is $1.00 
 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0 0 0 
Mean recovery time for successful malaria 
treatment 
0 0 0 
Prevalence of typhoid in the patient 
population presenting 
0 0 0 
Probability of first successful typhoid 
treatment 
0 0 0 
Utility when experiencing typhoid symptoms 0 0 0 
Specificity of Widal test 0 0 0 
Sensitivity of Widal test 0 0 0 
Specificity of the HT-test 0 0 0 
Sensitivity of the HT-test 0 0 0 
 


























As shown in Fig A9-5, at a WTP threshold of $951/QALY, the overall EVPI for the specified 
decision relevance time horizon of 5 years is $406. 
Table A9-5 Single parameter EVPPI when the HT-test is $0.5 
 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0 0 0.00 
Mean recovery time for successful malaria 
treatment 
0 0 0.00 






Probability of first successful typhoid 
treatment 
0 0 0.00 
Utility when experiencing typhoid 
symptoms 
0 0 0.00 
Specificity of Widal test 0 0 0.00 
Sensitivity of Widal test 0 0 0.00 
Specificity of the HT-test 0 0 0.00 
Sensitivity of the HT-test 0 0 0.00 
 
Table A9-5 shows that the prevalence of typhoid in the patient population presenting is the 




















Appendix 10: Headroom analysis the HT-test vs. blood culture 
 
































Headroom analysis (sensitivity and specificity of the HT-test; 1,1)

























Headroom analysis (sensitivity and specificity of the HT-test; 1,1)
NMB (HT-test) NMB (Blood culture)
10.08
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Appendix 11: Incremental effectiveness (QALYs) and headroom 
(HT-test vs blood culture) 
Table A11-1 Incremental effectiveness (QALYs) at each sensitivity and specificity pair 
for HT-test vs blood culture (Triage Role) 
             
 100 0.0003 0.0001 -0.0002 -0.0005 -0.0009 -0.0013 -0.0018 -0.0024 -0.0030 -0.0036   
 90 0.0003 0.0001 -0.0002 -0.0005 -0.0009 -0.0014 -0.0019 -0.0024 -0.0030     
 80 0.0003 0.0001 -0.0002 -0.0005 -0.0009 -0.0014 -0.0019 -0.0024       
Sensitivity 70 0.0003 0.0001 -0.0002 -0.0006 -0.0010 -0.0014 -0.0019         
 60 0.0003 0 -0.0002 -0.0006 -0.0010 -0.0014           
 50 0.0002 0 -0.0003 -0.0006 -0.0010             
 40 0.0002 0 -0.0003 -0.0006               
 30 0.0002 0 -0.0003                 
 20 0.0002 0                   
 10 0.0002                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
 
Table A11-2 Maximum price at which HT-test is still cost-effective at each sensitivity 
and specificity pair for HT-test vs blood culture (Triage role) 
 
             
 100 7.14 6.5 5.82 5.12 4.4 3.65 2.89 2.1 1.31 0.5   
 90 6.94 6.31 5.64 4.95 4.23 3.49 2.73 1.95 1.16     
 80 6.75 6.13 5.47 4.78 4.07 3.33 2.58 1.8       
Sensitivity 70 6.56 5.94 5.29 4.61 3.9 3.17 2.42         
 60 6.37 5.76 5.12 4.44 3.74 3.02           
 50 6.19 5.58 4.95 4.28 3.58             
 40 6 5.41 4.78 4.11               
 30 5.82 5.23 4.61                 
 20 5.64 5.06                   
 10 5.46                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
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Table A11-3 Incremental effectiveness (QALYs) at each sensitivity and specificity pair 
for HT-test vs blood culture (Add-on role) 
             
 100 0.0002 0 -0.0002 -0.0004 -0.0006 -0.0008 -0.0010 -0.0013 -0.0015 -0.0017   
 90 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009 -0.0011 -0.0013 -0.0015     
 80 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009 -0.0011 -0.0013       
Sensitivity 70 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009 -0.0011         
 60 0.0001 -0.0001 -0.0003 -0.0005 -0.0007 -0.0009           
 50 0.0001 -0.0001 -0.0003 -0.0005 -0.0007             
 40 0.0001 -0.0001 -0.0003 -0.0005               
 30 0 -0.0002 -0.0004                 
 20 0 -0.0002                   
 10 0                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity      
 
 
Table A11-4 Maximum price at which HT-test is still cost-effective at each sensitivity 
and specificity pair for HT-test vs blood culture (Add-on role) 
 
 
             
 100 10.08 9.37 8.66 7.95 7.24 6.53 5.82 5.11 4.40 3.69   
 90 9.93 9.22 8.51 7.8 7.09 6.38 5.67 4.97 4.26     
 80 9.79 9.08 8.37 7.66 6.95 6.24 5.53 4.82       
Sensitivity 70 9.64 8.93 8.22 7.51 6.8 6.09 5.38         
 60 9.49 8.78 8.07 7.36 6.65 5.94           
 50 9.35 8.64 7.93 7.22 6.51             
 40 9.2 8.49 7.78 7.07               
 30 9.05 8.34 7.63                 
 20 8.91 8.2                   
 10 8.76                     
 0                       
  100 90 80 70 60 50 40 30 20 10 0 
             
       Specificity     
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Appendix 12: CEACs of the HT-test vs. blood culture 
 
Fig A12-1 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 





Fig A12-2 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 

























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)
P(HT-test, 0.7:0.90) P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
 199	
Fig A12-3 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




Fig A12-4 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1)
P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) P(HT-test, 0.7:0.90)
P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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Fig A12-5 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 






Fig A12-6 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 



























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1)
P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) P(HT-test, 0.7:0.90)























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1)
P(HT-test, 1:0.6) P(HT-test, 0.9:0.9) P(HT-test, 0.7:0.90)
P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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Fig A12-7 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 
price of $7.00) at a WTP of 951 (Triage role: the HT-test vs. blood culture)   
 
 
Curves for the other sensitivity and specificity pairs are not shown because at a price of $7, only the (1,1) pair 
has any chance of cost-effectiveness, and even then only above the current threshold. 
 
Fig A12-8 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 






















































P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)
P(HT-test, 0.7:0.90) P(HT-test, 0.9:0.70) P(HT-test, 0.8:0.8) P(HT-test, 0.7:0.7)
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Fig A12-9 CEAC (with variations in the sensitivity and specificity of the HT-test at a fixed 




Fig A12-10 CEAC (with variations in the sensitivity and specificity of the HT-test at a 




Curves for the other sensitivity and specificity pairs are not shown because at a price of $11.00, only the (1,1) 























P(HT-test, 1:1) Threshold P(HT-test, 0.6:1) P(HT-test, 1:0.6) P(HT-test, 0.9:0.9)

























Appendix 13: VOI analysis (the HT-test vs. blood culture) 
Fig A13-1 VOI analysis of the HT-test vs. blood culture in the replacement role at a 
price of $7.00  
 
 
As shown in Fig A13-1, at a WTP threshold of $951/QALY, the overall EVPI for the 
specified decision relevance time horizon of 5 years is $157,531. 
Table A13-1 Single parameter EVPPI when the HT-test is $7.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0.00 0.0 
Mean recovery time for successful malaria 
treatment 
0.00 0.00 0.0 












Utility when experiencing typhoid 
symptoms 
0.00 0.00 0.0 
Specificity of blood culture 0.470341 0.02 131876 
 
Sensitivity of blood culture 0.326644 0.03 91586 
 
Specificity of the HT-test 0.003495 0.01 980 
 




Table A13-1 shows that the prevalence of typhoid in the patient population presenting, 
probability of first successful typhoid treatment, specificity and sensitivity of blood culture and 

















Expected Value of Perfect Information
EVPI/TP Threshold
 204	





As shown in Fig A13-2, at a WTP threshold of $951/QALY, the overall EVPI for the 
specified decision relevance time horizon of 5 years is $121,748. 
 
Table A13-2 Single parameter EVPPI when the HT-test is $6.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0.00 0 
Mean recovery time for successful malaria 
treatment 
0.00 0.00 0 












Utility when experiencing typhoid 
symptoms 
0.00 0.00 0 
Specificity of blood culture 0.263581 0.02 73904 
 
Sensitivity of blood culture 0.186888 0.02 52400 
 
Specificity of the HT-test 0.00 0.00 0 
Sensitivity of the HT-test 0.00 0.00 0 
 
 
Table A13-2 shows that the prevalence of typhoid in the patient population presenting, 
probability of first successful typhoid treatment and specificity and sensitivity of blood culture 

















Expected Value of Perfect Information
EVPI/TP Threshold
 205	





As shown in Fig A13-3, at a WTP threshold of $951/QALY, the overall EVPI for the 
specified decision relevance time horizon of 5 years is $94,691. 
Table A13-3 Single parameter EVPPI when the HT-test is $5.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0.00 0 
Mean recovery time for successful malaria 
treatment 
0.00 0.00 0 












Utility when experiencing typhoid 
symptoms 
0.00 0.00 0 
Specificity of blood culture 0.142465 0.02 39945 
 
Sensitivity of blood culture 0.118373 0.02 33190 
 
Specificity of the HT-test 0.00 0.00 0 
Sensitivity of the HT-test 0.00 0.00 0 
 
Table A13-3 shows that the prevalence of typhoid in the patient population presenting, 
probability of first successful typhoid treatment and specificity and sensitivity of blood culture 


















Expected Value of Perfect Information
EVPI/TP Threshold
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As shown in Fig A13-4, at a WTP threshold of $951/QALY, the overall EVPI for the 
specified decision relevance time horizon of 5 years is $153,154. 
Table A13-4 Single parameter EVPPI when the HT-test is $10.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful 
typhoid treatment 
0.00 0.00 0 
Mean recovery time for successful 
malaria treatment 
0.00 0.00 0 






Probability of first successful typhoid 
treatment 
0.00 0.00 0 
Utility when experiencing typhoid 
symptoms 
0.00 0.00 0 
Specificity of blood culture 0.331406 0.03 92921 
 
Sensitivity of blood culture 0.312028 0.02 87488 
Specificity of the HT-test 0.00 0.00 0 
Sensitivity of the HT-test 0.00 0.00 0 
 
Table A13-4 shows that the prevalence of typhoid in the patient population presenting and 





















Expected Value of Perfect Information
EVPI/TP Threshold
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Fig A13-5 VOI analysis of the HT-test vs. blood culture in the add-on role at a price of 




As shown in Fig A13-5, at a WTP threshold of $951/QALY, the overall EVPI for the 
specified decision relevance time horizon of 5 years is $202,829. 
Table A13-5 Single parameter EVPPI when the HT-test is $9.00 
 




EVPPI for Ghana over 5 
years ($) 
Mean recovery time for successful typhoid 
treatment 
0.00 0.01 0 
Mean recovery time for successful malaria 
treatment 
0.00 0.01 0 












Utility when experiencing typhoid 
symptoms 
0.00 0.00 0 




Sensitivity of blood culture 0.476746 0.03 133672 
 
Specificity of the HT-test 0.00 0.01 0 
Sensitivity of the HT-test 0.00 0.01 0 
 
 
Table A13-5 shows that the prevalence of typhoid in the patient population presenting, 
probability of first successful typhoid treatment and specificity and sensitivity of blood culture 
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